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1. Introduction 
1.1. Background 
Ventilator-associated pneumonia (VAP) is the most common infectious complication in ICU 
patients requiring mechanical ventilation (MV). The reported incidence of VAP rates ranges 
between 8 and 28%.56 VAP is known to increase the length of ICU and hospital stay, and it is 
associated with a high morbidity and mortality.2, 3, 107, 149, 182, 331, 368 It is well established that VAP 
is associated with prolonged ventilation, ICU stay and additional hospital costs of greater than 
$40,000 per patient.285 However, whether the about 30% higher mortality in patients with VAP is 
due to VAP itself or due to the more frequent presence of underlying determinants in patients 
who develop VAP, remains controversial.56, 266, 285  
Microaspirations of oropharyngeal or gastric secretions are assumed to be the leading cause in 
the pathogenesis of VAP.3, 70, 117 Here the cuff of the endotracheal tube (ET-tube) itself plays a 
decisive role, considering that the natural defense mechanisms to clear the airways from 
secretions are impaired and leakage around the tube cuff facilitates the descent of pathogens into 
the lower airways, especially in atelectatic areas. Sedation, the existence of a nasogastric tube, 
bacterial overgrowth in the stomach and oropharynx and a compromised immune defense due to 
the underlying disease of critically ill patients are additional contributing factors in the 
pathogenesis of VAP. Hematogenic spread from other infectious sources can also account for the 
development of VAP. 
VAP is commonly distinguished into early (<96 h after intubation) and late (>96 hours after 
intubation) onset VAP. Early onset VAP is generally caused by antibiotic sensitive pathogens 
such as oxacillin-sensitive staphylococcus aureus, hemophilus influenzae and streptococcus 
pneumonia.185 Late VAP is generally caused by antibiotic resistant pathogens such as methicillin 
resistant staphylococcus aureus, pseudomonas aeroginosa and acinetobacter species.3 
The prevention of VAP has been the subject of investigation for several decades with numerous 
strategies and techniques aimed at interrupting the oropharyngeal, gastropharyngeal and 
bloodstream route of infection. 
There are a number of systematic reviews that compared the efficacy of various interventions for 
the prevention of VAP.11 In addition, the Center for Disease Control, the American Thoracic 
Society and other additional expert groups have published guidelines for the prevention of VAP.3, 
67, 92, 117, 164, 184, 331, 340
 However, this leaves the clinician with an abundant literature that is 
difficult to interpret, and despite the large number of systematic reviews and guidelines to date 
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there is currently no comprehensive quantitative systematic review summarizing the efficacy of 
all published interventions for the prevention of VAP. The vast number of meta-analyses 
conducted for single interventions as well as the different meta-analytic techniques used, makes 
it virtually impossible for clinicians to qualify effective VAP prevention. 
1.2. Research question 
Therefore, we have conducted a comprehensive and up-to-date quantitative systematic review of 
VAP prevention methods of randomized controlled trials (RCTs). By analyzing all of the results 
with one statistical technique we have made them comparable with one another, allowing for 
easier interpretation of successful prevention strategies for clinicians working in ICU wards. 
Methods 
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2. Methods 
2.1. Search strategy 
a) Electronic databases 
The search of electronic databases is the foundation of our search strategy. It was performed in 
two steps. 
Step I 
To get an overview of the literature and clinical trials of interventions for the prevention of VAP 
we conducted a preliminary PubMed search for the MeSH Term “Ventilator-associated 
Pneumonia”, limited to randomized controlled trials: 
("pneumonia, ventilator-associated"[MeSH Terms] OR ventilator-associated pneumonia[Text 
Word]) AND (randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] 
AND controlled[Title/Abstract] AND trial[Title/Abstract]). 
Subsequently we limited our search term to meta-analyses and systematic reviews: 
("pneumonia, ventilator-associated"[MeSH Terms] OR ventilator-associated pneumonia[Text 
Word]) AND systematic[sb]. 
We were aware of the fact that this search would not lead to a highly sensitive outcome, since the 
MeSH Term “Ventilator Associated Pneumonia” was only introduced to PubMed in 2007. 
Therefore, we reviewed titles, abstracts and MeSH-Term listings of relevant articles and 
preventive strategies found by the initial search. We then formed the following thematic groups 
and subgroups for the development of a more detailed search strategy: 
1. Oral care: toothbrushing, chlorhexidine decontamination. 
2. Gastrointestinal interventions: antibiotics, selective digestive tract decontamination, early 
gastrostomy, small-intestinal feeding, metoclopramide, acidification of enteral feeding, 
sucralfate, intermittent enteral feeding, immunonutrition. 
3. Airway management: weaning protocols, early tracheostomy, noninvasive positive-pressure 
ventilation NPPV, endotracheal suctioning, ventilator circuit changes, heat and moisture 
exchangers.  
4. Endotracheal (ET) tubes: subglottic suctioning, gel lubrication of the tracheal tube cuff, 
silver-coated endotracheal tube. 
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5. Positioning: semi-recumbent positioning, kinetic bed therapy, oscillating beds, prone 
positioning, chest physiotherapy. 
Step II 
Pubmed 
The second step of our search strategy was the development of a more sensitive and exact search 
string. Hereby we implemented a selection of those previously screened MeSH Terms that would 
identify as many randomized controlled trials as possible for each of the five intervention groups. 
Due to the heterogeneity of the intervention groups we developed a specific search string for 
each one with the support of a professional librarian. This group-specific search string was then 
linked to a search string covering the general fields of pneumonia, mechanical ventilation, 
intensive care unit and randomized controlled trial. 
The group-specific search strings were the following: 
Oral Care: 
("anti-bacterial agents"[MAJR] OR "anti-bacterial agents"[Pharmacological Action] OR Anti-
Bacterial Agents[Text Word] OR ("local anti-infective agents"[Text Word] OR "anti-infective 
agents, local"[MAJR] OR "anti-infective agents, local"[Pharmacological Action] OR Anti-
Infective Agents, Local[Text Word]) OR ("chlorhexidine"[MeSH Terms] OR Chlorhexidine[Text 
Word]) OR ("decontamination"[MeSH Terms] OR Decontamination[Text Word]) OR "antibiotic 
prophylaxis"[MAJR] OR ("mouthwashes"[TIAB] NOT Medline[SB]) OR 
"mouthwashes"[MeSH Terms] OR "mouthwashes"[Pharmacological Action] OR 
(mouthwash[TIAB] OR mouthwash/water[TIAB] OR mouthwash'[TIAB] OR 
mouthwashes[TIAB] OR mouthwashes/daily[TIAB] OR mouthwasheses[TIAB] OR 
mouthwashing[TIAB] OR mouthwashings[TIAB]) OR "toothbrushing"[MeSH Terms] OR 
(toothbrush[TIAB] OR toothbrush/chewing[TIAB] OR toothbrush/dentifrice[TIAB] OR 
toothbrush/irrigator[TIAB] OR toothbrush/paste[TIAB] OR toothbrush/toothpaste[TIAB] OR 
toothbrush'[TIAB] OR toothbrush's[TIAB] OR toothbrushed[TIAB] OR toothbrusher[TIAB] OR 
toothbrushers[TIAB] OR toothbrushes[TIAB] OR toothbrushing[TIAB] OR 
toothbrushing'[TIAB] OR toothbrushings[TIAB]) OR "dentifrices"[MeSH Terms] OR ("dental 
plaque"[MeSH Terms] OR Dental Plaque[Text Word]) OR ("gels"[MeSH Terms] OR Gels[Text 
Word]) OR ("chemoprevention"[MeSH Terms] OR Chemoprevention[Text Word]) OR "Anti-
Infective Agents"[MAJR:noexp] OR "Anti-Infective Agents"[Pharmacological Action] OR 
MOUTHRINSE OR MOUTHRINS*[TIAB]) AND (PC[SH]) AND ((Humans[Mesh])) 
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Gastrointestinal Interventions: 
(("antacids"[MeSH Terms] OR "antacids"[Pharmacological Action] OR Antacids[Text Word]) 
OR ("anti-ulcer agents"[MeSH Terms] OR "anti-ulcer agents"[Pharmacological Action] OR 
Anti-Ulcer Agents[Text Word]) OR "enteral nutrition"[MAJR] OR ("peptic ulcer"[MeSH Terms] 
OR Peptic Ulcer[Text Word]) OR ("sucralfate"[MeSH Terms] OR Sucralfate[Text Word]) OR 
("gastrostomy"[MeSH Terms] OR Gastrostomy[Text Word]) OR DIGESTIVE 
SYSTEM[MAJR:noexp] OR "DIGESTIVE TRACT"[TI] OR "INTESTINAL TRACT"[TI]) 
Airway Management: 
(("Nebulizers and Vaporizers"[MeSH] OR Nebulizer*[TIAB] OR Vaporizer*[TIAB] OR 
"Suction"[MeSH] OR "suction*"[Text Word] OR "Filtration"[MeSH] OR "Filtration"[Text 
Word] OR "Heat"[MeSH] OR "Heat"[Text Word] OR "Humidity"[MeSH] OR "Humidity"[Text 
Word] OR "Tracheostomy"[MeSH] OR "Tracheostomy"[Text Word] OR "Ventilators, 
Mechanical"[MH] OR MECHANICAL VENTILATOR*) 
ET-Tubes: 
Suction[MH] OR Suction* OR Drainage[MH] OR Drainage[Text Word] OR Glottis[MH] OR 
Silver[MH] OR Tracheostomy[MH] OR Tracheostomy[Text Word] OR Equipment Design[MH] 
OR Equipment Contamination[MH]) 
Positioning: 
(ROTATION[MH] OR ROTATION*[TIAB] OR PRONE POSITION[MH] OR (PRONE[TIAB] 
AND POSITION*[TIAB]) OR SUPINE POSITION[MH] OR SUPINE[TIAB] OR 
POSTURE[MH] OR POSTURE[TIAB] OR POSTURAL[TIAB]) 
 
The search string covering the fields of pneumonia, mechanical ventilation, intensive care unit 
and randomized controlled trial was the following: 
(RANDOMIZED CONTROLLED TRIAL OR RANDOMIZED CONTROLLED TRIALS OR 
(RANDOM*[TIAB] AND TRIAL*[TIAB]) OR RCT[TIAB] OR RCTS[TIAB]) AND 
((PNEUMONIA[MH:noexp] OR BRONCHOPNEUMONIA[MH] OR "Pneumonia, 
Aspiration"[MeSH] OR "Pneumonia, Aspiration"[Text Word] OR "Pneumonia, 
Bacterial"[MeSH] OR "Pneumonia, Bacterial"[Text Word] OR "Pneumonia, Ventilator-
Associated"[MeSH] OR ventilator-associated pneumonia*[Text Word] OR (PNEUMONIA AND 
VENTILATOR ASSOCIATED) OR (PNEUMONIA[TIAB] AND (MECHANICAL 
VENTILATORS OR MECHANICAL VENTILATOR OR MECHANICAL VENTILATION OR 
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ARTIFICIAL RESPIRATION OR MECHANICALLY VENTILATED))) OR ((INTENSIVE 
CARE UNITS[MH] OR CRITICAL CARE[MH:noexp] OR INTENSIVE CARE[MH:noexp]) 
AND RESPIRATION, ARTIFICIAL[MH]) OR RESPIRATORY TRACT 
INFECTIONS/PC[MH:noexp] OR RESPIRATORY SYSTEM/MICROBIOLOGY[MH:noexp] 
OR OROPHARYNX[MH] OR DIGESTIVE SYSTEM[MH:noexp] OR DIGESTIVE 
SYSTEM[TIAB]) 
 Embase and Cochrane 
Since EMBASE and the Cochrane Library differ from PubMed in their content, we repeated our 
search strategy in a simplified form in these databases focusing our search on the following 
keywords: 
EMBASE database: 
((('ventilator associated pneumonia'/exp OR 'ventilator associated pneumonia') OR 'ventilator 
associated pneumonias') OR (('pneumonia'/exp OR 'pneumonia') AND (('ventilator'/exp OR 
'ventilator') OR ('mechanical ventilation'/exp OR 'mechanical ventilation') OR 'mechanically 
ventilated' OR ('artificial respiration'/exp OR 'artificial respiration'))) AND ([cochrane 
review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim OR [systematic 
review]/lim)) OR (((('ventilator associated pneumonia'/exp OR 'ventilator associated 
pneumonia') OR 'ventilator associated pneumonias') OR (('pneumonia'/exp OR 'pneumonia') 
AND (('ventilator'/exp OR 'ventilator') OR ('mechanical ventilation'/exp OR 'mechanical 
ventilation') OR 'mechanically ventilated' OR ('artificial respiration'/exp OR 'artificial 
respiration')))) AND ('randomized controlled trial'/exp)) 
Cochrane database: 
(ventilator OR mechanical ventilation OR mechanically ventilated OR artificial 
respiration):ti,ab,kw and (pneumonia):ti,ab,kw. 
Email-alerts 
All electronic database searches had an activated e-mail alert that informed us weekly of new 
references in our search strategy. We finalized our search and the selection of included trials on 
October 15th 2008, thus potential references after this date are not included in our analysis. 
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b) Review methods 
We screened the titles and abstracts of the identified references and selected potentially relevant 
randomized controlled trials (RCTs) for retrieval. The screening was done by two of the 
reviewers (Simona Voegele (SV) and Dr. Serpil Cakmakkaya (SC)). In case there were doubts 
about the selection of references a consensus was formed within our own research team that 
included Dr. Oliver Radke (OR) and my mentor Dr. Christian C. Apfel (CCA)). 
Once potentially relevant articles were retrieved, a reviewer (SV or SC) was responsible for the 
data entry of each of the intervention groups. If methodological questions arose, trials were 
discussed with at least one additional reviewer from our team. Upon completion of the 
methodological evaluation and data entry, the results of the intervention groups were presented 
to the group members, discussed and finalized.  
c) Hand search of reference lists 
All reference lists of retrieved trials were screened to identify and evaluate any potentially 
relevant RCTs. 
d) Institute of Scientific Indexing (ISI) 
In order to identify recently published trials, we entered studies that were published after 2001 
into the Cited Reference Search of the Science Citation Index. Then we performed a prospective 
search from the date of publication and identified all publications citing the entered trial. 
e) Contacting authors  
Authors were contacted for missing data and methodological details of their trials which could 
not be clarified within our group. 
We made at least two attempts to contact an author. Otherwise we tried to contact colleagues that 
had recently published with them. If these attempts were unsuccessful and essential information 
for inclusion was missing, their trial was not included. 
f) Clinicaltrials.gov 
We searched clinicaltrials.gov, a service of the U.S. National Institutes of Health, entering the 
term “ventilator-associated pneumonia” in order to identify ongoing unpublished studies. 
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If a trial was potentially useful, the study coordinators were contacted via email for preliminary 
data to be included into our anaylsis. 
g) Language 
We placed no language barriers in order to ensure this work is the most comprehensive review to 
date. 
Members of our team analysed the English, German, Spanish, French and Italian articles. All 
other languages were translated by physicians and other health care workers from our institution. 
h) Publication type 
Any type of publication, as well as data from unpublished trials, was eligible for our meta-
analysis, if there was enough information available to satisfy our inclusion criteria. 
2.2. Inclusion and exclusion criteria 
a) Methodological criteria 
To be included in our meta-analysis, studies had to be randomised, controlled clinical trials.  
Blinding was not a mandatory inclusion criterion because it is not possible to blind a majority of 
the preventive strategies for VAP, such as positioning or airway management. 
We utilized allocation concealment as a tool for quality assessment. Allocation concealment is 
considered to have an even greater impact on the possible introduction of bias to a study than 
blinding167, 168 and it is the quality measure applied in the RevMan Program 4.2 of the Cochrane 
Collaboration. The score we used (A = adequate, B = unclear, C = inadequate, D = not used) was 
adapted from the RevMan Program 4.2. 
We did not rate our studies with a quality score. It has been shown that quality score ratings are 
very inconsistent in their outcomes when compared to each other.168 In view of this fact, some 
authorities consider the evaluation of topic-specific details, such as the definition of pneumonia 
in our case, to be of more relevance to the quality of a meta-analysis than a quality score.102 
Therfore we outlined relevant details of study quality in our study characteristics tables. 
b) Patient population  
The study population consisted of critically ill adult patients requiring mechanical ventilation 
(MV) on an ICU or other special care unit, such as a respiratory care unit. 
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This systematic review included clinical trials of adults greater than 18 years old; however, trials 
that contained some patients under 18 years of age were included, if their primary focus was 
unequivocally on adult patients. 
We excluded trials of cardiac surgery patients due to their expected short duration on MV, unless 
the trial reported abstractable pneumonia data of a subgroup of patients requiring MV for more 
than 48 hours. 
Trials of transplant patients were also excluded since their condition, under immunosuppressive 
medication, is rather unique and can not be compared to that of other critically ill trauma, 
medical or surgical patients. 
c) Outcomes 
To be included pneumonia had to be either a primary or a secondary outcome of a study. If a trial 
studied a preventive strategy for VAP but only reported on one of our secondary outcomes, it was 
not selected for our meta-analysis. 
d) Mechanical ventilation 
If less than 100% of patients were mechanically ventilated, we only included the trial if it was 
fair to assume that MV was evenly distributed between treatment and control groups. We 
assumed this to be the case when more than 90% received MV in a study. 
For inclusion at least 90% of the study patients in treatment and control groups had to be 
mechanically ventilated for at least 48 hours. We assumed that intubation was equal to MV, 
unless noted otherwise. 
e) Definition of VAP 
Currently there is no “gold standard” criteria basis for the diagnosis of VAP.56, 283 We therefore 
accepted a trial if the definition of VAP coincided with international standards, as suggested by 
the Centers for Disease Control and Prevention (CDC), the American Thoracic Society or other 
feasible authorities and guidelines.3, 331, 342 
If there was more than one definition for pneumonia given in a trial, we chose the most 
frequently used and abstracted the corresponding data. 
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2.3. Primary and secondary outcomes 
The primary outcome of our meta-analysis was the incidence of ventilator-associated pneumonia 
(VAP). 
Even though pneumonia cases were not explicitly described as VAP, we considered them to be 
ventilator-associated if at least 90% of patients were ventilated for more than 48 hours. 
Secondary outcomes were mortality, the duration of MV and length of ICU stay. 
All results are outlined in tables and figures of the corresponding paragraph. We did not outline 
results in figures when only one study was available for a preventive technique. 
The secondary outcomes, duration of MV and the length of ICU stay, are outlined in the results 
tables, but are only explicitly mentioned in the text if their outcomes contribute significantly to 
the character of a preventive strategy. 
2.4. Data abstraction and statistics 
We used the review manager program 4.2 (RevMan 4.2) of the Cochrane Collaboration for our 
statistical analysis. 
Overall estimates of dichotomous data are expressed as odds ratios and 95% confidence 
intervals, overall estimates of continuous data as weighted mean differences and 95% confidence 
intervals. The fixed effects model was used for analysis if the test for heterogeneity was not 
significant at the level of p=0.05, the random effects model if it was statistically significant. 
The weight we assigned to the studies through the RevMan program was calculated as follows: 
1/SD (standard deviation). 
We grouped trials of a preventive strategy when possible and calculated summary effect 
estimates. Subgroups were formed to emphasize a difference in the intervention strategy or when 
studies were not comparable. 
We abstracted dichotomous data of pneumonia and mortality rates, as well as the mean and 
standard deviation for the continuous outcomes like duration of MV and length of ICU stay. If 
outcomes were reported differently and data could not be integrated in our analysis, we 
expressed this by brackets around outcomes in the study characteristics tables. 
Since studies reported mortality rates for different time intervals, e.g. ICU mortality, hospital 
mortality, 60-day mortality, we always abstracted the data of the longest time interval, assuming 
that the occurrence of death is a constant process over time. 
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In studies with more than one study group, we divided the control group by the number of study 
groups such that every study patient was included only once in our analysis. If some of the 
groups were out of our focus of interest, we only integrated some of the groups to maintain the 
power of our interest groups. 
We controlled for potential confounders, especially if more than one intervention was studied in 
a trial. 
2.5. Adjustments to predefined methods 
As mentioned above, included studies had a protocol that expected the patients to be ventilated 
for at least 48 hours. We also considered studies with an average MV duration of clearly more 
than 48 hours even if it was not predefined in the study’s protocol or if it was appropriate to 
assume secondary to the critically ill status of the study population. However, if the criterion was 
not mentioned or it seemed unlikely, that the vast majority of patients were ventilated over 48 
hours, these studies had to be excluded. 
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3. Results 
3.1. Search results 
Figure 1 illustrates the process of our search and election process over time. 
We reviewed the results of our PubMed search for every single intervention group, totalling in 
1181 refrences. We discarded trials not in accordance with our inclusion criteria and retrieved 
190 potentially relevant articles for closer evaluation. Duplicates that were identified due to 
similarities in the general part of the group-specific search strings were discarded. 
Our EMBASE search led to 403 results, with 84 potentially relevant references. Sixty-four of the 
84 were discarded as duplicates. Thus our EMBASE search added 20 potentially relevant articles 
to our final selection of articles. 
The Cochrane search resulted in 364 results, with 109 potentially relevant references. Eighty-
seven of the 109 were identified as duplicates and discarded. Twenty-two were added to our final 
subset of articles. 
In total, the search of electronic databases identified 1948 references, of which 232 were 
retrieved for analysis. 
At the time of our search, clinicaltrials.gov reported 24 ongoing studies in the patient recruitment 
phase, of which 9 were chosen for follow up. The corresponding authors were contacted, but 
none could provide usable data for our analysis. 
Twenty-seven trials were additionally identified by the hand search of the reference lists of 
included articles. 
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Figure 1: Trial-flow 
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3.2. Relevant trials 
In total, 169 studies met our inclusion criteria and were included in our analysis. Detailed 
information of the trials are outlined in the study characteristics tables in the appendix. Not all 
preventative strategies mentioned in our primary intervention groups were studied by RCTs and 
therefore do not appear in the final analysis. Conversely, additional methods for the prevention 
of VAP were identified during the search process and were added to the according intervention 
groups. A sixth group, “Non-classifiable preventive strategies” was created for methods not 
matching any of the other intervention groups. 
3.3. Excluded trials 
Ninety trials were excluded from our anaylsis for methodological reasons or if they fulfilled one 
or more exclusion criteria. The specific reasons for exclusion can be inferred from the flow chart 
of our search and from the table of excluded trials in the appendix.  
3.4. Oral care 
a) Antiseptic decontamination 
Pneumonia 
Overall the results for oral care with an antiseptic agent show a statistically significant reduction 
of pneumonia rates (OR=0.60, 0.45-0.82) (Figure 2) (Table 1). 
Five trials administering chlorhexidine to the buccal cavity for decontamination met our 
inclusion criteria.44, 118, 119, 179, 333 The overall results show a significant reduction of VAP rates 
(OR = 0.57, 0.36 – 0.89). 
Another trial achieved a significant reduction of the incidence of pneumonia with the 
administration of povidone-iodine instead of chlorhexidine (OR = 0.14, 0.04 – 0.58).306 
The results of a decontamination regimen with iseganan in a large study failed to reach statistical 
significance, although the odds ratio was numerically less than one (OR = 0.76, 0.49 – 1.16).192 
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Figure 2: Oral Care: Antiseptic decontamination, pneumonia outcomes 
Review: Oral Care
Comparison: 01 Antiseptic decontamination                                                                                 
Outcome: 01 Pneumonia                                                                                                  
Study  Decontamination  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Chlorhexidine
 Bopp 2006                  0/2                1/3           0.97      0.33 [0.01, 12.82]       
 Fourrier 2000              4/30              11/30          8.60      0.27 [0.07, 0.96]        
 Tantipong 2008             5/58              10/52          8.69      0.40 [0.13, 1.25]        
 Fourrier 2005             13/114             12/114         9.59      1.09 [0.48, 2.51]        
 Koeman 2006               13/127             23/130        18.41      0.53 [0.26, 1.10]        
Subtotal (95% CI) 331                329  46.27      0.57 [0.36, 0.89]
Total events: 35 (Decontamination), 57 (Control)
Test for heterogeneity: Chi² = 4.22, df = 4 (P = 0.38), I² = 5.1%
Test for overall effect: Z = 2.46 (P = 0.01)
02 Povidone-iodine
 Seguin 2006                3/36              12/31         10.67      0.14 [0.04, 0.58]        
Subtotal (95% CI) 36                 31  10.67      0.14 [0.04, 0.58]
Total events: 3 (Decontamination), 12 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.006)
03 Iseganan
 Kollef 2006               45/282             57/284        43.07      0.76 [0.49, 1.16]        
Subtotal (95% CI) 282                284  43.07      0.76 [0.49, 1.16]
Total events: 45 (Decontamination), 57 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 649                644 100.00      0.60 [0.45, 0.82]
Total events: 83 (Decontamination), 126 (Control)
Test for heterogeneity: Chi² = 9.42, df = 6 (P = 0.15), I² = 36.3%
Test for overall effect: Z = 3.29 (P = 0.001)
 0.01  0.1  1  10  100
 Favours decontamin.  Favours control
 
Mortality 
Overall, there was no evidence for an effect of oral care with anitiseptics on mortality rates 
(OR=1.14, 0.85-1.53) (Figure 3) (Table 1).  
This was also true for the results of the subgroups, of which none reached statistical significance. 
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Figure 3: Oral Care: Antiseptic decontamination, mortality outcomes 
Review: Oral Care
Comparison: 01 Antiseptic decontamination                                                                                 
Outcome: 02 Mortality                                                                                                  
Study  Decontamination  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Chlorhexidine
 Bopp 2006                  0/2                0/3                 Not estimable         
 Koeman 2006                0/127              0/130               Not estimable         
 Fourrier 2000              3/30               7/30          7.60      0.37 [0.08, 1.58]        
 Fourrier 2005             31/114             24/114        21.09      1.40 [0.76, 2.58]        
Subtotal (95% CI) 273                277  28.70      1.13 [0.65, 1.96]
Total events: 34 (Decontamination), 31 (Control)
Test for heterogeneity: Chi² = 2.77, df = 1 (P = 0.10), I² = 63.9%
Test for overall effect: Z = 0.42 (P = 0.67)
02 Povidone-iodine
 Seguin 2006                6/36              10/31         10.81      0.42 [0.13, 1.33]        
Subtotal (95% CI) 36                 31  10.81      0.42 [0.13, 1.33]
Total events: 6 (Decontamination), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
03 Isaganan
 Kollef 2006               80/362             63/347        60.49      1.28 [0.88, 1.85]        
Subtotal (95% CI) 362                347  60.49      1.28 [0.88, 1.85]
Total events: 80 (Decontamination), 63 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 671                655 100.00      1.14 [0.85, 1.53]
Total events: 120 (Decontamination), 104 (Control)
Test for heterogeneity: Chi² = 6.00, df = 3 (P = 0.11), I² = 50.0%
Test for overall effect: Z = 0.88 (P = 0.38)
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Table 1: Outcomes Oral Care: Antiseptic decontamination 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Bopp 
2006 
Chlorhexidine 2/ 
3 
0.33 
[0.01, 12.82] 
Not estimable   
Fourrier 
2000 
Chlorhexidine 30/ 
30 
0.27 
[0.07, 0.96] 
0.37 
[0.08, 1.58] 
-5.00 
[-13.35, 3.35] 
-6.00 
[-14.89, 2.89] 
Fourrier 
2005 
Chlorhexidine 114/ 
114 
1.09 
[0.48, 2.51] 
1.40 
[0.76, 2.58] 
1.10 
[-1.16, 3.36] 
-0.70 
[-2.95, 1.55] 
Koeman 
2006 
Chlorhexidine 127/ 
130 
0.53 
[0.26, 1.10] 
Not estimable 2.21 
[-0.30, 4.72] 
1.32 
[-2.38, 5.02] 
Tantipong 
2008 
Chlorhexidine 58/ 
52 
0.40 
[0.13, 1.25] 
   
Subtotal:   0.57 
[0.36, 0.89] (f) 
0.13 
[0.65, 1.96] (f) 
1.34 
[-0.31, 2.99] (f) 
-0.42 
[-2.29, 1.46] (f) 
       
Seguin 
2006 
Povidone-iodine 36/ 
31 
0.14 
[0.04, 0.58] 
0.42 
[0.13, 1.33] 
-1.00 
[-4.36, 2.36] 
1.00 
[-5.23, 7.23] 
       
Kollef 
2006 
Iseganan 282/ 
284 
0.76 
[0.49, 1.16] 
1.28 
[0.88, 1.85] 
  
Totals   0.60 
[0.45, 0.89] (f) 
1.14 
[0.85, 1.53] (f) 
0.89 
[-0.59, 2.37] (f) 
-0.30 
[-2.09, 1.50] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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3.5. Airway management  
a) Tracheostomy 
Pneumonia 
Seven trials reported on the incidence of pneumonia in patients with a tracheostomy performed 
early (days 1-8 of MV) compared to patients undergoing prolonged intubation or late 
tracheostomy performed after day 8 of MV (Figure 4) (Table 2). 19, 34, 45, 291, 298, 302, 330 
Overall the results do not show a statistically significant reduction of VAP, although the odds 
ratio is numerically less than one (OR = 0.66, 0.31 - 1.38), which is also true for the early versus 
late tracheostomy subgroup analysis (OR = 0.44, 0.10 - 2.04). 
Figure 4: Airway Management: Tracheostomy, pneumonia outcomes. 
Review: Airway Management
Comparison: 01 Tracheostomy                                                                                               
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Early tracheostomy vs prolonged intubation
 Bouderka 2004             18/31              19/31         18.09      0.87 [0.32, 2.41]        
 Sugerman 1997             26/53              32/56         21.33      0.72 [0.34, 1.54]        
 Blot 2007                 41/61              37/62         21.56      1.39 [0.66, 2.89]        
Subtotal (95% CI) 145                149  60.98      0.98 [0.61, 1.56]
Total events: 85 (Treatment), 88 (Control)
Test for heterogeneity: Chi² = 1.52, df = 2 (P = 0.47), I² = 0%
Test for overall effect: Z = 0.09 (P = 0.93)
02 Early tracheostomy vs late tracheostomy
 Saffle 2002               21/21              22/23          4.36      2.87 [0.11, 74.28]       
 Barquist 2006             28/29              28/31          7.42      3.00 [0.29, 30.62]       
 Rodriguez 1990            40/51              53/55         12.36      0.14 [0.03, 0.65]        
 Rumbak 2004                3/60              15/60         14.87      0.16 [0.04, 0.58]        
Subtotal (95% CI) 161                169  39.02      0.44 [0.10, 2.04]
Total events: 92 (Treatment), 118 (Control)
Test for heterogeneity: Chi² = 7.52, df = 3 (P = 0.06), I² = 60.1%
Test for overall effect: Z = 1.05 (P = 0.30)
Total (95% CI) 306                318 100.00      0.66 [0.31, 1.38]
Total events: 177 (Treatment), 206 (Control)
Test for heterogeneity: Chi² = 14.99, df = 6 (P = 0.02), I² = 60.0%
Test for overall effect: Z = 1.10 (P = 0.27)
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Mortality 
Although the second subgroup analysis, comparing early with late tracheostomy, resulted in a 
significant reduction of mortality (OR = 0.43, 0.26 - 0.72). This could not be confirmed by the 
overall assessment (OR = 0.80, 0.45 – 1.42) (Figure 5) (Table 2). 
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Figure 5: Airway Management: Tracheostomy, mortality outcomes. 
Review: Airway Management
Comparison: 01 Tracheostomy                                                                                               
Outcome: 02 Mortality                                                                                                  
Study  Treatment  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Early tracheostomy vs prolonged intubation
 Bouderka 2004             12/31               7/31         13.57      2.17 [0.71, 6.57]        
 Sugerman 1997             13/53              11/59         16.33      1.42 [0.57, 3.51]        
 Blot 2007                 16/61              15/62         17.72      1.11 [0.49, 2.52]        
Subtotal (95% CI) 145                152  47.62      1.41 [0.83, 2.40]
Total events: 41 (Treatment), 33 (Control)
Test for heterogeneity: Chi² = 0.90, df = 2 (P = 0.64), I² = 0%
Test for overall effect: Z = 1.27 (P = 0.21)
02 Early tracheostomy vs late tracheostomy
 Barquist 2006              2/29               5/31          7.89      0.39 [0.07, 2.16]        
 Saffle 2002                4/21               6/23         10.14      0.67 [0.16, 2.79]        
 Rodriguez 1990             9/51              13/55         15.67      0.69 [0.27, 1.79]        
 Rumbak 2004               19/60              37/60         18.69      0.29 [0.14, 0.61]        
Subtotal (95% CI) 161                169  52.38      0.43 [0.26, 0.72]
Total events: 34 (Treatment), 61 (Control)
Test for heterogeneity: Chi² = 2.43, df = 3 (P = 0.49), I² = 0%
Test for overall effect: Z = 3.18 (P = 0.001)
Total (95% CI) 306                321 100.00      0.80 [0.45, 1.42]
Total events: 75 (Treatment), 94 (Control)
Test for heterogeneity: Chi² = 13.13, df = 6 (P = 0.04), I² = 54.3%
Test for overall effect: Z = 0.77 (P = 0.44)
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Length of ICU stay 
The length of ICU stay, reported by four trials, was significantly reduced by early tracheostomy 
(WMD: -8.96, -17.53 - -0.39) (Table 2). 
Table 2: Outcomes Airway Management: Tracheostomy 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Blot 
2007 
Early Tracheostomy 
vs. prolonged intubation 
61/ 
62 
1.39 
[0.66, 2.89] 
1.11 
[0.49, 2.52] 
  
Bouderka 
2004 
Early tracheostomy 
vs. prolonged intubation 
31/ 
31 
0.87 
[0.32, 2.41] 
2.17 
[0.71, 6.57] 
-3.00 
[-7.53, 1.53] 
 
Sugerman 
1997 
Early tracheostomy 
vs. prolonged intubation 
53/ 
59 
0.72 [0.42, 1.54] 1.42 
[0.57, 3.51] 
 -4.00 
[-4.74, -3.26] 
Subtotal   0.98 
[0.61, 1.56] (r) 
1.41 
[0.83, 2.40] (r) 
  
       
Saffle 
2002 
Early tracheostomy 
vs. late tracheostomy 
21/ 
23 
2.87 
[0.11, 74.28] 
0.67 
[0.16, 2.79] 
4.10 
[1.23, 6.97] 
1.10 
[-3.14, 5.34] 
Barquist 
2006 
Early 
vs. late tracheostomy 
29/ 
31 
3.00 
[0.29, 30.62] 
0.39 
[0.07, 2.16] 
  
Rodriguez 
1990 
Early 
vs. late tracheostomy 
51/ 
55 
0.14 
[0.03, 0.65] 
0.69 
[0.27, 1.79] 
-20.00 
[-20.84, -19.16] 
-21.00 
[-22.09, -19.91] 
Rumbak 
2004 
Early 
vs. late tracheostomy 
60/ 
60 
0.16 
[0.04, 0.58] 
0.29 
[0.14, 0.61] 
-9.80 
[-11.48, -8.12] 
-11.40 
[-12.42, -10.38] 
Subtotal   0.44 
[0.10, 2.04] (r) 
0.43 
[0.26, 0.72] (r) 
-8.64 
[-20.63, 3.35] (r) 
-10.71 
[-19.43, -1.99] (r) 
       
Total:   0.66 
[0.31, 1.38] (r) 
0.80 
[0.45, 1.42] (r) 
-7.27 
[-17.70, 3.17] (r) 
-8.96 
[-17.53, -0.39] (r) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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b) Weaning 
Pneumonia 
Nine trials studied the influence of weaning procedure changes on pneumonia, either by 
implementing a weaning protocol232 or by non-invasive instead of invasive MV13, 58, 69, 110, 128, 253, 
345, 373
 (Figure 6) (Table 3). Of the trials implementing non-invasive MV, in all trials but two13, 69, 
patients received invasive MV before randomization to non-invasive or invasive MV. 
In the subgroup implementing a weaning protocol the odds ratio was numerically less than one, 
but the result did not achieve statistical significance (OR = 0.53, 0.24 – 1.14), whereas non-
invasive MV resulted in a significant reduction of VAP rates (OR = 0.14, 0.07 – 0.25). 
Figure 6: Airway Manangement: Weaning, pneumonia outcomes. 
Review: Airway Management
Comparison: 02 Weaning                                                                                                    
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Weaning protocol
 Marelich 2000             11/166             20/169       100.00      0.53 [0.24, 1.14]        
Subtotal (95% CI) 166                169 100.00      0.53 [0.24, 1.14]
Total events: 11 (Treatment), 20 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
02 Non-invasive vs. invasive MV
 Girault 1999               1/17               1/16          1.47      0.94 [0.05, 16.37]       
 Chen 2001                  0/12               7/12         10.90      0.03 [0.00, 0.61]        
 Conti 2002                 3/23               9/26         11.10      0.28 [0.07, 1.22]        
 Nava 1998                  0/25               7/25         11.12      0.05 [0.00, 0.90]        
 Antonelli 1998             1/32               8/32         11.71      0.10 [0.01, 0.83]        
 Ferrer 2003                5/21              13/22         14.62      0.22 [0.06, 0.81]        
 Wang 2005                  3/47              12/43         17.73      0.18 [0.05, 0.68]        
 Trevisan 2008              1/28              17/37         21.35      0.04 [0.01, 0.36]        
Subtotal (95% CI) 205                213 100.00      0.14 [0.07, 0.25]
Total events: 14 (Treatment), 74 (Control)
Test for heterogeneity: Chi² = 6.01, df = 7 (P = 0.54), I² = 0%
Test for overall effect: Z = 6.31 (P < 0.00001)
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Mortality 
Mortality was significantly reduced by non-invasive MV as opposed to invasive MV (OR = 0.41, 
0.24 – 0.71) (Table 3). The implementation of a weaning protocol did not lead to a benefit of 
survival (OR = 1.81, 0.81 – 4.09). 
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Figure 7: Airway Management: Weaning, mortality outcomes.  
Review: Airway Management
Comparison: 02 Weaning                                                                                                    
Outcome: 02 Mortality                                                                                                  
Study  Treatment  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Weaning protocol
 Marelich 2000             17/166             10/169       100.00      1.81 [0.81, 4.09]        
Subtotal (95% CI) 166                169 100.00      1.81 [0.81, 4.09]
Total events: 17 (Treatment), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
02 Non-invasive vs invasive MV
 Girault 1999               0/17               2/16          4.83      0.17 [0.01, 3.73]        
 Chen 2001                  0/12               3/12          4.92      0.11 [0.00, 2.36]        
 Wang 2005                  1/47               7/43          8.65      0.11 [0.01, 0.95]        
 Nava 1998                  2/25               7/25         11.78      0.22 [0.04, 1.21]        
 Ferrer 2003                6/21              13/22         15.89      0.28 [0.08, 0.99]        
 Conti 2002                 6/23              12/26         16.63      0.41 [0.12, 1.38]        
 Trevisan 2008              9/28              10/37         18.28      1.28 [0.44, 3.75]        
 Antonelli 1998            10/32              16/32         19.01      0.45 [0.16, 1.26]        
Subtotal (95% CI) 205                213 100.00      0.41 [0.24, 0.71]
Total events: 34 (Treatment), 70 (Control)
Test for heterogeneity: Chi² = 7.69, df = 7 (P = 0.36), I² = 9.0%
Test for overall effect: Z = 3.22 (P = 0.001)
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Duration of MV/ Length of ICU stay 
While the duration of MV was not significantly influenced (WMD = -1.88, -6.33 - 2.56), the 
length of ICU stay was significantly reduced in the group of patients receiving non-invasive MV 
(WMD=-4.78, -6.90 - -2.67) (Table 3). It was not assessed by the trial of protocol weaning. 
Table 3: Outcomes Airway Management: weaning 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of 
MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Marelich 
2000 
Weaning Protocol 166/ 
169 
0.53 
[0.24, 1.14] 
1.81 
[0.81, 4.09] 
  
       
Antonelli 
1998 
Non-invasive 
vs. invasive MV 
32/ 
32 
0.10 
[0.01, 0.83] 
0.45 
[0.16, 1.26] 
-3.00 
[-5.67, -0.33] 
-7.00 
[-13.37, -0.63] 
Chen 
2001 
Non-invasive 
vs. invasive MV 
12/ 
12 
0.03 
[0.00, 0.61] 
0.11 
[0.00, 2.36] 
-8.00 
[-15.22, -2.18] 
 
Conti 
2002 
Non-invasive 
vs. invasive MV 
23/ 
26 
0.28 
[0.07, 1.22] 
0.41 
[0.12, 1.38] 
1.00 
[-10.20, 12.20] 
1.00 
[-9.93, 11.93] 
Ferrer 
2003 
Non-invasive 
vs. invasive MV 
21/ 
22 
0.22 
[0.06, 0.81] 
0.28 
[0.08, 0.99] 
-8.70 
[-15.22, -2.18] 
-10.90 
[-17.44, -4.36] 
Girault 
1999 
Non-invasive 
vs. invasive MV 
17/ 
16 
0.94 
[0.05, 16.37] 
0.17 
[0.01, 3.73] 
8.08 
[5.49, 10.67] 
-1.71 
[-6.63, 3.21] 
Nava 
1998 
Non-invasive 
vs. invasive MV 
25/ 
25 
0.05 
[0.00, 0.90] 
0.22 
[0.04, 1.21] 
-6.40 
[-11.74, -1.06] 
-8.90 
[-14.67, -3.13] 
Trevisan 
2008 
Non-invasive 
vs. invasive MV 
28 
37 
0.04 
[0.01, 0.36] 
1.28 
[0.44, 3.75] 
-2.39 
[-7.38, 2.60] 
-1.90 
[-7.36, 3.56] 
Wang 
2005 
Non-invasive 
vs. invasive MV 
47/ 
43 
0.18 
[0.05, 0.68] 
0.11 
[0.01, 0.95] 
2.00 
[-0.86, 4.86] 
-4.00 
[-8.01, 0.01] 
Subtotal:   0.14 
[0.07, 0.25] (f) 
0.41 
[0.24, 0.71] (r) 
-1.88 
[-6.33, 2.56](r) 
-4.78 
[-6.90, -2.67] (f) 
 
      
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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c) Closed vs. open endotracheal suctioning 
Pneumonia 
Nine trials utilizing a closed rather than an open endotracheal suction catheter system met our 
inclusion criteria.68, 88, 165, 207, 216, 220, 280, 339, 384 Pneumonia rates were not significantly different, 
although the odds ratio was numerically less than one (OR = 0.83, 0.62 – 1.11) (Figure 8) (Table 
4). 
Figure 8: Airway Management: Closed vs. open endotracheal suctioning, pneumonia outcomes. 
Review: Airway Management
Comparison: 01 Closed vs. open endotracheal suctioning                                                                    
Outcome: 01 Pneumonia                                                                                                  
Study  Closed  Open  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Johnson 1994               8/16              10/19          4.47      0.90 [0.24, 3.41]        
 Rabitsch 2004              0/12               5/12          5.17      0.05 [0.00, 1.13]        
 Topeli 2004               13/41               9/37          6.31      1.44 [0.53, 3.92]        
 Zeitoun 2003               7/23              11/24          7.32      0.52 [0.16, 1.71]        
 Combes 2000                4/50               9/54          7.78      0.43 [0.12, 1.51]        
 Deppe 1990                12/46              11/38          8.70      0.87 [0.33, 2.27]        
 Lee 2004                   2/32              14/38         11.72      0.11 [0.02, 0.55]        
 Lorente 2006 I            32/112             30/101        22.01      0.95 [0.52, 1.71]        
 Lorente 2005              42/144             41/164        26.53      1.24 [0.75, 2.04]        
Total (95% CI) 476                487 100.00      0.83 [0.62, 1.11]
Total events: 120 (Closed), 140 (Open)
Test for heterogeneity: Chi² = 14.59, df = 8 (P = 0.07), I² = 45.2%
Test for overall effect: Z = 1.27 (P = 0.21)
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Mortality 
In those studies with abstractable mortality data the choice of the suctioning system did not have 
an impact on mortality (OR = 0.90, 0.53 – 1.54) (Table 4). 
Figure 9: Airway Management: Closed vs. open endotracheal suctioning, mortality outcomes. 
Review: Airway Management
Comparison: 01 Closed vs. open endotracheal suctioning                                                                    
Outcome: 03 Mortality                                                                                                  
Study  Closed  Open  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Deppe 1990                12/46              11/38         31.19      0.87 [0.33, 2.27]        
 Topeli 2004               27/41              25/37         31.43      0.93 [0.36, 2.38]        
 Combes 2000               13/50              15/54         37.38      0.91 [0.38, 2.18]        
Total (95% CI) 137                129 100.00      0.90 [0.53, 1.54]
Total events: 52 (Closed), 51 (Open)
Test for heterogeneity: Chi² = 0.01, df = 2 (P = 0.99), I² = 0%
Test for overall effect: Z = 0.38 (P = 0.71)
 0.01  0.1  1  10  100
 Favours treatment  Favours control
 
Duration of MV/ Length of ICU stay 
In the two trials assessing the duration of MV, the time period was significantly increased with 
the closed suctioning technique (WMD = 0.68, 0.29 – 1.06) (Table 4). Although it should be 
noted that one of the two studies339 was weighted with 99.47%, hence resembling a large part of 
this outcome. 
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Results for the length of ICU stay were not significant. 
Table 4: Outcomes Airway Management: closed vs. open endotracheal suctioning 
Study ID Intervention Study 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Combes 
2000 
Closed vs. open endotracheal 
suctioning 
50/ 
54 
0.43 
[0.12, 1.51] 
0.91 
[0.38, 2.18] 
-3.60 
[-8.92, 1.72] 
-4.30 
[-10.10, 1.50] 
Deppe 
1990 
Closed vs. open endotracheal 
suctioning 
46/ 
38 
0.87 
[0.33, 2.27] 
0.87 
[0.33, 2.27] 
  
Johnson 
1994 
Closed vs. open endotracheal 
suctioning 
16/ 
19 
0.90 
[0.24, 3.41] 
   
Lee 
2004 
Closed vs. open endotracheal 
suctioning 
32/ 
38 
0.11 
[0.02, 0.55] 
  -13.10 
[-20.41, -5.79] 
Lorente 
2005 
Closed vs. open endotracheal 
suctioning 
144/ 
164 
1.24 
[0.75, 2.04] 
   
Lorente 
2006 I 
Closed vs. open endotracheal 
suctioning 
112/ 
101 
0.95 
[0.52, 1.71] 
   
Rabitsch 
2004 
Closed vs. open endotracheal 
suctioning 
12/ 
12 
0.05 
[0.00, 1.13] 
   
Topeli 
2004 
Closed vs. open endotracheal 
suctioning 
41/ 
37 
1.44 
[0.53, 3.92] 
0.93 
[0.36, 2.38] 
0.70 
[0.31, 1.09] 
0.80 
[0.24, 1.36] 
Zeitoun 
2003 
Closed vs. open endotracheal 
suctioning 
23/ 
24 
0.52 
[0.16, 1.71] 
   
Total:   0.83 
[0.62, 1.11] (f)  
0.90 
[0.53, 1.54] (f) 
0.68 
[0.29, 1.06] (f) 
-4.86 
[-12.59, 2.87] (r) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
d) Daily vs. no daily changes of in-line suction catheters 
Pneumonia 
Two trials studied the effects of a change of in-line (closed) suction catheters every 24 hours 
versus every 48 hours78 and versus no routine changes187. VAP rates were not significantly 
different between the groups (OR = 0.91, 0.59 – 1.40) (Figure 10) (Table 5). 
Figure 10: Airway Management: Daily vs. no daily changes of in-line suction catheters. 
Review: Airway Management
Comparison: 02 Daily vs. no daily changes of in-line suction catheters                                                    
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 daily vs. no routine changes
 Kollef 1997               39/263             38/258        74.70      1.01 [0.62, 1.64]        
Subtotal (95% CI) 263                258  74.70      1.01 [0.62, 1.64]
Total events: 39 (Treatment), 38 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
02 24hr vs. 48hr change
 Darvas 2003               10/53              13/48         25.30      0.63 [0.25, 1.60]        
Subtotal (95% CI) 53                 48  25.30      0.63 [0.25, 1.60]
Total events: 10 (Treatment), 13 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 316                306 100.00      0.91 [0.59, 1.40]
Total events: 49 (Treatment), 51 (Control)
Test for heterogeneity: Chi² = 0.78, df = 1 (P = 0.38), I² = 0%
Test for overall effect: Z = 0.42 (P = 0.67)
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Mortality 
The frequency of catheter changes had no impact on mortality rates (OR=0.94, 0.66-1.26) (Table 
5). 
Table 5: Outcomes Airway Management: daily vs. no daily changes of in-line suction catheters 
Study 
ID 
Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Kollef 
1997 
Daily 
vs. no routine change of suction 
catheters 
263/ 
258 
1.01 
[0.62, 1.64] 
0.92 
[0.62, 1.36] 
-0.30 
[-1.73, 1.13] 
0.10 
[-1.43, 1.63] 
       
Darvas 
2003 
Daily 
vs. 48-h change of suction catheters  
53/ 
48 
0.63 
[0.25, 1.60] 
1.04 
[0.45, 2.41] 
1.28 
[-2.09, 4.65] 
1.21 
[-3.26, 5.68] 
Total:   0.91 
[0.59, 1.40] (f) 
0.94 
[0.66, 1.34] (f) 
-0.06 
[-1.38, 1.26] (f) 
0.22 
[-1.23, 1.66] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
e) Heat and moisture exchanger (HME) vs. heated humidifier (HH) 
Pneumonia 
Eleven trials assessed the influence of different heat and moisture exchangers (HME) versus 
heated humidifiers (HH) on the development of pneumonia.42, 43, 95, 176, 217, 233, 238, 295 Since one 
trial42 contributed two comparisons to this group twelve data sets were evaluable. 
Neither the overall results, nor the subgroup results, revealed a significant difference in 
pneumonia rates in patients ventilated with a HME or HH (OR = 0.87, 0.69 – 1.11) (Figure 11) 
(Table 6).  
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Figure 11: Airway Management: Heat and moisture exchanger (HME) vs. heated humidifier (HH), 
pneumonia outcomes. 
Review: Airway Management
Comparison: 03 Heat and moisture exchanger (HME) vs. heated humidifier (HH)                                               
Outcome: 01 Pneumonia                                                                                                  
Study  HME  HH  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Hydrophobic HME vs. HH
 Martin 1990                2/31               8/42          4.33      0.29 [0.06, 1.49]        
 Roustan 1992               5/55               9/61          5.29      0.58 [0.18, 1.84]        
Subtotal (95% CI) 86                 103   9.62      0.45 [0.18, 1.14]
Total events: 7 (HME), 17 (HH)
Test for heterogeneity: Chi² = 0.45, df = 1 (P = 0.50), I² = 0%
Test for overall effect: Z = 1.68 (P = 0.09)
02 Hygroscopic HME vs. HH
 Boots 1997 A               3/21               7/41          2.77      0.81 [0.19, 3.51]        
 Dreyfuss 1995              6/61               8/70          4.58      0.85 [0.28, 2.59]        
 Memish 2001               14/123             19/120        11.61      0.68 [0.33, 1.43]        
Subtotal (95% CI) 205                231  18.96      0.74 [0.42, 1.31]
Total events: 23 (HME), 34 (HH)
Test for heterogeneity: Chi² = 0.11, df = 2 (P = 0.94), I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)
03 Hygroscopic HME vs. HH with heated wire circuits
 Lorente 2006 II           21/53               8/51          3.35      3.53 [1.39, 8.98]        
 Boots 2006 A              16/95              13/94          7.40      1.26 [0.57, 2.79]        
 Boots 2006 B              16/95              14/97          7.85      1.20 [0.55, 2.62]        
 Kirton 1997                9/140             22/140        14.03      0.37 [0.16, 0.83]        
 Lacherade 2005            47/185             53/184        27.01      0.84 [0.53, 1.33]        
Subtotal (95% CI) 568                566  59.64      0.98 [0.73, 1.32]
Total events: 109 (HME), 110 (HH)
Test for heterogeneity: Chi² = 13.83, df = 4 (P = 0.008), I² = 71.1%
Test for overall effect: Z = 0.13 (P = 0.90)
04 Hygroscopic condenser humidifier vs. HH with heated wire circuits
 Branson 1996 A             3/54               3/49          2.02      0.90 [0.17, 4.69]        
 Kollef 1998               15/163             15/147         9.76      0.89 [0.42, 1.89]        
Subtotal (95% CI) 217                196  11.78      0.89 [0.45, 1.77]
Total events: 18 (HME), 18 (HH)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 0.99), I² = 0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 1076               1096 100.00      0.87 [0.69, 1.11]
Total events: 157 (HME), 179 (HH)
Test for heterogeneity: Chi² = 17.04, df = 11 (P = 0.11), I² = 35.4%
Test for overall effect: Z = 1.11 (P = 0.27)
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Mortality 
Overall, there was no effect on mortality (OR = 1.03, 0.82 – 1.28). Three of the subgroups had 
no significant impact on mortality, while the second subgroup which compared a hygroscopic 
HME with a HH with non-heated wires, showed a significant increase of mortality in the HME 
group (OR = 1.56, 1.00 – 2.44) (Figure 12) (Table 6). 
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Figure 12: Airway Management: Heat and moisture exchanger (HME) vs. heated humidifier (HH), mortality 
outcomes. 
Review: Airway Management
Comparison: 03 Heat and moisture exchanger (HME) vs. heated humidifier (HH)                                               
Outcome: 03 Mortality                                                                                                  
Study  HME  HH  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 hygroscopic HME vs. HH
 Martin 1990                7/31              11/42          4.68      0.82 [0.28, 2.44]        
 Roustan 1992              10/55              15/61          7.53      0.68 [0.28, 1.68]        
Subtotal (95% CI) 86                 103  12.21      0.74 [0.37, 1.47]
Total events: 17 (HME), 26 (HH)
Test for heterogeneity: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%
Test for overall effect: Z = 0.87 (P = 0.38)
02 Hygroscopic HME vs. HH
 Boots 1997 A               3/21               4/41          1.50      1.54 [0.31, 7.63]        
 Dreyfuss 1995             17/61              12/70          5.21      1.87 [0.81, 4.31]        
 Memish 2001               40/123             30/120        13.26      1.45 [0.83, 2.53]        
Subtotal (95% CI) 205                231  19.97      1.56 [1.00, 2.44]
Total events: 60 (HME), 46 (HH)
Test for heterogeneity: Chi² = 0.25, df = 2 (P = 0.88), I² = 0%
Test for overall effect: Z = 1.96 (P = 0.05)
03 Hygroscopic HME vs. HH with heated wire circuits
 Boots 2006 A              18/95              15/94          7.91      1.23 [0.58, 2.62]        
 Boots 2006 B              19/95              24/97         12.29      0.76 [0.38, 1.50]        
 Lacherade 2005            60/185             63/184        27.61      0.92 [0.60, 1.42]        
Subtotal (95% CI) 375                375  47.80      0.93 [0.67, 1.29]
Total events: 97 (HME), 102 (HH)
Test for heterogeneity: Chi² = 0.87, df = 2 (P = 0.65), I² = 0%
Test for overall effect: Z = 0.42 (P = 0.67)
04 Hygroscopic condenser humidifier vs. HH with heated wire circuits
 Kollef 1998               40/163             39/147        20.02      0.90 [0.54, 1.50]        
Subtotal (95% CI) 163                147  20.02      0.90 [0.54, 1.50]
Total events: 40 (HME), 39 (HH)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 829                856 100.00      1.03 [0.82, 1.28]
Total events: 214 (HME), 213 (HH)
Test for heterogeneity: Chi² = 6.07, df = 8 (P = 0.64), I² = 0%
Test for overall effect: Z = 0.24 (P = 0.81)
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Table 6: Outcomes Airway Management: Heat and moisture exchanger (HME) vs. heated humidifier (HH) 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of 
MV 
WMD 
[95% CI] 
Length of 
ICU stay 
WMD 
[95% CI] 
Martin 
1990 
Hydrophobic HME 
vs. HH 
31/ 
42 
0.29 
[0.06, 1.49] 
0.82 
[0.28, 2.44] 
-3.80 
[-8.44, 0.84] 
 
Roustan 
1992 
Hydrophobic HME 
vs. HH 
55/ 
61 
0.58 
[0.18, 1.84] 
0.68 
[0.28, 1.68] 
2.70 
[-2.16, 7.56] 
4.60 
[-0.48, 9.68] 
Subtotal:   0.45 
[0.18, 1.14] (f) 
0.74 
[0.37, 1.47] (f) 
-0.70 
[-4.05, 2.66] (f) 
 
       
Boots 
1997 A 
Hygroscopic HME 
vs. HH 
21/ 
41 
0.81 
[0.19, 3.51] 
1.54 
[0.31, 7.63] 
  
Dreyfuss 
1995 
Hygroscopic HME 
vs. HH 
61/ 
70 
0.85 
[0.28, 2.59] 
1.87 
[0.81, 4.31] 
-2.50 
[-6.47, 1.47] 
 
Memish 
2001 
Hygroscopic HME 
vs. HH 
123/ 
120 
0.68 
[0.33, 1.42] 
1.45 
[0.83, 2.53] 
-1.60 
[-4.09, 0.89] 
 
Subtotal:   0.74 
[0.42, 1.31] (f) 
1.56 
[1.00, 2.44] (f) 
-1.85 
[-3.97, 0.26] (f) 
 
       
Lorente 
2006 II 
Hygroscopic HME 
vs. HH with heated wire circuits 
53/ 
51 
3.53 
[1.39, 8.98] 
 -1.35 
[-7.79, 5.09] 
 
Boots 
2006 A 
Hygroscopic HME 
vs. HH with heated wire circuits 
95/ 
94 
1.26 
[0.57, 2.79] 
1.23 
[0.58, 2.62] 
  
Boots 
2006 B 
Hygroscopic HME 
vs. HH with heated wire circuits 
95/ 
97 
1.20 
[0.55, 2.62] 
0.76 
[0.38, 1.50] 
  
Kirton 
1997 
Hygroscopic HME 
vs. HH with heated wire circuits 
140/ 
140 
0.37 
[0.16, 0.83] 
   
Lacherade 
2005 
Hygroscopic HME 
vs. HH with heated wire circuits 
185/ 
184 
0.84 
[0.53, 1.33] 
0.92 
[0.60, 1.42] 
-1.40 
[-4.61, 1.81] 
-3.90 
[-9.18, 1.38] 
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Subtotal:   0.98 
[0.73, 1.32] (f) 
0.93 
[0.67, 1.29] (f) 
-1.39 
[-4.26, 1.48] 
 
       
Branson 
1996 A 
Hygroscopic condenser humidifier 
vs. HH with heated wire circuits 
54/ 
49 
0.90 
[0.17, 4.69] 
 -0.40 
[-1.79, 0.99] 
 
Kollef 
1998 
Hygroscopic condenser humidifier 
vs. HH with heated wire circuits 
163/ 
147 
0.89 
[0.42, 1.89] 
0.90 
[0.54, 1.50] 
0.90 
[-0.21, 2.01] 
0.40 
[-0.85, 1.65] 
Subtotal:   0.89 
[0.45, 1.77] (f) 
 0.39 
[-0.47, 1.26] (f) 
 
 
      
Total:   0.87 
[0.69, 1.11] (f) 
1.03 
[0.82, 1.28] (f) 
-0.07 
[-0.82, 0.68] (f) 
0.41 
[-0.77, 1.59] 
(f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
f) Extended use of heat and moisture exchanger (HME) 
Pneumonia 
Two trials assessed the effect of the extended use of HME with a 5- or a 7-day change versus 
daily changes of HME, on pneumonia rates.81, 334 None of the results achieved statistical 
significance; however, the overall odds ratio was numerically less than one (OR = 0.55, 0.28 – 
1.09) (Figure 13) (Table 7). 
Figure 13: Airway Management: Extended use of heat and moisture exchanger, pneumonia outcomes. 
Review: Airway Management
Comparison: 04 Extended use of heat and moisture exchanger                                                                
Outcome: 01 Pneumonia                                                                                                  
Study  Extended use  Brief use  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 7-day vs. 1-day change
 Thomachot 2002            10/71              22/84         75.56      0.46 [0.20, 1.06]        
Subtotal (95% CI) 71                 84  75.56      0.46 [0.20, 1.06]
Total events: 10 (Extended use), 22 (Brief use)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.07)
02 5-day vs. 1-day change
 Davis 2000                 4/60               8/100        24.44      0.82 [0.24, 2.85]        
Subtotal (95% CI) 60                 100  24.44      0.82 [0.24, 2.85]
Total events: 4 (Extended use), 8 (Brief use)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 131                184 100.00      0.55 [0.28, 1.09]
Total events: 14 (Extended use), 30 (Brief use)
Test for heterogeneity: Chi² = 0.57, df = 1 (P = 0.45), I² = 0%
Test for overall effect: Z = 1.70 (P = 0.09)
 0.01  0.1  1  10  100
 Favours ext. use  Favours brief use
 
Mortality 
Mortality rates were not significantly influenced by an extended use of HME (Table 7). 
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Table 7: Outcomes Airway Management: Extended use of heat and moisture exchanger 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Davis 
2000 
5-day 
vs. 1-day HME change 
60/ 
100 
0.82 
[0.24, 2.85] 
 0.50 
[-0.43, 1.43] 
 
Thomachot 
2002 
7-day 
vs. 1-day HME change 
71/ 
84 
0.46 
[0.20, 1.06] 
1.38 
[0.71, 2.68] 
-0.90 
[-3.38, 1.58] 
0.70 
[-4.00, 5.40] 
Total:   0.55 
[0.28, 1.09] (f) 
 0.33 
[-0.55, 1.20] (f) 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
g) Components of heat and moisture exchanger (HME) 
Pneumonia 
Two different models of HME46 and HMEF335 and a hydrophobic versus a hygroscopic HMEF336 
were studied, but none of the compared VAP rates were significantly different (Figure 14) (Table 
8). Due to the heterogeneity of the components no overall estimate was calculated. 
Figure 14: Airway Management: Components of Heat and Moisture Exchanger, pneumonia outcomes. 
Review: Airway Management
Comparison: 05 Components of HME                                                                                          
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 CaCl2 Impregnated Paper vs. AlCl2 Impregnated Foam HMEF
 Thomachot 1999            24/77              21/63        100.00      0.91 [0.44, 1.85]        
02 hygroscopic vs. hydrophobic HMEF
 Thomachot 1998            21/66              26/70        100.00      0.79 [0.39, 1.61]        
03 2 models of hygroscopic HME
 Boyer 2003                 9/22               9/21        100.00      0.92 [0.27, 3.10]        
 0.01  0.1  1  10  100
 Favours treatment  Favours control
 
Mortality/ Duration of MV 
When data of mortality rates and the duration of MV was available, no significant impact on 
these outcomes was evident (Table 8). 
Table 8: Outcomes Airway Management: Components of heat and moisture exchanger (HME) 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Boyer 
2003 
2 models of hygroscopic HME 22/ 
21 
0.92 
[0.27, 3.10] 
 -2.00 
[-15.46, 11.46] 
 
Thomachot 
1998 
Hygroscopic 
vs. hydrophobic HME 
66/ 
70 
0.79 
[0.39, 1.61] 
0.97 
[0.39, 2.37] 
-0.50 
[-4.37, 3.37] 
 
Thomachot 
1999 
CaCl2- 
vs. AlCl2- filter HME 
77/ 
63 
0.91 
[0.44, 1.85] 
1.08 
[0.44, 2.65] 
-1.20 
[-3.65, 1.25] 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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h) Change of ventilator circuits 
Pneumonia 
The impact of different intervals of ventilator circuit changes on VAP rates was studied by six 
trials.43, 75, 96, 189, 214, 215 Due to the varying change intervals of the treatment and control groups 
we could not calculate a summary estimate. In the study comparing one- to two-day circuit 
changes, VAP rates were significantly lower in the group receiving two-day changes. None of the 
other compared pneumonia rates were significantly different (Figure 15) (Table 9). 
Figure 15: Airway Management: Change of ventilator circuits, pneumonia outcomes. 
Review: Airway Management
Comparison: 06 Change of ventilator circuits                                                                              
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 1- vs. 2-day change
 Craven 1986               31/106             18/127       100.00      2.50 [1.31, 4.80]        
02 2-day vs. no routine change
 Dreyfuss 1991             11/35               8/28         24.21      1.15 [0.39, 3.40]        
 Lorente 2004              33/143             37/161        75.79      1.01 [0.59, 1.72]        
03 2-day vs. 4-day change
 Boots 1997 B               3/21               8/33        100.00      0.52 [0.12, 2.24]        
04 3- vs. 7-day change
 Long 1996                 27/213             26/234       100.00      1.16 [0.65, 2.06]        
05 7-day vs. no routine change
 Kollef 1995               44/153             36/147       100.00      1.24 [0.74, 2.08]        
 0.01  0.1  1  10  100
 Favours treatment  Favours control
 
Mortality 
None of the trials demonstrated a significant difference in mortality rates (Figure 16) (Table 9). 
Figure 16: Airway Management: Change of ventilator circuits, mortality outcomes. 
Review: Airway Management
Comparison: 06 Change of ventilator circuits                                                                              
Outcome: 03 Mortality                                                                                                  
Study  Treatment  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 2-day vs. no routine change
 Dreyfuss 1991              6/35               7/28         24.93      0.62 [0.18, 2.12]        
 Lorente 2004              52/143             46/161        75.07      1.43 [0.88, 2.31]        
02 2-day vs. 4-day change
 Boots 1997 B               3/21               7/33        100.00      0.62 [0.14, 2.72]        
03 7-day vs. no routine change
 Kollef 1995               50/153             61/147       100.00      0.68 [0.43, 1.10]        
 0.01  0.1  1  10  100
 Favours treatment  Favours control
 
Table 9: Outcomes Airway Management: Change of ventilator circuits 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Craven 
1986 
1-day 
vs. no routine change 
of ventilator circuits 
106/ 
127 
2.5 
[1.31, 4.80] 
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Dreyfuss 
1991 
2-day 
vs. no routine change 
of ventilator circuits 
35/ 
28 
1.15 
[0.39, 3.40] 
0.62 
[0.18, 2.12] 
2.80 
[-1.41, 7.01] 
 
Lorente 
2004 
2-day 
vs. no routine change 
of ventilator circuits 
143/ 
161 
1.01 
[0.59, 1.72] 
1.43 
[0.88, 2.31] 
-3.50 
[-7.64, 0.64] 
 
Boots 
1997 B 
2-day 
vs. 4-day change 
21/ 
33 
0.52 
[0.12, 2.24] 
0.62 
[0.14, 2.72] 
  
Long 
1996 
3-day 
vs. 7-day change 
213/ 
234 
1.16 
[0.65, 2.06] 
   
Kollef 
1995 
7-day 
vs. no routine change 
153/ 
147 
1.24 
[0.74, 2.08] 
0.68 
[0.43, 1.10] 
1.60 
[-1.46, 4.66] 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
i) Heated vs. non-heated wire circuits 
Pneumonia 
Results were not significantly different in a subgroup of a trial, assessing whether the use of 
heated or non-heated wire circuits had an impact on pneumonia rates (OR = 1.68, 0.51 – 5.55) 
(Table 10).47 
Table 10: Outcomes Airway Management: Heated vs. non-heated wire circuits 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Branson 
1996 B 
Heated 
vs. non-heated wire 
circuits 
49/ 
48 
1.68 
[0.51, 5.55] 
 1.90 
[-1.28, 5.08] 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
j) Oro- vs. nasotracheal intubation 
Pneumonia/ Mortality 
One large trial compared oro- with nasotracheal intubation in order to reduce contamination of 
tracheal secretions with bacteria from the nares.158 Results for VAP were not statistically 
significant, although the odds ratio was numerically less than one (0.49, 0.21 – 1.14) (Table 11). 
Differences in mortality rates were not significant, either (OR = 1.19, 0.75 – 1.89). 
Table 11: Outcomes Airway Management: Oro- vs. nasotracheal intubation 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Holzapfel 
1993 
Oro- 
vs. nasotracheal 
intubation  
151/ 
149 
0.49 
[0.21, 1.14] 
1.19 
[0.75, 1.89] 
 -1.50 
[-4.48, 1.48] 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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k) Bacterial filter 
Pneumonia/ Mortality 
In a trial assessing the impact of a bacterial filter in the ventilator circuits neither the incidence of 
pneumonia nor mortality rates were significantly altered (Table 12).219  
Table 12: Outcomes Airway Management: Bacterial filter 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of 
MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Lorente 
2003 
Bacterial filter 114/ 
116 
1.19 
[0.64, 2.19] 
1.51 
[0.85, 2.69] 
-1.16 
[-5.38, 3.06] 
-2.03 
[-6.51, 2.45] 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
3.6. Gastrointestinal interventions  
a) Selective decontamination of the digestive tract (SDD) 
Pneumonia 
Twenty-seven trials studying the effects of different regimens of selective decontamination of the 
digestive tract (SDD) met our inclusion criteria. There are different ways and agents used to 
implement SDD, represented by the four subgroups of our analysis. Topical antibiotic and 
antimycotic agents, normally including polymyxin E, tobramycin or amphotericin B, can be 
applied topically to the oropharynx alone, or additionally to the gastrointestinal (GI) tract. 
Systemic antibiotics can supplement the topical treatments. 
With all of the subgroups showing a significant reduction of pneumonia rates, the overall 
outcome emphasizes the evidence of that effect of SDD (OR = 0.32, 0.24 – 0.44) (Figure 17) 
(Table 13). 
The first subgroup, containing four trials reached a statistically significant effect by 
administering topical agents to the oropharynx only, without performing systemic prophylaxis 
(OR=0.19, 0.04-0.82). 27, 277, 288, 290 
The second subgroup, including twelve trials50, 111, 124, 140, 196, 206, 211, 279, 304, 356, 367, 377, with two 
trials50, 367 contributing two comparisons each, applied topical agents to the oropharynx and the 
GI without adminsitering systemic prophylaxis (OR=0.52, 0.41-0.66). 
The SDD-regimen of the trial of the third subgroup consisted of the application of topical agents 
to the oropharynx only and the administration of systemic antibiotics (OR=0.09, 0.03-0.25).4 
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The nine trials and one subgroup of a trial comprised the fourth subgroup. Their regimen 
consisted of topical antibiotic and antimycotic agents applied to the oropharynx and the GI tract 
with the administration of systemic antibiotics (OR=0.18, 011-0.31).8, 31, 113, 139, 173, 200, 264, 289, 304, 
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Figure 17: Gastrointestinal Interventions: SDD, pneumonia outcomes 
Review: Gastrointestinal Interventions
Comparison: 01 SDD                                                                                                        
Outcome: 01 Pneumonia                                                                                                  
Study  SDD  Control  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 SDD, topical (oral only)
 Rodriguez-Roldan1990        0/13              11/15          0.85      0.01 [0.00, 0.30]        
 Pugin 1991                 4/25              21/27          2.54      0.05 [0.01, 0.22]        
 Rios 2005                 17/47              17/49          3.92      1.07 [0.46, 2.46]        
 Bergmans 2001              9/87              38/139         4.07      0.31 [0.14, 0.67]        
Subtotal (95% CI) 172                230  11.38      0.19 [0.04, 0.82]
Total events: 30 (SDD), 87 (Control)
Test for heterogeneity: Chi² = 18.13, df = 3 (P = 0.0004), I² = 83.5%
Test for overall effect: Z = 2.22 (P = 0.03)
02 SDD, topical (oral+GI)
 Unertl 1987                1/19               9/20          1.42      0.07 [0.01, 0.61]        
 Wiener 1995                8/30               8/31          3.12      1.05 [0.33, 3.27]        
 Ferrer 1994                7/39              10/41          3.26      0.68 [0.23, 2.01]        
 Hammond 1992               8/114              8/125         3.44      1.10 [0.40, 3.04]        
 Langlois-Karaga 1995       14/47              28/50          3.92      0.33 [0.14, 0.77]        
 Camus 2005 B              10/129             24/130         4.07      0.37 [0.17, 0.81]        
 Korinek 1993              15/63              25/60          4.10      0.44 [0.20, 0.95]        
 SanchezGarcia 1998 A       11/96              28/101         4.13      0.34 [0.16, 0.72]        
 Quinio 1996               19/76              37/72          4.32      0.32 [0.16, 0.63]        
 Camus 2005 A              15/130             30/126         4.38      0.42 [0.21, 0.82]        
 Verwaest 1997 A           22/193             20/93          4.41      0.47 [0.24, 0.91]        
 Verwaest 1997 B           31/200             20/92          4.52      0.66 [0.35, 1.24]        
 Gastinne 1992             26/220             33/225         4.72      0.78 [0.45, 1.35]        
 Lingnau 1997              57/162             61/148         4.96      0.77 [0.49, 1.23]        
Subtotal (95% CI) 1518               1314  54.75      0.52 [0.41, 0.66]
Total events: 244 (SDD), 341 (Control)
Test for heterogeneity: Chi² = 18.19, df = 13 (P = 0.15), I² = 28.5%
Test for overall effect: Z = 5.30 (P < 0.00001)
03 SDD, topical (oral only) + systemic
 Abele-Horn 1997           13/58              23/30          3.35      0.09 [0.03, 0.25]        
Subtotal (95% CI) 58                 30   3.35      0.09 [0.03, 0.25]
Total events: 13 (SDD), 23 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
04 SDD, topical (oral+GI) +systemic
 Aerdts 1990                1/17              27/39          1.48      0.03 [0.00, 0.23]        
 Hammond 1995               1/59               7/76          1.49      0.17 [0.02, 1.42]        
 Finch 1991                 4/20               7/24          2.54      0.61 [0.15, 2.48]        
 SanchezGarcia 1998 B        4/35              13/39          2.90      0.26 [0.07, 0.89]        
 Kerver 1988                6/49              40/47          3.04      0.02 [0.01, 0.08]        
 Palomar 1997               7/41              21/42          3.44      0.21 [0.07, 0.57]        
 Rocha 1992                 7/47              25/54          3.57      0.20 [0.08, 0.53]        
 Blair 1991                 6/124             23/131         3.65      0.24 [0.09, 0.61]        
 Krueger 2002               6/265             29/262         3.75      0.19 [0.08, 0.46]        
 Stoutenbeek 2007          19/201             46/200         4.66      0.35 [0.20, 0.62]        
Subtotal (95% CI) 858                914  30.51      0.18 [0.11, 0.31]
Total events: 61 (SDD), 238 (Control)
Test for heterogeneity: Chi² = 21.97, df = 9 (P = 0.009), I² = 59.0%
Test for overall effect: Z = 6.15 (P < 0.00001)
Total (95% CI) 2606               2488 100.00      0.32 [0.24, 0.44]
Total events: 348 (SDD), 689 (Control)
Test for heterogeneity: Chi² = 90.96, df = 28 (P < 0.00001), I² = 69.2%
Test for overall effect: Z = 7.32 (P < 0.00001)
 0.01  0.1  1  10  100
 Favours SDD  Favours control
 
Mortality 
From all but two trials mortality data was abstractable (Table 13) (Figure 18). 
The only subgroup with a significant reduction of mortality rates was the fourth, administering 
topical agents orally and to the GI plus systemic prophylaxis (OR = 0.80, 0.64 – 0.98). 
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The result of the first subgroup was not significant, although the odds ratio was numerically less 
than one (OR = 0.79, 0.52 – 1.20). 
With the data available there was no evidence for an effect in the the second and third subgroup 
(OR = 0.95, 0.80 – 1.14) (OR = 1.17, 0.37 – 3.74). 
With p=0.06 the overall outcome failed to reach statistical significance, although the odds ratio 
was numerically less than one (OR = 0.88, 0.77 – 1.00). 
Figure 18: Gastrointestinal Interventions: SDD, mortality outcomes 
Review: Gastrointestinal Interventions
Comparison: 01 SDD                                                                                                        
Outcome: 02 Mortality                                                                                                  
Study  SDD  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 SDD, topical (oral only)
 Rodriguez-Roldan1990        4/13               5/15          0.66      0.89 [0.18, 4.37]        
 Pugin 1991                 7/25               7/27          1.00      1.11 [0.33, 3.79]        
 Rios 2005                 18/47              21/49          2.62      0.83 [0.37, 1.87]        
 Bergmans 2001             30/87              59/139         6.14      0.71 [0.41, 1.24]        
Subtotal (95% CI) 172                230  10.42      0.79 [0.52, 1.20]
Total events: 59 (SDD), 92 (Control)
Test for heterogeneity: Chi² = 0.46, df = 3 (P = 0.93), I² = 0%
Test for overall effect: Z = 1.11 (P = 0.27)
02 SDD, topical (oral+GI)
 Unertl 1987                5/19               6/20          0.89      0.83 [0.21, 3.38]        
 Ferrer 1994               12/39              11/41          1.53      1.21 [0.46, 3.20]        
 Quinio 1996               13/76              10/72          1.76      1.28 [0.52, 3.13]        
 Wiener 1995               11/30              15/31          1.93      0.62 [0.22, 1.72]        
 Korinek 1993               8/63              11/60          2.03      0.65 [0.24, 1.74]        
 Lingnau 1997              19/162             16/148         3.05      1.10 [0.54, 2.22]        
 Hammond 1992              21/114             21/125         3.37      1.12 [0.57, 2.18]        
 Verwaest 1997 B           31/200             15/92          3.58      0.94 [0.48, 1.85]        
 Verwaest 1997 A           34/193             16/93          3.67      1.03 [0.54, 1.98]        
 SanchezGarcia 1998 A       41/96              47/101         5.42      0.86 [0.49, 1.50]        
 Camus 2005 B              28/129             36/130         5.79      0.72 [0.41, 1.28]        
 Camus 2005 A              39/130             41/126         6.02      0.89 [0.52, 1.51]        
 Gastinne 1992             82/220             76/225         9.73      1.16 [0.79, 1.72]        
Subtotal (95% CI) 1471               1264  48.76      0.97 [0.81, 1.16]
Total events: 344 (SDD), 321 (Control)
Test for heterogeneity: Chi² = 4.50, df = 12 (P = 0.97), I² = 0%
Test for overall effect: Z = 0.37 (P = 0.71)
03 SDD, topical (oral only) + systemic
 Abele-Horn 1997           11/58               5/30          1.10      1.17 [0.37, 3.74]        
Subtotal (95% CI) 58                 30   1.10      1.17 [0.37, 3.74]
Total events: 11 (SDD), 5 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
04 SDD, topical (oral+GI) + systemic
 Finch 1991                15/20              10/24          0.47      4.20 [1.15, 15.37]       
 Aerdts 1990                2/17               6/39          0.66      0.73 [0.13, 4.07]        
 Palomar 1997              10/41              13/42          2.00      0.72 [0.27, 1.89]        
 Kerver 1988               14/49              15/47          2.26      0.85 [0.36, 2.04]        
 Hammond 1995              10/59              17/76          2.55      0.71 [0.30, 1.69]        
 SanchezGarcia 1998 B       10/35              19/39          2.65      0.42 [0.16, 1.11]        
 Rocha 1992                10/47              24/54          3.63      0.34 [0.14, 0.82]        
 Blair 1991                17/126             22/130         3.87      0.77 [0.39, 1.52]        
 Stoutenbeek 2007          42/201             44/200         7.20      0.94 [0.58, 1.51]        
 Krueger 2002             102/265            113/262        14.43      0.83 [0.58, 1.17]        
Subtotal (95% CI) 860                913  39.71      0.80 [0.64, 0.98]
Total events: 232 (SDD), 283 (Control)
Test for heterogeneity: Chi² = 12.27, df = 9 (P = 0.20), I² = 26.6%
Test for overall effect: Z = 2.12 (P = 0.03)
Total (95% CI) 2561               2437 100.00      0.88 [0.77, 1.00]
Total events: 646 (SDD), 701 (Control)
Test for heterogeneity: Chi² = 19.61, df = 27 (P = 0.85), I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)
 0.01  0.1  1  10  100
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Duration of MV 
Evaluating the results of the eight trials assessing the duration of MV, an adverse effect in terms 
of an increase of the duration of MV was observed (WMD = 0.46, 0.04 – 0.89) (Table 13). 
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This is mainly due to the second subgroup (WMD = 0.56, 0.13 – 1.00) where one large trial with 
an assigned weight of 89.62% had a big impact on this outcome.211  
The results of subgroups one, three, and four were not significant. 
Length of ICU stay 
The length of ICU stay, assessed by eleven trials, could be significantly reduced by SDD (WMD 
= -0.53, -0.89 - -0.16). 
However, only the results of the second and the third subgroup complied with this overall 
estimate, whereas subgroups one and four failed to show an effect (Table 13). 
Table 13: Outcomes Gastrointestinal Interventions: Selective decontamination of the digestive tract (SDD) 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Bergmans 
2001 
SDD, topical 
(oral only) 
87/ 
139 
0.31 
[0.14, 0.67] 
0.71 
[0.41, 1.24] 
  
Pugin 
1991 
SDD, topical 
(oral only) 
25/ 
27 
0.05 
[0.01, 0.22] 
1.11 
[0.33, 3.79] 
-1.10 
[-4.62, 2.42] 
-1.90 
[-5.87, 2.07] 
Rios 
2005 
SDD, topical 
(oral only) 
47/ 
49 
1.07 
[0.46, 2.46] 
0.83 
[0.37, 1.87] 
-4.00 
[-9.94, 1.94] 
3.00 
[-3.64, 9.64] 
Rodriguez-
Roldan 
1990 
SDD, topical 
(oral only) 
13/ 
15 
0.01 
[0.00, 0.30] 
0.89 
[0.18, 4.37] 
  
Subtotal:   0.19 
[0.04, 0.82] (r) 
0.79 
[0.52, 1.20] (f) 
-1.85 
[-4.88, 1.17] (f) 
-0.61 
[-4.02, 2.80] (f) 
       
Camus 
2005 A 
SDD, topical 
(oral+GI) 
130/ 
126 
0.42 
[0.21, 0.82] 
0.89 
[0.52, 1.51] 
  
Camus 
2005 B 
SDD, topical 
(oral+GI) 
129/ 
130 
0.37 
[0.17, 0.81] 
0.72 
[0.41, 1.28] 
  
Ferrer 
1994 
SDD, topical 
(oral+GI) 
39/ 
41 
0.68 
[0.23, 2.01] 
1.21 
[0.46, 3.20] 
0.90 
[-3.41, 2.61] 
1.00 
[-2.85, 4.85] 
Gastinne 
1992 
SDD, topical 
(oral+GI) 
220/ 
225 
0.78 
[0.45, 1.35] 
1.16 
[0.79, 1.72] 
 -1.00 
[-4.27, 2.27] 
Hammond 
1992 
SDD, topical 
(oral+GI) 
114/ 
125 
1.10 
[0.40, 3.04] 
1.12 
[0.57, 2.18] 
 -0.60 
[-4.00, 2.80] 
Korinek 
1993 
SDD, topical 
(oral+GI) 
63/ 
60 
0.44 
[0.20, 0.95] 
0.65 
[0.24, 1.74] 
-0.40 [-3.41, 2.61] -1.20 
[-7.07, 4.67] 
Langlois-
Karaga 
1995 
SDD, topical 
(oral+GI) 
47/ 
50 
0.33 
[0.14, 0.77] 
   
Lingnau 
1997 
SDD, topical 
(oral+GI) 
162/ 
148 
0.77 
[0.49, 1.23] 
1.10 
[0.54, 2.22] 
0.60 
[0.15, 1.05] 
-0.50 
[-0.88, -0.12] 
Quinio 
1996 
SDD, topical 
(oral+GI) 
76/ 
72 
0.32 
[0.16, 0.63] 
1.28 
[0.52, 3.13] 
-0.30 
[-3.07, 2.47] 
0.30 
[-3.99, 4.59] 
Sanchez Garcia 
1998 A 
SDD, topical 
(oral+GI) 
96/ 
101 
0.34 
[0.16, 0.72] 
0.86 
[0.49, 1.50] 
  
Unertl 
1987 
SDD, topical 
(oral+GI) 
19/ 
20 
0.07 
[0.01, 0.61] 
0.83 
[0.21, 3.38] 
  
Verwaest 
1997 A 
SDD, topical 
(oral+GI) 
193/ 
93 
0.47 
[0.24, 0.91] 
1.03 
[0.54, 1.98] 
  
Verwaest 
1997 B 
SDD, topical 
(oral+GI) 
200/ 
92 
0.66 
[0.35, 1.24] 
0.94 
[0.48, 1.85] 
  
Wiener 
1995 
SDD, topical 
(oral+GI) 
30/ 
31 
1.05 
[0.33, 3.27] 
0.62 
[0.22, 1.72] 
  
Subtotal:   0.52 
[0.41, 0.66] (r) 
0.97 
[0.81, 1.16] (f) 
0.56 
[0.13, 1.00] (f) 
-0.49 
[-0.86, -0.12] (f) 
       
Abele-Horn 
1997 
SDD, topical 
(oral only) + 
systemic 
58/ 
30 
0.09 
[0.03, 0.25] 
1.17 
[0.37, 3.74] 
-1.70 
[-4.67, 1.27] 
-4.00 
[-7.73, -0.27] 
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Aerdts 
1990 
SDD, topical 
(oral+GI) + 
systemic 
17/ 
39 
0.03 
[0.00, 0.23] 
0.73 
[0.13, 4.07] 
  
Blair 
1991 
SDD, topical 
(oral+GI) + 
systemic 
124/ 
131 
0.24 
[0.09, 0.61] 
0.77 
[0.39, 1.52] 
  
Finch 
1991 
SDD, topical 
(oral+GI) + 
systemic 
20/ 
24 
0.61 
[0.15, 2.48] 
4.20 
[1.15, 15.37] 
  
Hammond 
1995 
SDD, topical 
(oral+GI) + 
systemic 
59/ 
76 
0.17 
[0.02, 1.42] 
0.71 
[0.30, 1.69] 
 -1.30 
[-6.34, 3.74] 
Kerver 
1988 
SDD, topical 
(oral+GI) + 
systemic 
49/ 
47 
0.02 
[0.01, 0.08] 
0.85 
[0.36, 2.04] 
  
Krueger 
2002 
SDD, topical 
(oral+GI) + 
systemic 
265/ 
262 
0.19 
[0.08, 0.46] 
0.94 
[0.58, 1.17] 
  
Palomar 
1997 
SDD, topical 
(oral+GI) + 
systemic 
41/ 
42 
0.21 
[0.07, 0.57] 
0.72 
[0.27, 1.89] 
  
Rocha 
1992 
SDD, topical 
(oral+GI) + 
systemic 
47/ 
54 
0.20 
[0.08, 0.53] 
0.34 
[0.14, 0.82] 
-0.10 
[-5.01, 4.81] 
1.00 
[-5.98, 7.98] 
Sanchez Garcia 
1998 B 
SDD, topical 
(oral+GI) + 
systemic 
35/ 
39 
0.26 
[0.07, 0.89] 
0.42 
[0.16, 1.11] 
  
Stoutenbeek 
2007 
SDD, topical 
(oral+GI) + 
systemic 
201/ 
200 
0.35 
[0.20, 0.62] 
0.94 
[0.58, 1.51] 
  
Subtotal:   0.18 
[0.11, 0.31] (r) 
0.80 
[0.64, 0.98] (f) 
 -0.51 [-4.60, 3.57] 
       
Total:   0.32 
[0.24, 0.44] (r) 
0.88 
[0.77, 1.00] (f) 
0.46 
[0.04, 0.89] (f) 
-0.53 
[-0.89, -0.16] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
b) Selective decontamination of the digestive tract (SDD) with additional topical 
antibiotics 
Pneumonia 
Three trials compared the application of either topical gentamicin194, 204 or mupirocin250 in 
addition to a SDD regimen, of which only the study adding mupirocin could show a significant 
reduction of pneumonia rates (OR=0.32, 0.16-0.62) (Table 14). 
Mortality 
There was no evidence for an effect on mortality rates (Table 14). 
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Table 14: Outcomes Gastrointestinal Interventions: SDD with additional topical agents 
Study ID Intervention Treatment/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Konrad 
1991 
Additional 
gentamicin vs. 
SDD: topical 
(oral+GI) + 
systemic 
20/ 
20 
1.00 
[0.13, 7.89] 
1.00 
[0.24, 4.18] 
  
Laggner 
1994 
Additional 
gentamicin vs. 
SDD: topical 
(oral only) 
33/ 
34 
0.23 
[0.02, 2.22] 
0.54 
[0.19, 1.50] 
-4.10 
[-17.26, 9.06] 
-6.60 
[-30.21, 17.01] 
Nardi 
2001 
Additional 
mupirocin vs. 
SDD: topical 
(oral+GI) 
119/ 
104 
0.32 
[0.16, 0.62] 
0.80 
[0.43, 1.49] 
-1.80 
[-4.67, 1.07] 
-1.20 
[-4.04, 1.64] 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
c) Interventions to reduce the bacterial reflux load 
Pneumonia 
Sucralfate vs. H2-antagonists 
Fourteen trials compared the administration of sucralfate versus H2-anatgonists for stress ulcer 
prophylaxis.66, 71, 99, 101, 106, 169, 170, 203, 270, 276, 299, 323, 337, 352 Herein the objective was to keep 
stomach pH-levels low with sucralfate thereby reducing the bacterial reflux load of potential 
aspiration contents. 
The incidence of pneumonia could be significantly reduced by administering sucralfate as 
opposed to H2-antagonists (OR = 0.77, 0.64 – 0.93) (Figure 19). 
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Figure 19: Gastrointestinal Interventions: Interventions to reduce the bacterial reflux load, pneumonia 
outcomes 
Review: Gastrointestinal Interventions
Comparison: 03 Interventions to reduce the bacterial reflux load                                                          
Outcome: 01 Pneumonia                                                                                                  
Study  Load reduction  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Sucralfate vs. H2-Antagonists
 Stoehr 1998 A              1/16               1/34          0.14      2.20 [0.13, 37.59]       
 Driks 1987 B               2/21               1/17          0.23      1.68 [0.14, 20.33]       
 Laggner 1989               0/16               2/16          0.57      0.18 [0.01, 3.97]        
 Pickworth 1993             6/39               5/44          0.93      1.42 [0.40, 5.07]        
 Ryan 1993                  8/58               7/56          1.43      1.12 [0.38, 3.33]        
 Kantorova 2004             6/69               7/71          1.47      0.87 [0.28, 2.74]        
 Eddleston 1991             3/30              10/30          2.10      0.22 [0.05, 0.91]        
 Thomason 1996 A           15/40              27/80          2.62      1.18 [0.53, 2.60]        
 Prod'hom 1994 A            5/42              21/80          2.97      0.38 [0.13, 1.09]        
 Tsiotras 1993              8/50              17/50          3.33      0.37 [0.14, 0.96]        
 Colardyn 1990             21/56              24/57          3.46      0.83 [0.39, 1.75]        
 Kappstein 1991            13/49              25/55          4.03      0.43 [0.19, 0.99]        
 Fabian 1993               29/99              52/179         6.10      1.01 [0.59, 1.74]        
 Cook 1998                120/604            140/596        26.31      0.81 [0.61, 1.06]        
Subtotal (95% CI) 1189               1365  55.69      0.77 [0.64, 0.93]
Total events: 237 (Load reduction), 339 (Control)
Test for heterogeneity: Chi² = 14.19, df = 13 (P = 0.36), I² = 8.4%
Test for overall effect: Z = 2.66 (P = 0.008)
02 Sucralfate vs. Antacids
 Driks 1987 A               2/20               9/39          1.28      0.37 [0.07, 1.91]        
 Tryba 1987                 3/29              11/32          2.18      0.22 [0.05, 0.89]        
 Prod'hom 1994 B            5/41              18/81          2.48      0.49 [0.17, 1.42]        
 Bonten 1995               15/67              16/74          2.75      1.05 [0.47, 2.32]        
 Thomason 1996 B           15/40              30/82          2.86      1.04 [0.48, 2.27]        
 Mahul 1992 A              13/73              17/72          3.28      0.70 [0.31, 1.57]        
Subtotal (95% CI) 270                380  14.83      0.70 [0.47, 1.02]
Total events: 53 (Load reduction), 101 (Control)
Test for heterogeneity: Chi² = 5.61, df = 5 (P = 0.35), I² = 10.8%
Test for overall effect: Z = 1.85 (P = 0.06)
03 Sucralfate vs. placebo
 Eddleston 1994             1/14               0/12          0.11      2.78 [0.10, 74.70]       
Subtotal (95% CI) 14                 12   0.11      2.78 [0.10, 74.70]
Total events: 1 (Load reduction), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
04 Sucralfate vs. H2-Antagonists+Antacids
 Driks 1987 C               1/20               6/13          1.61      0.06 [0.01, 0.60]        
 Sirvent 1994               9/26              11/25          1.71      0.67 [0.22, 2.09]        
 Maier 1994                10/47              14/51          2.46      0.71 [0.28, 1.81]        
Subtotal (95% CI) 93                 89   5.78      0.52 [0.27, 1.01]
Total events: 20 (Load reduction), 31 (Control)
Test for heterogeneity: Chi² = 4.00, df = 2 (P = 0.14), I² = 50.0%
Test for overall effect: Z = 1.94 (P = 0.05)
05 No Treatment vs. H2-Antagonists+Antacids
 Holzapfel 1990             8/67               5/61          1.07      1.52 [0.47, 4.92]        
Subtotal (95% CI) 67                 61   1.07      1.52 [0.47, 4.92]
Total events: 8 (Load reduction), 5 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
06 Placebo vs. Pirenzepine
 Hanisch 1998 A             6/28              10/44          1.42      0.93 [0.29, 2.92]        
Subtotal (95% CI) 28                 44   1.42      0.93 [0.29, 2.92]
Total events: 6 (Load reduction), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
07 Placebo vs. H2-Antagonists
 Hanisch 1998 B             6/29              10/57          1.25      1.23 [0.40, 3.79]        
Subtotal (95% CI) 29                 57   1.25      1.23 [0.40, 3.79]
Total events: 6 (Load reduction), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
08 Acidified Enteral Feeds
 Tulaimat 2005              3/16               1/13          0.21      2.77 [0.25, 30.38]       
 Heyland 1999               3/49               7/46          1.58      0.36 [0.09, 1.50]        
Subtotal (95% CI) 65                 59   1.79      0.64 [0.21, 1.98]
Total events: 6 (Load reduction), 8 (Control)
Test for heterogeneity: Chi² = 2.05, df = 1 (P = 0.15), I² = 51.2%
Test for overall effect: Z = 0.77 (P = 0.44)
09 Early Gastrostomy
 Kostadima 2005             2/20               8/21          1.64      0.18 [0.03, 0.99]        
Subtotal (95% CI) 20                 21   1.64      0.18 [0.03, 0.99]
Total events: 2 (Load reduction), 8 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.05)
10 Small Intestinal vs. Gastric Feeding
 Kearns 2000                4/21               3/23          0.54      1.57 [0.31, 8.01]        
 Montecalvo 1992            0/19               2/19          0.57      0.18 [0.01, 4.00]        
 Kortbeek 1999             10/37              18/43          2.83      0.51 [0.20, 1.32]        
Subtotal (95% CI) 77                 85   3.94      0.61 [0.28, 1.32]
Total events: 14 (Load reduction), 23 (Control)
Test for heterogeneity: Chi² = 2.01, df = 2 (P = 0.37), I² = 0.5%
Test for overall effect: Z = 1.26 (P = 0.21)
11 Intermittent Enteral Feeding
 Skiest 1996                0/9                0/7                 Not estimable         
 Bonten 1996                5/30               5/30          0.97      1.00 [0.26, 3.89]        
 Tamowicz 2007              4/20               7/20          1.30      0.46 [0.11, 1.94]        
 MacLeod 2007              38/79              33/81          3.94      1.35 [0.72, 2.52]        
Subtotal (95% CI) 138                138   6.22      1.11 [0.66, 1.87]
Total events: 47 (Load reduction), 45 (Control)
Test for heterogeneity: Chi² = 1.82, df = 2 (P = 0.40), I² = 0%
Test for overall effect: Z = 0.39 (P = 0.70)
12 Enteral Naloxone
 Meissner 2003             13/38              24/43          3.45      0.41 [0.17, 1.01]        
Subtotal (95% CI) 38                 43   3.45      0.41 [0.17, 1.01]
Total events: 13 (Load reduction), 24 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.05)
13 Enteral Metoclopramide
 Yavagal 2000              17/58              20/78          2.81      1.20 [0.56, 2.57]        
Subtotal (95% CI) 58                 78   2.81      1.20 [0.56, 2.57]
Total events: 17 (Load reduction), 20 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 2086               2432 100.00      0.77 [0.66, 0.88]
Total events: 430 (Load reduction), 624 (Control)
Test for heterogeneity: Chi² = 41.45, df = 37 (P = 0.28), I² = 10.7%
Test for overall effect: Z = 3.64 (P = 0.0003)
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Sucralfate vs. antacids 
The six trials comparing sucralfate versus antacids for stress ulcer prophylaxis failed to show a 
significant reduction of pneumonia rates, although the odds ratio was numerically less than one 
(OR = 0.70, 0.47 – 1.02) (Figure 19).40, 99, 227, 276, 337, 346 
Other interventions 
Of the other interventions attempting to reduce the bacterial reflux load by keeping the gastric 
pH low, only early gastrostomy (OR = 0.18, 0.03 – 0.99) could show a significant reduction in 
pneumonia rates (Figure 19).198 
With the confidence interval extending to 1.01 the intervention of sucralfate as opposed to H2-
antagonists in combination with antacids99, 228, 316 (OR = 0.52, 0.27 – 1.01), and the 
administration of enteral naloxone237 in order to fasten emptying of the stomach (OR = 0.41, 
0.17 – 1.01) just failed statistical significance. 
The remaining interventions, sucralfate vs. placebo100, no treatment vs. H2-antagonists plus 
antacids159, placebo vs. pirenzepine141, placebo vs. H2-antagonists141, acidification of enteral 
feeds151, 353, small intestinal vs. gastric feeding171, 197, 244, intermittent enteral feeding41, 224, 317, 332, 
and enteral metoclopramide381 also failed to show a significant effect. 
Overall, the attempt to reduce the bacterial reflux load decreased pneumonia-rates significantly 
(OR = 0.75, 0.65 – 0.87) (Figure 19). 
Mortality 
Sucralfate vs. H2-antagonists 
There was no effect on mortality rates in this reference group (OR = 0.97, 0.80 – 1.17) (Figure 
20). 
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Figure 20: Gastrointestinal Interventions: Interventions to reduce the bacterial reflux load, mortality 
outcomes 
Review: Gastrointestinal Interventions
Comparison: 03 Interventions to reduce the bacterial reflux load                                                          
Outcome: 02 Mortality                                                                                                  
Study  Load reduction  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Sucralfate vs. H2-Antagonists
 Pickworth 1993             2/39               4/44          1.08      0.54 [0.09, 3.13]        
 Laggner 1989               8/16               8/16          1.21      1.00 [0.25, 4.00]        
 Stoehr 1998 A              3/16               8/34          1.26      0.75 [0.17, 3.31]        
 Thomason 1996 A            5/40               8/80          1.41      1.29 [0.39, 4.22]        
 Eddleston 1991             8/30               7/30          1.55      1.19 [0.37, 3.85]        
 Tsiotras 1993             14/50              12/50          2.61      1.23 [0.50, 3.02]        
 Kantorova 2004            13/69              11/71          2.66      1.27 [0.52, 3.06]        
 Kappstein 1991             9/49              14/55          3.26      0.66 [0.26, 1.69]        
 Ryan 1993                 22/58              19/56          3.63      1.19 [0.55, 2.56]        
 Prod'hom 1994 A           13/42              27/80          3.88      0.88 [0.39, 1.96]        
 Colardyn 1990             29/56              31/57          4.48      0.90 [0.43, 1.89]        
 Fabian 1993               16/99              32/179         5.78      0.89 [0.46, 1.71]        
 Cook 1998                138/604            140/596        32.87      0.96 [0.74, 1.26]        
Subtotal (95% CI) 1168               1348  65.67      0.97 [0.80, 1.17]
Total events: 280 (Load reduction), 321 (Control)
Test for heterogeneity: Chi² = 2.59, df = 12 (P = 1.00), I² = 0%
Test for overall effect: Z = 0.31 (P = 0.76)
02 Sucralfate vs. Antacids
 Tryba 1987                17/50              15/50          2.99      1.20 [0.52, 2.79]        
 Thomason 1996 B            5/40              19/82          3.30      0.47 [0.16, 1.38]        
 Bonten 1995               32/67              27/74          4.05      1.59 [0.81, 3.12]        
 Prod'hom 1994 B           12/41              32/81          4.60      0.63 [0.28, 1.42]        
Subtotal (95% CI) 198                287  14.94      0.97 [0.65, 1.45]
Total events: 66 (Load reduction), 93 (Control)
Test for heterogeneity: Chi² = 5.12, df = 3 (P = 0.16), I² = 41.4%
Test for overall effect: Z = 0.14 (P = 0.89)
03 Sucralfate vs. placebo
 Eddleston 1994             4/14               6/12          1.40      0.40 [0.08, 2.02]        
Subtotal (95% CI) 14                 12   1.40      0.40 [0.08, 2.02]
Total events: 4 (Load reduction), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
04 Sucralfate vs. H2-Antagonists+Antacids
 Maier 1994                 6/47              11/51          2.78      0.53 [0.18, 1.58]        
Subtotal (95% CI) 47                 51   2.78      0.53 [0.18, 1.58]
Total events: 6 (Load reduction), 11 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
06 Placebo vs. Pirenzepine
 Hanisch 1998 A             6/28              12/44          2.22      0.73 [0.24, 2.23]        
Subtotal (95% CI) 28                 44   2.22      0.73 [0.24, 2.23]
Total events: 6 (Load reduction), 12 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
07 Placebo vs. H2-Antagonists
 Hanisch 1998 B             6/29               7/57          1.13      1.86 [0.56, 6.17]        
Subtotal (95% CI) 29                 57   1.13      1.86 [0.56, 6.17]
Total events: 6 (Load reduction), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
08 Acidified Enteral Feeds
 Tulaimat 2005              1/16               2/13          0.63      0.37 [0.03, 4.57]        
 Heyland 1999              15/49               7/46          1.51      2.46 [0.90, 6.74]        
Subtotal (95% CI) 65                 59   2.14      1.85 [0.75, 4.56]
Total events: 16 (Load reduction), 9 (Control)
Test for heterogeneity: Chi² = 1.89, df = 1 (P = 0.17), I² = 47.0%
Test for overall effect: Z = 1.33 (P = 0.18)
09 Early Gastrostomy
 Kostadima 2005             6/20              10/21          2.06      0.47 [0.13, 1.70]        
Subtotal (95% CI) 20                 21   2.06      0.47 [0.13, 1.70]
Total events: 6 (Load reduction), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
10 Small Intestinal vs. Gastric Feeding
 Kortbeek 1999              4/37               3/43          0.75      1.62 [0.34, 7.74]        
 Montecalvo 1992            5/19               5/19          1.11      1.00 [0.24, 4.24]        
 Kearns 2000                5/21               6/23          1.32      0.89 [0.23, 3.48]        
Subtotal (95% CI) 77                 85   3.18      1.10 [0.48, 2.53]
Total events: 14 (Load reduction), 14 (Control)
Test for heterogeneity: Chi² = 0.34, df = 2 (P = 0.84), I² = 0%
Test for overall effect: Z = 0.22 (P = 0.83)
11 Intermittent Enteral Feeding
 Bonten 1996                9/30               6/30          1.27      1.71 [0.52, 5.62]        
 MacLeod 2007              11/79               6/81          1.54      2.02 [0.71, 5.76]        
Subtotal (95% CI) 109                111   2.81      1.88 [0.86, 4.13]
Total events: 20 (Load reduction), 12 (Control)
Test for heterogeneity: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%
Test for overall effect: Z = 1.58 (P = 0.11)
12 Enteral Naloxone
 Meissner 2003              6/38               7/43          1.67      0.96 [0.29, 3.17]        
Subtotal (95% CI) 38                 43   1.67      0.96 [0.29, 3.17]
Total events: 6 (Load reduction), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 1793               2118 100.00      0.99 [0.85, 1.16]
Total events: 430 (Load reduction), 502 (Control)
Test for heterogeneity: Chi² = 19.58, df = 29 (P = 0.91), I² = 0%
Test for overall effect: Z = 0.09 (P = 0.93)
 0.01  0.1  1  10  100
 Favours load reduct.  Favours control
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Sucralfate vs. antacids 
Mortality rates were not different between the groups receiving sucralfate and antacids, 
respectively (OR = 0.97, 0.65 – 1.45). 
Other interventions 
There was no evidence for an effect on mortality rates in any of the reference groups of the other 
interventions. 
The overall result of the interventions attempting to preserve a low gastric pH was not 
statistically significant regarding mortality rates (OR = 0.99, 0.85 – 1.16). 
Length of ICU stay 
The overall result for the length of ICU stay showed no significant change in this outcome 
(WMD = 0.65, -0.70, 1.99), with discordant significant results of the two subgroups of sucralfate 
versus H2-antagonists plus antacids (WMD = -4.50, -8.89, -0.11) and intermittent enteral feeding 
(WMD = 1.10, 0.52, 1.68) (Table 15). Nevertheless, each of them was only represented by one 
study with abstractable data for this outcome. 
Table 15: Outcomes Gastrointestinal Interventions: Interventions to reduce the bacterial reflux load 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WM 
 [95% CI] 
Colardyn 
1990 
Sucralfate 
vs. H2-
antagonists
 
56/ 
57 
0.83 
[0.39, 1.75] 
0.90 
[0.43, 1.89] 
  
Cook 
1998 
Sucralfate 
vs. H2-
antagonists
 
604/ 
596 
0.81 
[0.61, 1.06] 
0.96 
[0.74, 1.26] 
  
Driks 
1987 B 
Sucralfate 
vs. H2-
antagonists
 
21/ 
17 
1.68 
[0.14, 20.33] 
   
Eddleston 
1991 
Sucralfate 
vs. H2-
antagonists 
30/ 
30 
0.22 
[0.05, 0.91] 
1.19 
[0.37, 3.85] 
2.20 
[1.55, 2.85] 
3.00 
[2.10, 3.90] 
Fabian 
1993 
Sucralfate 
vs. H2-
antagonists
 
99/ 
179 
1.01 
[0.59, 1.74] 
0.89 
[0.46, 1.71] 
  
Kantorova 
2004 
Sucralfate 
vs. H2-
antagonists 
69/ 
71 
0.87 
[0.28, 2.74] 
1.27 
[0.52, 3.06] 
-0.40 
[-3.10, 2.30] 
-2.20 
[-5.36, 0.96] 
Kappstein 
1991 
Sucralfate 
vs. H2-
antagonists
 
49/ 
55 
0.43 
[0.19, 0.99] 
0.66 
[0.26, 1.69] 
  
Laggner 
1989 
Sucralfate 
vs. H2-
antagonists
 
16/ 
16 
0.18 
[0.01, 3.97] 
1.00 
[0.25, 4.00] 
-0.30 
[-2.81, 2.21] 
 
Pickworth 
1993 
Sucralfate 
vs. H2-
antagonists
 
39/ 
44 
1.42 
[0.40, 5.07] 
0.54 
[0.09, 3.13] 
  
Prod’hom 
1994 A 
Sucralfate 
vs. H2-
antagonists
 
42/ 
80 
0.38 
[0.13, 1.09] 
0.88 
[0.39, 1.96] 
  
Ryan 
1993 
Sucralfate 
vs. H2-
antagonists
 
58/ 
56 
1.12 
[0.38, 3.33] 
1.19 
[0.55, 2.56] 
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Stoehr 
1998 A 
Sucralfate 
vs. H2-
antagonists
 
16/ 
34 
2.20 
[0.13, 37.59] 
0.75 
[0.17, 3.31] 
  
Thomason 
1996 A 
Sucralfate 
vs. H2-
antagonists
 
40/ 
80 
1.18 
[0.53, 2.60] 
1.29 
[0.39, 4.22] 
  
Tsiotras 
1993 
Sucralfate 
vs. H2-
antagonists 
50/ 
50 
0.37 
[0.14, 0.96] 
1.23 
[0.50, 3.02] 
-2.50 
[-4.11, -0.89] 
 
Subtotal:   0.77 
[0.64, 0.93] (f) 
0.97 
[0.80, 1.17] (f) 
-0.19 
[-2.88, 2.50] (r) 
0.63 
[-4.45, 5.71] (r) 
       
Bonten 
1995 
Sucralfate 
vs. antacids 
67/ 
74 
1.05 
[0.47, 2.32] 
1.59 
[0.81, 3.12] 
 -2.20 
[-12.73, 8.33] 
Driks 
1987 A 
Sucralfate 
vs. antacids 
20/ 
39 
0.37 
[0.07, 1.91] 
   
Mahul 
1992 A 
Sucralfate 
vs. antacids 
73/ 
72 
0.70 
[0.31, 1.57] 
   
Prod’hom 
1994 B 
Sucralfate 
vs. antacids 
41/ 
81 
0.49 
[0.17, 1.42] 
0.63 
[0.28, 1.42] 
  
Thomason 
1996 B 
Sucralfate 
vs. antacids 
40/ 
82 
1.04 
[0.48, 2.27] 
0.47 
[0.16, 1.38] 
  
Tryba 
1987 
Sucralfate 
vs. antacids 
29/ 
32 
0.22 
[0.05, 0.89] 
1.20 
[0.52, 2.79] 
  
Subtotal:   0.70 
[0.47, 1.02] (f) 
0.97 
[0.65, 1.45] (f) 
  
       
Eddleston 
1994 
Sucralfate 
vs. placebo 
14/ 
12 
2.78 
[0.10, 74.70] 
0.40 
[0.08, 2.02] 
  
       
Driks 
1987 C 
Sucralfate 
vs. H2-
antagonists + 
antacids 
20/ 
13 
0.06 
[0.01, 0.60] 
   
Maier 
1994 
Sucralfate 
vs. H2-
antagonists + 
antacids 
47/ 
51 
0.71 
[0.28, 1.81] 
0.53 
[0.18, 1.58] 
-4.40 
[-8.89, 0.09] 
-4.5 
[-8.89, -0.11] 
Sirvent 
1994 
Sucralfate 
vs. H2-
antagonists + 
antacids 
29/ 
32 
0.67 
[0.22, 2.09] 
   
Subtotal:   0.52 
[0.27, 1.01] (f) 
   
       
Holzapfel 
1990 
No treatment 
vs. H2-
antagonists + 
antacids
 
 
67/ 
61 
1.52 
[0.47, 4.92] 
   
       
Hanisch 
1998 A 
Placebo 
vs. pirenzepine 
28/ 
44 
1.23 
[0.40, 3.79] 
0.73 
[0.24, 2.23] 
  
       
Hanisch 
1998 B 
Placebo 
vs. H2-
antagonists 
29/ 
57 
1.23 
[0.40, 3.79] 
1.86 
[0.56, 6.17] 
  
       
Heyland 
1999 
Acidified 
enteral feeds 
49/ 
46 
0.36 
[0.09, 1.50] 
2.46 
[0.90, 6.74] 
  
Tulaimat 
2005 
Acidified 
enteral feeds 
16/ 
13 
2.77 
[0.25, 30.38] 
0.37 
[0.03, 4.57] 
  
Subtotal:   0.64 
[0.21, 1.98] (f) 
1.85 
[0.75, 4.56] (f) 
  
       
Kostadima 
2005 
Early 
gastrostomy 
20/ 
21 
0.18 
[0.03, 0.99] 
0.47 
[0.13, 1.70] 
-0.30 
[-8.43, 7.83] 
0.00 
[-8.46, 8.46] 
       
Kearns 
2000 
Small intestinal 
vs. gastric 
feeding 
21/ 
23 
1.57 
[0.31, 8.01] 
0.89 
[0.23, 3.48] 
-4.00 
[-10.21, 2.21] 
1.00 
[-0.18, 2.18] 
Kortbeek 
1999 
Small intestinal 
vs. gastric 
feeding 
37/ 
43 
0.51 
[0.10, 1.32] 
1.62 
[0.34, 7.74] 
  
Montecalvo 
1992 
Small intestinal 
vs. gastric 
feeding 
19/ 
19 
0.18 
[0.01, 4.00] 
1.00 
[0.24, 4.24] 
-1.20 
[-7.01, 4.61] 
-0.60 
[-6.70, 5.50] 
Subtotal:   0.61 
[0.28, 1.32] (f) 
1.10 
[0.48, 2.53] (f) 
-2.51 
[-6.75, 1.73] (r) 
0.94 
[-0.22, 2.10] (r) 
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Bonten 
1996 
Intermittent 
enteral feeding 
30/ 
30 
1.00 
[0.26, 3.89] 
1.71 
[0.52, 5.62] 
  
MacLeod 
2007 
Intermittent 
enteral feeding 
79/ 
81 
1.35 
[0.73, 2.26] 
2.02 
[0.71, 5.76] 
 1.10 
[0.52, 1.68] 
Skiest 
1996 
Intermittent 
enteral feeding 
9/ 
7 
Not estimable    
Tamowicz 
2007 
Intermittent 
enteral feeding 
20/ 
20 
0.46 
[0.11, 1.94] 
   
Subtotal:   1.11 
[0.66, 1.87] (f) 
1.88 
[0.86, 4.13] (f) 
  
       
Meissner 
2003 
Enteral 
naloxone 
38/ 
43 
0.41 
[0.17, 1.01] 
0.96 
[0.29, 3.17] 
  
       
Yavagal 
2000 
Enteral 
metoclopramide 
58/ 
78 
1.20 
[0.56, 2.57] 
   
 
      
Total:   0.77 
[0.66, 0.88] (f) 
0.99 
[0.85, 1.16] (f) 
-1.03 
[-3.41, 1.35] (r) 
0.65 
[-0.70, 1.99] (r) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
d) H2-antagonist vs.antacid 
Pneumonia 
One trial was identified comparing the H2-receptor antagonist ranitidine and the antacid 
pirenzepine for stress ulcer prophylaxis.347 The odds ratio was numerically larger than one (OR = 
4.00, 0.95 – 16.92), favoring pirenzepine, but the result failed to reach statistical significance (p 
= 0.06) (Table 16). 
Table 16: Outcomes Gastrointestinal Interventions: Ranitidine vs. pirenzepine 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Tryba 
1988 
H2-antagonist 
vs. antacid 
28/ 
33 
3.00 
[0.95, 16.92] 
   
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
e) Enriched enteral nutrition 
Pneumonia/ Mortality 
Summarizing the data of four trials implementing a formula of enriched enteral nutrition does 
not suggest a significant reduction of pneumonia (OR = 1.38, 0.51 – 3.75) or mortality rates (OR 
= 0.71, 0. 40 – 1.27) (Table 17).51, 160, 239, 321 
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Table 17: Outcomes Gastrointestinal Interventions: Enriched enteral nutrition 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Caparros 
2001 
Enriched 
enteral nutrition 
122/ 
98 
1.62 
[0.88, 2.98] 
0.70 
[0.39, 1.27] 
  
Houdijk 
1998 
Enriched 
enteral nutrition 
35/ 
37 
0.27 
[0.09, 0.81] 
   
Mendez 
1997 
Enriched 
enteral nutrition 
22/ 
21 
2.42 
[0.68, 8.64] 
0.95 
[0.06, 16.28] 
  
Spindler-Vesel 
2007 
Enriched 
enteral nutrition 
87/ 
26 
3.53 
[1.12, 11.13] 
   
Total:   1.38 
[0.51, 3.75] (r) 
0.71 
[0.04, 1.27] (f) 
  
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
f) Early enteral nutrition 
Pneumonia 
Two trials met our inclusion criteria, but both of them had discordant significant results, so no 
evidence for an effect of early enteral nutrition on the incidence of pneumonia could be shown 
(OR = 0.83, 0.11 – 6.23) (Table 18).163, 193 
Mortality 
The outcome for mortality was not significant (OR = 0.65, 0.31 – 1.37) (Table 18). 
Table 18: Outcomes Gastrointestinal Interventions: Early enteral nutrition 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Ibrahim 
2002 
Early enteral 
nutrition 
75/ 
75 
2.20 
[1.13, 4.29] 
0.69 
[0.32, 1.47] 
 3.80 
[0.18, 7.42] 
Kompan 
2004 
Early enteral 
nutrition 
27/ 
25 
0.28 
[0.09, 0.88] 
0.30 
[0.01, 7.63] 
-2.70 
[-9.71, 4.31] 
-4.70 
[-12.82, 3.42] 
Total:   0.83 
[0.11, 6.23] (r) 
0.65 
[0.31, 1.37] (f) 
 2.39 
[-0.92, 5.70] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
g) Enteral vs. parenteral feeding 
Pneumonia/ Duration of MV 
One trial comparing enteral with parenteral feeding met our inclusion criteria.201 
Pneumonia rates were significantly reduced in the patient group receiving enteral feeding 
(OR=0.30, 0.10-0.85), as was the duration of MV (WMD=-0.40, -0.75- -0.05) (Table 19). 
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Table 19: Outcomes Gastrointestinal Interventions: Enteral vs. parenteral feeding 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Kudsk 
1992 
Enteral 
vs. parenteral 
feeding 
51/ 
45 
0.30 
[0.10, 0.85] 
 -0.40 
[-0.75, -0.05] 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
3.7. Positioning  
a) Rotational therapy 
Pneumonia 
Six trials studying the effects of rotational therapy met our inclusion criteria. Four11, 86, 114, 126 
implemented a kinetic therapy, an automated turning of the patient in his bed of at least 40 
degrees to each side, and two175, 223 implemented a continuous lateral rotation therapy (CLRT), 
an automated turning of the patient of up to 40 degrees. 
Overall, pneumonia rates were significantly reduced in patients undergoing rotational therapy 
(OR = 0.34, 0.23 – 0.52). 
Both of the subgroups showed a significant reduction of the incidence of pneumonia, with a 
greater impact in the kinetic therapy group (Figure 21). 
Figure 21: Positioning: Rotational therapy, pneumonia outcomes. 
Review: Positioning
Comparison: 01 Rotational therapy                                                                                         
Outcome: 01 Pneumonia                                                                                                  
Study  Rotational Ther.  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Kinetic therapy
 Demarest 1989              0/16               4/14          5.75      0.07 [0.00, 1.45]        
 Gentilello 1988            5/27              13/38         10.91      0.44 [0.13, 1.42]        
 Fink 1990                  7/51              19/48         20.93      0.24 [0.09, 0.65]        
 Ahrens 2004               14/97              45/137        39.57      0.34 [0.18, 0.67]        
Subtotal (95% CI) 191                237  77.17      0.31 [0.19, 0.51]
Total events: 26 (Rotational Ther.), 81 (Control)
Test for heterogeneity: Chi² = 1.58, df = 3 (P = 0.66), I² = 0%
Test for overall effect: Z = 4.68 (P < 0.00001)
02 CLRT
 Kirschenbaum 2002          3/17              10/20          9.38      0.21 [0.05, 0.98]        
 MacIntyre 1999             9/52              13/51         13.45      0.61 [0.24, 1.59]        
Subtotal (95% CI) 69                 71  22.83      0.45 [0.20, 0.99]
Total events: 12 (Rotational Ther.), 23 (Control)
Test for heterogeneity: Chi² = 1.31, df = 1 (P = 0.25), I² = 23.5%
Test for overall effect: Z = 1.97 (P = 0.05)
Total (95% CI) 260                308 100.00      0.34 [0.23, 0.52]
Total events: 38 (Rotational Ther.), 104 (Control)
Test for heterogeneity: Chi² = 3.46, df = 5 (P = 0.63), I² = 0%
Test for overall effect: Z = 5.05 (P < 0.00001)
 0.01  0.1  1  10  100
 Favours rot. ther.  Favours control
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Mortality 
There was no significant impact on mortality rates in the subgroups or the overall estimate (OR = 
1.12, 0.77 – 1.63) (Figure 22). 
Figure 22: Positioning: Rotational therapy, mortality outcomes. 
Review: Positioning
Comparison: 01 Rotational therapy                                                                                         
Outcome: 02 Mortality                                                                                                  
Study  Rotational ther.  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Kinetic therapy
 Gentilello 1988            7/27               5/38          5.87      2.31 [0.65, 8.27]        
 Demarest 1989              8/16               6/14          6.10      1.33 [0.32, 5.64]        
 Fink 1990                 10/51               8/48         12.63      1.22 [0.44, 3.40]        
 Ahrens 2004               41/97              58/137        52.93      1.00 [0.59, 1.69]        
Subtotal (95% CI) 191                237  77.53      1.16 [0.76, 1.76]
Total events: 66 (Rotational ther.), 77 (Control)
Test for heterogeneity: Chi² = 1.48, df = 3 (P = 0.69), I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
02 CLRT
 Kirschenbaum 2002          1/17               2/20          3.30      0.56 [0.05, 6.81]        
 MacIntyre 1999            15/52              14/51         19.18      1.07 [0.45, 2.53]        
Subtotal (95% CI) 69                 71  22.47      1.00 [0.44, 2.24]
Total events: 16 (Rotational ther.), 16 (Control)
Test for heterogeneity: Chi² = 0.23, df = 1 (P = 0.63), I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 260                308 100.00      1.12 [0.77, 1.63]
Total events: 82 (Rotational ther.), 93 (Control)
Test for heterogeneity: Chi² = 1.81, df = 5 (P = 0.87), I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)
 0.01  0.1  1  10  100
 Favours rot. ther.  Favours control
 
Table 20: Outcomes Positioning: Rotational therapy 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of 
MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Ahrens 
2004 
Kinetic therapy 97/ 
137 
0.34 
[0.18, 0.67] 
1.00 
[0.59, 1.69] 
0.61 
[-2.40, 3.62] 
-0.18 
[-3.42, 3.06] 
Demarest 
1989 
Kinetic therapy 16/ 
14 
0.07 
[0.00, 1.45] 
1.33 
[0.32, 5.64] 
  
Fink 
1990 
Kinetic therapy 51/ 
48 
0.24 
[0.09, 0.65] 
1.22 
[0.44, 3.40] 
  
Gentilello 
1988 
Kinetic therapy 27/ 
38 
0.44 
[0.13, 1.42] 
2.31 
[0.65, 9.27] 
-1.50 
[-4.79, 1.79] 
1.80 
[-5.34, 8.94] 
Subtotal:   0.31 
[0.19, 0.51] 
(f) 
1.16 
[0.76, 1.76] 
(f) 
-0.35 
[-2.58, 1.87] 
(f) 
0.16 
[-2.79, 3.11] (f) 
       
Kirschenbaum 
2002 
Continous lateral rotation therapy 
(CLRT) 
17/ 
20 
0.21 
[0.05, 0.98] 
0.56 
[0.05, 6.81] 
-3.00 
[-7.19, 1.19] 
 
MacIntyre 
1999 
Continous lateral rotation therapy 
(CLRT) 
52/ 
51 
0.61 
[0.24, 1.59] 
1.07 
[0.45, 2.53] 
  
Subtotal:   0.45 
[0.20, 0.99] 
(f) 
1.00 
[0.44, 2.24] 
(f) 
  
       
Total:   0.34 
[0.23, 0.52] 
(f) 
1.12 
[0.77, 1.63] 
(f) 
-0.93 
[-2.90, 1.03] 
(f) 
 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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b) Prone vs. supine positioning 
Pneumonia 
Four trials studied prone as opposed to supine positioning in the prevention of pneumonia.30, 136, 
229, 370
 Prone sessions ranged from four hours daily30, to eight hours136, eight to twenty-three370  
and 20 hours229. Overall there was a lack of evidence for a treatment effect, although the odds 
ratio was numerically less than one (OR = 0.79, 0.59 – 1.07) (Figure 23) (Table 21). 
Figure 23: Positioning: Prone vs. Supine positioning, pneumonia outcomes. 
Review: Positioning
Comparison: 02 Prone vs. supine positioning                                                                               
Outcome: 02 Pneumonia                                                                                                  
Study  Prone pos.  Supine pos.  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Voggenreiter 2005         10/21              13/19          7.25      0.42 [0.12, 1.53]        
 Beuret 2002                5/25              10/26          7.95      0.40 [0.11, 1.41]        
 Mancebo 2006              14/76               9/60          8.32      1.28 [0.51, 3.20]        
 Guerin 2004               85/413             91/378        76.49      0.82 [0.58, 1.14]        
Total (95% CI) 535                483 100.00      0.79 [0.59, 1.07]
Total events: 114 (Prone pos.), 123 (Supine pos.)
Test for heterogeneity: Chi² = 3.15, df = 3 (P = 0.37), I² = 4.7%
Test for overall effect: Z = 1.53 (P = 0.13)
 0.01  0.1  1  10  100
 Favours prone pos.  Favours supine pos.
 
Mortality 
Results were similar for mortality; although not statistically significant, the odds ratio was 
numerically less than one (OR = 0.47, 0.20 – 1.13) (Figure 24). 
Figure 24: Positioning: Prone vs. supine positioning, mortality outcomes. 
Review: Positioning
Comparison: 02 Prone vs. supine positioning                                                                               
Outcome: 01 Mortality                                                                                                  
Study  Prone pos.  Supine pos.  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Voggenreiter 2005          5/21              16/19         16.15      0.06 [0.01, 0.29]        
 Beuret 2002                7/25              12/26         21.50      0.45 [0.14, 1.45]        
 Mancebo 2006              38/76              37/60         28.67      0.62 [0.31, 1.24]        
 Guerin 2004              179/413            159/378        33.67      1.05 [0.79, 1.40]        
Total (95% CI) 535                483 100.00      0.47 [0.20, 1.13]
Total events: 229 (Prone pos.), 224 (Supine pos.)
Test for heterogeneity: Chi² = 14.98, df = 3 (P = 0.002), I² = 80.0%
Test for overall effect: Z = 1.68 (P = 0.09)
 0.01  0.1  1  10  100
 Favours prone pos.  Favours supine pos.
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Table 21: Outcomes Gastrointestinal Interventions: Prone vs. supine positioning 
Study ID Intervention Study/ 
Control group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Beuret 
2002 
Prone 
vs. supine positioning 
25/ 
26 
0.40 
[0.11, 1.41] 
0.45 
[0.14, 1.45] 
-1.90 
[-9.75, 5.95] 
-2.90 
[-13.45, 7.65] 
Guerin 
2004 
Prone 
vs. supine positioning 
413/ 
378 
0.82 
[0.58, 1.14] 
1.05 
[0.79, 1.40] 
-0.40 
[-1.55, 0.75] 
 
Mancebo 
2006 
Prone 
vs. supine positioning 
76/ 
60 
1.28 
[0.51, 3.20] 
0.62 
[0.31, 1.24] 
 1.40 
[-5.73, 8.53] 
Voggenreiter 
2005 
Prone 
vs. supine positioning 
21/ 
19 
0.42 
[0.12, 1.53] 
0.06 
[0.01, 0.29] 
-9.00 
[-25.21, 7.21] 
 
Total:   0.79 
[0.59, 1.07] (f) 
 
0.47 
[0.20, 1.13] (r) 
-0.47 
[-1.61, 0.66] (f) 
0.05 
[-5.86, 5.96] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
c) Semirecumbent vs. supine positioning 
Pneumonia 
Three trials studied the impact of semirecumbent positioning as opposed to supine positioning on 
pneumonia rates.94, 172, 364 The result did not achieve significance (p=0.06), although the odds 
ratio was less than one (OR = 0.40, 0.15 – 1.04) (Figure 25). 
A fourth trial, combining semirecumbency with subglottic secretion drainage was integrated in a 
separate analysis, with the result for pneumonia rates remaining non-significant (p=0.07) 
(OR=0.47, 0.21-1.06) (Figure 26).129 Potential confounding due to subglottic secretion drainage 
is minimal, since results for this intervention proved to be highly significant in our analysis 
(3.8.a)), and would have led to more positive results than negative ones, as opposed to our case. 
Figure 25: Positioning: Semirecumbent vs. supine positioning, pneumonia outcomes, analysis I. 
Review: Positioning
Comparison: 03 Semirecumbent vs. supine positioning                                                                       
Outcome: 01 Pneumonia                                                                                                  
Study  Semirecumbent pos.  Supine pos.  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Keeley 2007                5/17               7/13         24.65      0.36 [0.08, 1.62]        
 Drakulovic 1999            3/39              16/47         28.69      0.16 [0.04, 0.61]        
 Nieuwenhoven 2006         16/112             20/109        46.66      0.74 [0.36, 1.52]        
Total (95% CI) 168                169 100.00      0.40 [0.15, 1.04]
Total events: 24 (Semirecumbent pos.), 43 (Supine pos.)
Test for heterogeneity: Chi² = 4.19, df = 2 (P = 0.12), I² = 52.2%
Test for overall effect: Z = 1.87 (P = 0.06)
 0.01  0.1  1  10  100
 Favours semirecumb.  Favours supine pos.
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Figure 26: Positioning: Semirecumbent vs. supine positioning, pneumonia outcomes, analysis II. 
Review: Positioning
Comparison: 03 Semirecumbent vs. supine positioning                                                                       
Outcome: 01 Pneumonia                                                                                                  
Study  Semirecumbent pos.  Supine pos.  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Girou 2004                 5/8                6/10         13.83      1.11 [0.16, 7.51]        
 Keeley 2007                5/17               7/13         19.68      0.36 [0.08, 1.62]        
 Drakulovic 1999            3/39              16/47         23.48      0.16 [0.04, 0.61]        
 Nieuwenhoven 2006         16/112             20/109        43.01      0.74 [0.36, 1.52]        
Total (95% CI) 176                179 100.00      0.47 [0.21, 1.06]
Total events: 29 (Semirecumbent pos.), 49 (Supine pos.)
Test for heterogeneity: Chi² = 4.82, df = 3 (P = 0.19), I² = 37.7%
Test for overall effect: Z = 1.83 (P = 0.07)
 0.01  0.1  1  10  100
 Favours semirecumb.  Favours supine pos.
 
Mortality 
Mortality rates were not influenced by the manner in which patients were positioned (OR = 0.92, 
0.54 – 1.56) (Figure 27). 
Figure 27: Positioning: Semirecumbent vs. supine positioning, mortality outcomes. 
Review: Positioning
Comparison: 03 Semirecumbent vs. supine positioning                                                                       
Outcome: 02 Mortality                                                                                                  
Study  Semirecumbent pos.  Supine pos.  OR (random)  Weight  OR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Drakulovic 1999            7/39              13/47         24.24      0.57 [0.20, 1.62]        
 Nieuwenhoven 2006         44/112             41/109        75.76      1.07 [0.62, 1.85]        
Total (95% CI) 151                156 100.00      0.92 [0.54, 1.56]
Total events: 51 (Semirecumbent pos.), 54 (Supine pos.)
Test for heterogeneity: Chi² = 1.11, df = 1 (P = 0.29), I² = 9.8%
Test for overall effect: Z = 0.30 (P = 0.76)
 0.01  0.1  1  10  100
 Favours semirecumb.  Favours supine pos.
 
Table 22: Outcomes Positioning: Semirecumbent vs. supine positioning 
Study ID Intervention Study/ 
Control group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Keeley 
2007 
Semirecumbent 
vs. supine positioning 
17/ 
13 
0.36 
[0.08, 1.62] 
   
Drakulovic 
1999 
Semirecumbent 
vs. supine positioning 
39/ 
47 
0.16 
[0.04, 0.61] 
0.57 
[0.20, 1.62] 
-1.10 
[-3.89, 1.69] 
-0.40 
[-3.57, 2.77] 
Nieuwenhoven 
1999 
Semirecumbent 
vs. supine positioning 
112/ 
109 
0.74 
[0.36, 1.52] 
1.07 
[0.62, 1.85] 
  
Total analysis 
I: 
  0.40 
[0.15, 1.04] (r) 
0.93 
[0.58, 1.51] (f) 
  
       
Girou 
2004 
Semirecumbency + 
subglottic secretion 
drainage 
8/ 
10 
1.11 
[0.16, 7.51] 
   
Total analysis 
II: 
  0.47 
[0.47, 0.21, 
1.06] (r) 
   
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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3.8. ET Tubes  
a) Subglottic secretion drainage 
Pneumonia 
Eight trials ventilating their patients using a special endotracheal tube that allows subglottic 
secretion drainage through a lumen above the tube cuff met our inclusion criteria.36, 212, 218, 227, 241, 
319, 323, 359
 
Lorente et al. additionally used a newly designed polyurethane cuff tube and this was therefore 
analyzed in a separate subgroup.218 
Overall, VAP rates were significantly decreased in patients undergoing subglottic secretion 
drainage (OR = 0.34, 0.24 – 0.49) (Figure 28), as was also true for both of the subgrous. 
Figure 28: ET Tubes: Subglottic secretion drainage, pneumonia outcomes 
Review: ET Tubes
Comparison: 01 Subglottic secretion drainage                                                                              
Outcome: 01 Pneumonia                                                                                                  
Study  Subgl. secr. drain.  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Subgl. secr. drain. with conventional (ployvinyl cuff) tube
 Stohr 1998 B               0/16               4/34          2.69      0.21 [0.01, 4.05]        
 Metz 1998                  5/10              10/14          3.93      0.40 [0.07, 2.18]        
 Liu 2006                   3/48              10/50          8.65      0.27 [0.07, 1.04]        
 Smulders 2002              3/75              12/75         10.85      0.22 [0.06, 0.81]        
 Bo 2000                    8/35              15/33         11.22      0.36 [0.13, 1.01]        
 Mahul 1992 B               9/70              21/75         16.65      0.38 [0.16, 0.90]        
 Valles 1995               14/76              25/77         19.09      0.47 [0.22, 1.00]        
Subtotal (95% CI) 330                358  73.09      0.36 [0.23, 0.54]
Total events: 42 (Subgl. secr. drain.), 97 (Control)
Test for heterogeneity: Chi² = 1.40, df = 6 (P = 0.97), I² = 0%
Test for overall effect: Z = 4.82 (P < 0.00001)
02 Subgl. secr. drain. with polyurethane cuff tube
 Lorente 2007              11/140             31/140        26.91      0.30 [0.14, 0.62]        
Subtotal (95% CI) 140                140  26.91      0.30 [0.14, 0.62]
Total events: 11 (Subgl. secr. drain.), 31 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.001)
Total (95% CI) 470                498 100.00      0.34 [0.24, 0.49]
Total events: 53 (Subgl. secr. drain.), 128 (Control)
Test for heterogeneity: Chi² = 1.59, df = 7 (P = 0.98), I² = 0%
Test for overall effect: Z = 5.79 (P < 0.00001)
 0.01  0.1  1  10  100
 Favours subgl. dr.  Favours control
 
Mortality 
Overall, there was no evidence for an effect regarding mortality rates (OR = 0.88, 0.64 – 1.22) 
(Figure 29). 
In the second subgroup, combining subglottic secretion drainage with a polyurethane cuff tube, 
the OR was numerically less than one, without reaching statistical significance (OR = 0.77, 0.43 
– 1.38). 
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Figure 29: ET Tubes: Subglottic secretion drainage, mortality outcomes 
Review: ET Tubes
Comparison: 01 Subglottic secretion drainage                                                                              
Outcome: 02 Mortality                                                                                                  
Study  Subgl. secr. drain.  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Subgl. secr. drain. with conventional (polyvinyl cuff) tube
 Bo 2000                    0/35               0/33                Not estimable         
 Stohr 1998 B               3/16              13/34          8.51      0.37 [0.09, 1.56]        
 Smulders 2002             12/75              10/75         10.58      1.24 [0.50, 3.07]        
 Liu 2006                   5/48              11/50         12.16      0.41 [0.13, 1.29]        
 Mahul 1992 B              17/70              16/75         14.73      1.18 [0.54, 2.57]        
 Valles 1995               30/76              28/77         21.20      1.14 [0.59, 2.19]        
Subtotal (95% CI) 320                344  67.18      0.94 [0.64, 1.38]
Total events: 67 (Subgl. secr. drain.), 78 (Control)
Test for heterogeneity: Chi² = 4.63, df = 4 (P = 0.33), I² = 13.6%
Test for overall effect: Z = 0.33 (P = 0.74)
02 Subgl secr. drain. with polyurethane cuff tube
 Lorente 2007              26/140             32/140        32.82      0.77 [0.43, 1.38]        
Subtotal (95% CI) 140                140  32.82      0.77 [0.43, 1.38]
Total events: 26 (Subgl. secr. drain.), 32 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 460                484 100.00      0.88 [0.64, 1.22]
Total events: 93 (Subgl. secr. drain.), 110 (Control)
Test for heterogeneity: Chi² = 4.98, df = 5 (P = 0.42), I² = 0%
Test for overall effect: Z = 0.77 (P = 0.44)
 0.01  0.1  1  10  100
 Favours subgl. dr.  Favours control
 
Duration of MV/ Length of ICU stay 
With abstractable data of only three trials, no significant difference could be shown in the 
duration of MV, although the weighted mean difference was numerically less than zero (WMD = 
-1.10, -2.49 – 0.30) (Table 23). 
The length of ICU stay was significantly decreased considering the two trials assessing this 
outcome (WMD = -2.76, from -4.48 to -1.04) (Table 23). 
Table 23: Outcomes ET Tubes: Subglottic secretion drainage 
Study ID Intervention Treatment/ 
Control 
group 
Pneumonia 
OR 
[96% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Stohr 
1998 
Subglottic 
secretion 
drainage 
32/ 
34 
1.06 
[0.06, 17.77] 
0.37 
[0.12, 1.15] 
  
Metz 
1998 
Subglottic 
secretion 
drainage 
10/ 
14 
0.40 
[0.07, 2.18] 
   
Liu 
2006 
Subglottic 
secretion 
drainage 
48/ 
50 
0.27 
[0.07, 1.04] 
0.41 
[0.13, 1.29] 
0.00 
[-4.83, 4.83] 
 
Smulders 
2002 
Subglottic 
secretion 
drainage 
75/ 
75 
0.22 
[0.06, 0.81] 
1.24 
[0.50, 3.07] 
-1.30 
[-2.88, 0.28] 
-3.00 
[-4.86, -1.14] 
Bo 
2000 
Subglottic 
secretion 
drainage 
35/ 
33 
0.36 
[0.13, 1.01] 
Not estimable   
Mahul 
1992 B 
Subglottic 
secretion 
drainage 
70/ 
75 
0.38 
[0.16, 0.90] 
1.18 
[0.54, 2.57] 
  
Valles 
1995 
Subglottic 
secretion 
drainage 
76/ 
77 
0.47 
[0.22, 1.00] 
1.14 
[0.59, 2.19] 
  
Subtotal   0.36 
[0.23, 0.54] 
0.94 
[0.64, 1.38] 
-1.18 
[-2.67, 0.32] 
 
       
Lorente 
2007 
Subglottic 
secretion 
140/ 
140 
0.30 
[0.14, 0.62] 
0.77 
[0.43, 1.38] 
-0.60 
[-4.33, 3.13] 
-1.40 
[-5.84, 3.04] 
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drainage  
Total:   0.34 
[0.24, 0.49] (f) 
0.88 
[0.64, 1.22] (f) 
-1.10 
[-2.49, 0.30] (f) 
-2.76 
[-4.48, -1.04] (f) 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
b) Silver-coated tube 
Pneumonia 
In two recently published trials comprising more than 1600 patients, the influence of a silver 
coated ET tube on VAP rates was investigated.186, 284 Overall, pneumonia rates were significantly 
reduced (OR=0.62, 0.44 – 0.89) (Figure 30) (Table 24). 
Figure 30: ET Tubes: Silver coated tube, pneumonia outcomes. 
Review: ET Tubes
Comparison: 02 Silver coated tube                                                                                         
Outcome: 01 Pneumonia                                                                                                  
Study  Silver coated tube  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Rello 2006                44/78              52/77         29.66      0.62 [0.32, 1.20]        
 Kollef 2008               37/766             56/743        70.34      0.62 [0.41, 0.96]        
Total (95% CI) 844                820 100.00      0.62 [0.44, 0.89]
Total events: 81 (Silver coated tube), 108 (Control)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%
Test for overall effect: Z = 2.59 (P = 0.010)
 0.01  0.1  1  10  100
 Favours coated tube  Favours control
 
Mortality/ Duration of MV 
Data of the two secondary outcomes, mortality and duration of MV, could only be abstracted 
from the trial of Rello et al. and were not significantly different, although the weighted mean 
difference for the duration of MV was larger than zero (WMD = 1.80, -0.04 – 3.64) (Table 24). 
Table 24: Outcomes ET Tubes: Silver coated endotracheal tube 
Study ID Intervention Treatment/ 
Control 
group 
Pneumonia 
OR 
[96% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Rello 
2006 
Silver coated 
endotracheal 
tube 
78/ 
77 
0.62 
[0.32, 1.20] 
1.29 
[0.62, 2.69] 
1.80 
[-0.04, 3.64] 
 
Kollef 
2008 
Silver coated 
endotracheal 
tube 
766/ 
743 
0.62 
[0.41, 0.96] 
   
Total:   0.62 
[0.44, 0.89] 
   
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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c) Automated control of endotracheal tube cuff pressure 
Pneumonia/ Mortality 
Whether the automated control of the tube cuff pressure had an impact on VAP rates was studied 
by one recently published trial.357 An effect on VAP rates could not be significantly proven, 
although the odds ratio was numerically less than one (OR = 0.69, 0.32 – 1.47) (Table 25).  
Although the odds ratio was larger than one, mortality rates were not significantly different (OR 
= 1.40, 0.70 – 2.77). 
Table 25: Outocmes ET Tubes: Automated control of endotracheal tube cuff pressure 
Study ID Intervention Treatment/ 
Control 
group 
Pneumonia 
OR 
[96% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU stay 
WMD 
[95% CI] 
Valencia 
2007 
Automated 
control of 
endotracheal 
tube cuff 
pressure 
73/ 
69 
0.69 
[0.32, 1.47] 
1.40 
[0.70, 2.77] 
 -2.58 
[-4.31, -0.85] 
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
3.9. Non-classifyable preventive strategies 
a) Aerosolized antibiotics 
Pneumonia 
Four trials applying the aerosolized antibiotics ceftazidime62, 379, gentamicin209 and polymyxin134 
to the lungs met our inclusion criteria. 
The overall outcome indicates a significant reduction of VAP rates in patients receiving 
aerosolized antibiotics (OR = 0.55, 0.34 – 0.87) (Figure 31). 
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Figure 31: Non-classifyable preventive strategies: Aerosolized antibiotics, pneumonia outcomes 
Review: Non-classifyable preventive strategies
Comparison: 01 Aerosolized antibiotics                                                                                    
Outcome: 01 Pneumonia                                                                                                  
Study  Aerosol. antibiotics  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 aerosolized ceftazidime
 Claridge 2007             26/53              26/52         28.48      0.96 [0.45, 2.07]        
 Wood 2002                  6/20              13/20         19.38      0.23 [0.06, 0.87]        
Subtotal (95% CI) 73                 72  47.85      0.67 [0.35, 1.27]
Total events: 32 (Aerosol. antibiotics), 39 (Control)
Test for heterogeneity: Chi² = 3.35, df = 1 (P = 0.07), I² = 70.1%
Test for overall effect: Z = 1.23 (P = 0.22)
02 aerosolized gentamicin
 Li 2002                   21/57              32/57         43.04      0.46 [0.22, 0.97]        
Subtotal (95% CI) 57                 57  43.04      0.46 [0.22, 0.97]
Total events: 21 (Aerosol. antibiotics), 32 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.04)
03 aerosolized polymyxin
 Greenfield 1973            2/33               4/25          9.11      0.34 [0.06, 2.02]        
Subtotal (95% CI) 33                 25   9.11      0.34 [0.06, 2.02]
Total events: 2 (Aerosol. antibiotics), 4 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 163                154 100.00      0.55 [0.34, 0.87]
Total events: 55 (Aerosol. antibiotics), 75 (Control)
Test for heterogeneity: Chi² = 4.23, df = 3 (P = 0.24), I² = 29.1%
Test for overall effect: Z = 2.52 (P = 0.01)
 0.01  0.1  1  10  100
 Favours aer. antib.  Favours control
 
Mortality 
The effect of aerosolized antibiotics on mortality rates failed to reach statistical significance, 
although the odds ratio was numerically less than one (OR = 0.66, 0.31 – 1.42) (Figure 32). 
Figure 32: Non-classifyable preventive strategies: Aerosolized antibiotics, mortality outcomes 
Review: Non-classifyable preventive strategies
Comparison: 01 Aerosolized antibiotics                                                                                    
Outcome: 02 Mortality                                                                                                  
Study  Aerosol. antibiotics  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 aerosolized ceftazidime
 Claridge 2007              7/53               6/52         32.14      1.17 [0.36, 3.74]        
 Wood 2002                  3/20               6/20         31.18      0.41 [0.09, 1.95]        
Subtotal (95% CI) 73                 72  63.32      0.79 [0.32, 1.98]
Total events: 10 (Aerosol. antibiotics), 12 (Control)
Test for heterogeneity: Chi² = 1.10, df = 1 (P = 0.29), I² = 9.4%
Test for overall effect: Z = 0.49 (P = 0.62)
02 aerosolized polymyxin
 Greenfield 1973            4/33               6/25         36.68      0.44 [0.11, 1.76]        
Subtotal (95% CI) 33                 25  36.68      0.44 [0.11, 1.76]
Total events: 4 (Aerosol. antibiotics), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 106                97 100.00      0.66 [0.31, 1.42]
Total events: 14 (Aerosol. antibiotics), 18 (Control)
Test for heterogeneity: Chi² = 1.61, df = 2 (P = 0.45), I² = 0%
Test for overall effect: Z = 1.06 (P = 0.29)
 0.01  0.1  1  10  100
 Favours aer. antib.  Favours control
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b) IV antibiotics 
Pneumonia 
Data about the influence of systemic antibiotic prophylaxis on VAP rates was available from 
three trials whose antibiotic regimens consisted of a three-day application of ampicillin-
sulbactam6, four-day administration of cefotaxime235, and two doses of cefuroxime315. There was 
evidence for a significant treatment effect of systemic antibiotic prophylaxis (OR = 0.56, 0.32 – 
0.99) (Figure 33). 
Figure 33: Non-classifyable preventive strategies: IV antibiotics, pneumonia outcomes 
Review: Non-classifyable preventive strategies
Comparison: 02 IV antibiotics                                                                                             
Outcome: 01 Pneumonia                                                                                                  
Study  IV antibiotics  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Acquarolo 2005             9/19              10/19         16.79      0.81 [0.23, 2.89]        
 Martinez-Pellus 1994        9/59               8/54         22.59      1.04 [0.37, 2.91]        
 Sirvent 1997              12/50              25/50         60.62      0.32 [0.13, 0.74]        
Total (95% CI) 128                123 100.00      0.56 [0.32, 0.99]
Total events: 30 (IV antibiotics), 43 (Control)
Test for heterogeneity: Chi² = 3.41, df = 2 (P = 0.18), I² = 41.4%
Test for overall effect: Z = 1.98 (P = 0.05)
 0.01  0.1  1  10  100
 Favours iv antibiot.  Favours control
 
Mortality/ Duration of MV 
There was no significant difference in mortality rates (OR = 1.14, 0.59 – 2.18) (Table 26). The 
duration of MV was significantly increased in the group receiving systemic antibiotic 
prophylaxis (WMD = 1.70, -0.04 – 3.44). 
c) Pharyngeal vs. tracheal decontamination 
Pneumonia/ Mortality/ Duration of MV/ Length of ICU stay 
Whether a decontamination regimen was administered to the pharynx or directly into the trachea 
had no significant impact on pneumonia (OR = 1.93, 0.32 – 11.43) (Table 26).236 
There was no effect on mortality rates (OR = 0.72, 0.21 – 2.48). Neither the results for the 
duration of MV (WMD = 3.00, -0.32 – 6.32) nor the length of ICU stay (WMD = 2.00, -1.83 – 
5.83) were statistically significant, although the weighted mean differences for both of the 
outcomes were larger than zero. 
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d) Systemic search for maxillary sinusitis 
Pneumonia/ Mortality 
Whether the search for maxillary sinusitis in nasotracheally intubated patients, in order to reduce 
cross infection, had an impact on the occurrence of VAP was studied by one large randomized 
controlled trial.157 Using a log-rank test the authors were able to describe a significant reduction 
in the rate of VAP (relative risk 0.61, p=0.02 log rank test) and in the morality rate (relative risk 
0.71, p=0.03 logrank test). However, this meta-analysis was using a binary approach that does 
not take the time course into consideration and therefore the odds ratio for the VAP rate (0.67, 
0.41 – 1.08) and mortality rates (OR = 0.68, 0.46 – 1.02) failed statistical signficance (Table 26). 
e) Chest physiotherapy 
Pneumonia/ Mortality 
A study of chest physiotherapy demonstrated a significant reduction of VAP (OR = 0.14, 0.03 – 
0.70); however, there was no evidence of a treatment effect regarding mortality rates (OR = 1.20, 
0.33 – 4.42) (Table 26).258 
f) Manual lung hyperinflation and postural drainage 
Pneumonia/ Mortality 
A trial studying the effects of manual lung hyperinflation and postural drainage showed neither a 
significant effect on VAP rates (OR=0.79, 0.16-4.00) nor on mortality rates (0.20, 0.01-4.40) 
(Table 26).257 
g) Granulocyte colony-stimulating factor 
Pneumonia 
A study administering two different doses of a granulocyte-stimulating factor failed to show a 
significant effect on the incidence of pneumonia (OR = 2.15, 0.38 – 12.06) (Table 26).143 
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h) Decontamination of the subglottic area 
Pneumonia/ Mortality/ Length of ICU stay 
Decontamination of the subglottic area with nonabsorbable antibiotics led to a significant 
reduction of pneumonia rates in the trial implementing this regimen (OR = 0.17, 0.05 – 0.56) 
(Table 26).273 
Whereas the results for mortality rates were statistically not significant, the length of ICU stay in 
the study group was significantly reduced (WMD = -7.00, -10.78 - -3.22) (Table 26). 
i) Early PEEP 
Pneumonia/ Mortality 
The administration of early PEEP, studied by two trials, demonstrated significantly decreased 
VAP rates (OR = 0.41, 0.18 – 0.91), but had no impact on mortality rates (OR = 0.96, 0.54 – 
1.71) (Table 26).231, 269 
j) Antioxidant therapy 
Pneumonia/ Mortality/ Length of ICU stay 
Two small trials demonstrated a significant reduction of pneumonia rates by administering two 
different regimen of antioxidant therapy (OR = 0.12, 0.03 – 0.42) (Figure 34) (Table 26).24, 274 
In the trial where data on mortality and the length of ICU stay was abstractable, no deaths 
occurred. The length of ICU stay was significantly reduced (WMD = -13.80, -21.52 - -6.09) 
(Table 26). 
Figure 34: Non-claasifyable preventive strategies: Antioxidant therapy, pneumonia outcomes. 
Review: Non-classifyable preventive strategies
Comparison: 13 Antioxidant therapy                                                                                        
Outcome: 01 Pneumonia                                                                                                  
Study  Treatment  Control  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Porter 1999                3/9                8/9          37.43      0.06 [0.01, 0.76]        
 Berger 2006                6/18              13/17         62.57      0.15 [0.03, 0.68]        
Total (95% CI) 27                 26 100.00      0.12 [0.03, 0.42]
Total events: 9 (Treatment), 21 (Control)
Test for heterogeneity: Chi² = 0.37, df = 1 (P = 0.54), I² = 0%
Test for overall effect: Z = 3.29 (P = 0.001)
 0.01  0.1  1  10  100
 Favours antiox ther  Favours control
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k) Endonasal mupirocin 
Pneumonia 
The effect of the administration of endonasal mupirocin on MRSA pneumonia was not 
significant (OR = 0.54, 0.11 – 2.58) (Table 26).91  
Table 26: Outcomes non-classifyable preventive strategies 
Study ID Intervention Study/ 
Control 
group 
Pneumonia 
OR 
[95% CI] 
Mortality 
OR 
[95% CI] 
Duration of MV 
WMD 
[95% CI] 
Length of ICU 
stay 
WMD 
[95% CI] 
Claridge 
2007 
Aerosolized 
ceftazidime 
53/ 
52 
0.96 
[0.45, 2.07] 
1.17 
[0.36, 3.74] 
  
Greenfield 
1973 
Aerosolized 
polymyxin 
33/ 
25 
0.34 
[0.22, 0.97] 
0.44 
[0.11, 1.76] 
  
Li 
2002 
Aerosolized 
gentamicin 
57/ 
57 
0.46 
[0.22, 0.97] 
   
Wood 
2002 
Aerosolized 
ceftazidime 
20/ 
20 
0.23 
[0.06, 0.87] 
0.41 
[0.09, 1.95] 
-2.00 
[-9.46, 5.46] 
-2.00 
[-9.13, 5.13] 
Total:   0.55 
[0.34, 0.87] (f) 
0.66 
[0.31, 1.42] (f) 
  
       
Acquarolo 
2005 
Iv antibiotics 19/ 
19 
0.07 
[0.00, 1.32] 
0.80 
[0.22, 2.95] 
-0.70 
[-5.94, 4.54] 
0.20 
[-5.66, 6.06] 
Martinez-Pellus 
1994 
Iv antibiotics 59/ 
54 
1.04 
[0.37, 2.91] 
1.05 
[0.35, 3.13] 
2.00 
[0.15, 3.85] 
1.00 
[-2.87, 4.87] 
Sirvent 
1997 
Iv antibiotics 50/ 
50 
0.32 
[0.13, 0.74] 
1.54 
[0.53, 4.42] 
 -3.00 
[-6.77, 0.77] 
Total:   0.44 
[0.24, 0.80] (f) 
1.14 
[0.59, 2.18] (f) 
1.70 
[-0.04, 3.44] (f) 
-0.83 
[-3.29, 1.62] (f) 
       
Martinez-Pellus 
1996 
Pharyngeal 
vs. tracheal 
decontamination 
31/ 
28 
1.93 
[0.32, 11.43] 
0.72 
[0.21, 2.48] 
3.00 
[-0.32, 6.32] 
2.00 
[-1.83, 5.83] 
       
Holzapfel 
1999 
Systemic search 
for maxillary 
sinusitis 
199/ 
200 
0.67 
[0.41, 1.08] 
0.68 
[0.46, 1.02] 
1.50 
[-1.32, 4.32] 
1.90 
[-0.95, 4.75] 
       
Ntoumenopoulos 
2002 
Chest 
physiotherapy 
24/ 
36 
0.14 
[0.03, 0.70] 
1.20 
[0.33, 4.42] 
  
       
Ntoumenopoulos 
1998 
Manual lung 
hyperinflation and 
postural drainage 
22/ 
24 
0.79 
[0.16, 4.00] 
0.20 
[0.01, 4.40] 
0.90 
[-1.76, 3.56] 
0.60 
[-2.41, 3.61] 
       
Heard 
1998 A 
Granulocyte 
colony-stimulating 
factor 
13/ 
8 
1.27 
[0.10, 16.81] 
   
Heard 
1998 B 
Granulocyte 
colony-stimulating 
factor 
14/ 
9 
3.2 
[0.30, 34.59] 
   
Total:   2.15 
[0.38, 12.06] (f) 
   
       
Pneumatikos 
2002 
Decontamination 
of subglottic area 
31/ 
30 
0.17 
[0.05, 0.56] 
0.63 
[0.18, 2.27] 
-1.00 
[-3.06, 1.06] 
-7.00 
[-10.78, -3.22] 
       
Manzano 
2008 
Early PEEP 64/ 
63 
0.30 
[0.11, 0.84 
1.24 
[0.57, 2.71] 
  
Pepe 
1984 
Early PEEP 44/ 
48 
0.70 
[0.18, 2.67] 
0.70 
[0.29, 1.67] 
  
       
Porter 
1999 
Antioxidant 
therapy 
9/ 
9 
0.06 
[0.01, 0.76] 
  -13.80 
[-21.52, -6.09] 
Berger 
2006 
Antioxidant 
therapy 
18/ 
17 
0.15 
[0.03, 0.68] 
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Total:  27/ 
26 
0.12 
[0.03, 0.42] (f) 
   
       
Di Filippo 1999 Endonasal 
mupirocin 
24/ 
24 
0.54 
[0.11, 2.58] 
   
Abbreviations: OR: odds ratio, CI: confidence interval, WMD: weighted mean difference, (f): fixed effects model, (r): random effects model. 
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4. Discussion 
The results of this meta-anylsis and systematic review suggest that it is possible to reduce the 
rate of VAP by certain mechanical, chemical and antibiotic strategies. 
Of the five intervention groups, the interventions that were statistically significant and were 
supported by more than one study are non-invasive ventilation, the aspiration of subglottic 
secretions, the administration of antibiotics, either in form of selective decontamination of the 
digestive tract (SDD), administered as an aerosol to the lungs or administered intravenously. The 
same is true for oral care with antiseptics, positioning of the patient with rotational therapy, 
sucralfate (instead of H2-antagonists) and antioxidant therapy. 
Various interventions proved to be effective, but were represented by only one study. These 
included antioxidant therapy, chest physiotherapy, trace element supplementation, subglottic 
decontamination, early gastrostomy and enteral (instead of parenteral) nutrition. 
The results and their clinical relevance are discussed below. All interventions are evaluated in 
regard to earlier recommendations for its usage by the current VAP prevention guidelines of 
different expert groups. The exact guideline recommendations are listed in the appendix of this 
document (Table 54). The quoted guidelines are the current CDC guidelines for the prevention of 
health-care associated pneumonia331, the guidelines published by the American Thoracic 
Society3, the original and updated version by a Canadian expert group92, 248, of a European expert 
group340 and of an American expert group67. 
4.1. Oral Care 
a) Antiseptic decontamination 
Our results show a significant reduction of pneumonia rates in long-term ventilated patients 
receiving oral decontamination with antiseptics, including chlorhexidine, iseganan and povidone-
iodine. There was no evidence for an effect on mortality rates. 
In their central guidelines for the prevention of VAP and nosocomial pneumonia, the CDC and 
the American Thoracic Society recommend chlorhexidine use for cardiac surgery only.3, 331 
According to their statement there is no evidence for a benefit in the general ICU population, 
what is in contrast to our results. Their recommendations are mainly based on two randomised 
controlled trials showing a positive effect on VAP rates in cardiac surgery patients.89, 161, whereas 
other trials identified by our search remain unmentioned. Nevertheless, in the latest guideline on 
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VAP prevention of the Canadian expert group, the authors state that the use of chlorhexidine and 
povidone-iodine should be considered, whereas they do not recommend the use of iseganan.248 
Of the three agents, chlorhexidine is the most intensively studied, being a promising antiseptic 
agent, with resistance rates of pathogens that are lower than those developing with antibiotic 
decontamination.32, 318, 322 Recently, three metaanalyses were published and also showed a 
significant reduction of pneumonia rates by chlorhexidine application.54, 59, 181 As opposed to our 
anaylsis though, cardiac surgery patients were included in their calculations. This may have led 
to an overinterpretation of their results, since VAP per definition derives from long-term 
ventilation, which is not the case in most of cardiac surgery patients. 
Iseganan and povidone-iodine have each been studied by one recently published trial. 
In a large multicenter study, Kollef et al. did not show a significant reduction of pneumonia or 
mortality rates by applying a solution of iseganan to the buccal cavity.192  Although low 
resistance rates make iseganan an attractive agent247, taking the results of this high quality and 
well powered trial into account, currently there is no evidence for a reduction of VAP rates with 
iseganan use.  
The application of a povidone-iodine solution to the nares and pharynx in a study by Seguin et 
al. led to a highly significant reduction of pneumonia rates in a population of head injury 
patients.306 Due to the small sample size and the limited patient population of this study, these 
results should be reproduced in a large randomized controlled trial in order to evaluate the effect 
in a general ICU population. If results are positive, povidone-iodine could be considered a 
powerful oral antiseptic agent in the prevention of VAP. 
Even though our inclusion criteria were strict, some limitations to our results have to be 
mentioned.  
First, studies were rather heterogeneous in their designs, applying chlorhexidine in varying 
concentrations, intervals and application manners. The study of Koeman et al. was the only study 
with a significant reduction of pneumonia rates in our statistical model.179  At the same time, it 
was one of two studies with the highest concentrations and the highest frequency of 
chlorhexidine application, including the buccal cavity and not teeth and gingiva alone, as in other 
studies. 
Secondly, there were two studies that were included in other meta-analyses and would have met 
our inclusion criteria.133, 225 However, in the original publications important data on VAP rates 
was missing, and the data reported in those meta-analyses was inconsistent.54, 59, 181 Thus, we 
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made several attempts for clarification from the primary authors of the studies but did not get 
verification that allowed us to included any data from these two studies. 
Overall, oral decontamination with antiseptics, especially chlorhexidine, seems to be an effective 
and safe strategy for the prevention of VAP. 
4.2. Airway Management 
a) Tracheostomy 
Thus far no clear recommendations have been formulated regarding the timing of tracheostomy 
in ventilated patients,  by various reviews and the VAP prevention guideline of the Canadian 
expert group.92, 135, 144, 222, 248 This is mainly due to the lack of good quality data and 
prospectively designed studies. In their evidence-based guidelines on weaning and discontinuing 
ventilatory support, MacIntyre et al. therefore recommend early tracheostomy only if there is a 
benefit for the patient, as there is less sedation, lower respiratory resistance, a psychological 
benefit and enhanced mobility.222 
Although more recently conducted RCTs included in our meta-analysis have not been considered 
by these guidelines, the question of when to perform a tracheostomy can not be completely 
clarified with the evidence available.19, 34, 45, 298, 302 The data seems to show a trend towards a 
reduction of pneumonia rates in early tracheostomized patients. Nevertheless, the differing time 
points for early and late tracheostomy or prolonged intubation between the studies as a potential 
confounder have to be considered. Also, whereas most of the studies were nonsignificant in their 
results regarding VAP, two studies did show a significant reduction of pneumonia rates.291, 298 
Hence it could be possible, that the sample size is too small to demonstrate a significant overall 
treatment effect of early tracheostomy. 
Early tracheostomy is considered superior to prolonged intubation because mortality rates were 
significantly reduced in the subgroup of early versus late tracheostomy. The length of ICU stay 
was significantly reduced in both of the studied subgroups. 
At this point there is no clear evidence for a clinically relevant effect of early tracheostomy on 
VAP. Nevertheless, early tracheostomy performed on days 1-8 seems to be favourable 
considering a trend in the reduction of pneumonia and mortality rates, the duration of MV and 
the length of ICU stay. 
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b) Weaning 
Our data demonstrated a significant reduction of pneumonia and mortality rates in patients that 
were extubated early and then ventilated with non-invasive pressure ventilation. This is in 
accordance with the fact that the ET tube is considered to be one of the greatest risk factors for 
VAP by the authorities and experts in the field; therefore, it should be removed as soon as 
possible.92, 135, 144, 222, 248 By removing the tube, natural defense mechanisms and clearing of the 
airway is made possible, and the collection of contaminated secretions above the tube cuff and its 
microleakage are prevented. A European expert group has proposed to further invastigate the 
benefit of non-invasive ventilation for VAP prevention in 2001340 and the CDC and the American 
Thoracic Society have recommended its implementation as soon as possible.3, 331 
Even though two of the included trials strictly speaking did not perform weaning, since they 
randomized their patients to either non-invasive or invasive MV from the beginning, without 
having performed invasive MV with an endotracheal tube before, we included them in this group 
due to the equivalence of the performed intervention in critically ill patients.13, 69 The fact that by 
performing a sensitivity analysis excluding these trials, results for weaning with non-invasive 
MV regarding VAP rates remain highly significant (p<0.001) proves that no bias was introduced 
by the inclusion of these two trials. 
The implementation of a weaning protocol in the study of Marelich et al. failed to reach 
statistical significance in reducing pneumonia rates in comparison with physician directed 
weaning.232 Still, it seems reasonable to implement weaning protocols in ICUs due to the 
advantages that have been shown in earlier trials and the advantages stated by clinical practice 
guidelines.103, 104, 190, 222 The American Thoracic Society also recommends the implementation of 
weaning protocols in their prevention guidelines.3 
Considering our results and the advantages explained above, non-invasive MV should be 
implemented in the weaning process whenever possible. 
c) Closed vs. open endotracheal suctioning 
According to our data, whether patients were suctioned by a closed or open method had no 
significant impact on VAP. Our results agree with those of three recently published meta-
analyses on this issue and the CDC-guidelines and those of the European expert group, that do 
not recommend one method or the other for preventing VAP.166, 307, 328, 331, 340, 372 Nevertheless, a 
Canadian expert group has recommended closed suctioning in their original and updated 
guidelines.92, 248 Although we identified one additional RCT in our analysis which showed a 
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significant reduction of pneumonia rates by closed suctioning, it did not lead to a change of the 
overall outcome and was a trial of limited quality.207 The results for the duration of MV, which 
was significantly increased by the closed suctioning technique, could also have limited validity, 
since it is basically resembled by one small study with a weight of 99.47%.339  
The advantage of the closed suctioning catheter system is an unchanged lung volume, alveolar 
recruitment, oxygenation and lower levels of environmental contamination52, 64, 226 , but on the 
other hand there is evidence for an increased microbial colonization of the catheter surface and 
the lower respiratory tract.88, 121, 339 The closed system seems to be more expensive than the open 
system, although there are arguments for the contrary if the catheter changes are limited to the 
clinically necessary.92, 216, 220  
Taking into account our results and the literature reports, closed suctioning does not appear to be 
superior to the open suctioning technique in the prevention of VAP. 
d) Daily vs. no daily changes of in-line suction catheters 
Our results gave no reason to assume that extended use of suction catheters increases pneumonia 
rates. The CDC and the European expert group give no recommendation regarding this issue, and 
in a recently published VAP prevention guideline, changes with every new patient have been 
recommended.248, 331, 340 As mentioned above, there are studies reporting a contamination of in-
line suction catheters88, 120, 339 but the effect of changing suction catheters daily or at longer 
intervals doesn’t seem to have an effect on pneumonia rates. To change suction catheters less 
frequently in order to save costs therefore seems feasible and safe. 
e) Heat and moisture exchanger (HME) vs. heated humidifier (HH) 
When comparing HMEs and HHs in VAP prevention various metaanalyses and guidelines now 
recommend the use of HMEs70, 92, 180. In contrast, most authors don’t recommend one 
humidification device or the other.3, 67, 248, 255, 308, 331, 340 One argument in favour of HMEs is to 
keep away contaminated condensation of the wire circuits that could otherwise reach the 
patient’s trachea and provoke infection233. However, this has been alleviated by newer HH 
devices with heated wire circuits that reduce the condensate to a considerable degree. And since 
it is normally the patient’s bacteria that contaminates the circuits and not environmental germs, it 
is not clear whether the contaminated condensate plays a role in the development of VAP.95, 146 
None of the subgroups showed a significant reduction of VAP rates with any of the devices. Only 
two single studies reached statistical significance, one using a HME, the other using a HH: 
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Kirton et al. demonstrated a significant reduction of pneumonia rates in patients ventilated with a 
HME, even though they were using heated wire circuits in their HH system.176 In the latest 
published study, Lorente et al. used an auto-feed chamber in addition to heated wire circuits to 
further reduce bacterial contamination, leading to a highly significant reduction of pneumonia 
rates compared to the group ventilated with a HME.217 Whether this auto-feed chamber is a new 
device with the ability to significantly reduce contamination and pneumonia rates should be 
further evaluated in another RCT. 
HMEs can persuade with less care provider time and cost savings176, 188, and since at this point 
none of the humidification systems seem to lead to a better outcome in VAP rates the choice 
should be made by individual considerations. 
f) Extended use of heat and moisture exchangers (HME) 
An extended use of HME for up to one week can save costs and seems to be a feasible and safe 
option according to our data. This is in accordance with recommendations of the current 
prevention guidelines.67, 92, 248, 331 Our results show a trend towards less VAP rates by less 
changes of the HME, while there was no significant impact on the secondary outcomes. 
In a study by Boisson et al. contamination rates and performance of a 48 hour versus a daily 
change of HME as recommended by the manufacturers were compared. A contamination of the 
ventilator’s side of the HME after 48 hours of use could not be found and a change in the HME’s 
performance after 48 hours was not witnessed, either.37 If these results are also true for a use of 
up to 7 days needs to be proven, but seems to be likely due to our results. 
g) Components of heat and moisture exchanger (HME) 
There have been attempts to improve the performance of HME by changing some of the filter 
components, an aspect that has not been evaluated by the guidelines so far. According to the lack 
of effect obvious from our results, at this point there is no evidence for superiority of one 
component over others. 
h) Change of ventilator circuits 
In addition to RCTs considered by earlier guidelines and reviews3, 67, 92, 248, 331, 340, we have 
identified new evidence43, 75, 215 that strengthens earlier recommendations to only change 
ventilator circuits when they are malfunctioning or visibly soiled. 
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Our data shows that in a study by Craven et al., patients receiving circuit changes at a two day 
interval instead of daily had a significantly lower VAP rate. 75 It was therefore questioned, 
whether by changing the circuits, the airway could be contaminated with environmental bacteria. 
Even though in none of the other studies a less frequent change of the circuits, with change-
intervals of up to seven days,  led to a significant reduction of pneumonia or mortality rates, not 
changing circuits frequently seemed to have no negative impact on the development of VAP. 
Furthermore, by changing circuits less frequently costs and workload can be reduced.147, 199 
i) Heated vs. non-heated wire circuits 
Even though we mentioned earlier that heated wire circuits are believed to reduce VAP rates by 
partially hindering the formation of contaminated condensation in the circuits, there was no 
evidence for a reduction of pneumonia rates in the study of Branson et al.47 Whether there is a 
true lack of effect or if this was due to the small sample size of this study, needs to be proven by 
larger trials. As mentioned above, it might also be that the pathogenic role of the condensates are 
overestimated.95, 146 None of the guidelines has evaluated this detail in the airway management 
strategy and its role for VAP prevention so far. 
j) Oro- vs. nasotracheal intubation 
Based on the only study from Holzapfel et al. no clear statement can be made as to whether oro- 
or nasotracheal intubation leads to lower VAP rates.158 Although this trial is the only one on this 
issue, orotracheal intubation has widely been recommended by current guidelines as the 
preferable way of intubation.3, 92, 248, 331, 340  This is due to the evidence that although airway 
complications might occur more often in orally intubated patients, maxillary sinusitis is a 
frequent complication in nasotracheally intubated patients, and should therefore be considered a 
reason to choose the oral route of intubation.16, 242, 294, 303 
k) Bacterial filter 
According to the nonsignificant results of Lorente et al. a recommendation for the use of 
bacterial filters to prevent VAP does not seem accurate. 219 Of the current guidelines, the CDC 
gives no recommendation, and another expert group does not recommend its usage.248, 331 
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4.3. Gastrointestinal Interventions 
Although there is an ongoing debate about the relevance of the colonization of the upper 
intestinal tract for the development of VAP3, 39, 341, various GI interventions, most importantly the 
selective decontamination of the digestive tract (SDD) and strategies to reduce the bacterial 
reflux load, are subject of VAP research.  
a) Selective decontamination of the digestive tract (SDD) 
Considering the highly significant result (p < 0.001) of our analysis there is no doubt about the 
effectiveness of SDD in reducing VAP rates. All of the slightly varying methods of SDD show a 
significant effect, with the application of topical agents to the buccal cavity and the GI tract with 
or without adding systemic antibiotics having the most significant treatment effect. Mortality 
rates could only be reduced significantly by combining topical application with systemic 
antibiotics.  
Since Stoutenbeek et al. first published the concept of SDD in 1984326, there have been more 
than fifty trials investigating its effects on infection rates and mortality in ICU patients. Eleven 
meta-analyses concerning SDD have been published in the last two decades , all reporting a 
significant reduction in pneumonia or other infections, and all but three reporting significant 
reductions of mortality rates, with two emphasizing the efficacy of topical and systemic 
antibiotics combined.1, 77, 150, 162, 183, 210, 251, 301, 309, 310, 366 Our analysis is the first exclusively 
taking into account its effectiveness in mechanically ventilated ICU patients. Although there is as 
much evidence for a benefit as in the other fields of preventive strategies, the fear of provoking 
multiresistant bacterial strains keeps authorities and guidelines from recommending this strategy 
for routine use in ICU patients.3, 67, 92, 248, 331, 340 There is an ongoing debate as to what extent 
resistance can develop and in which patients it should still be implemented. Also there are expert 
groups negating the risk to enforce resistancies.311 Of the twenty-seven trials included in our 
analysis eight reported an increase in resistant bacteria strains, endorsing the concerns regarding 
SDD.140, 204, 206, 279, 289, 304, 367, 377 
SDD is effective in preventing VAP, but it is in everyone’s interest to prevent the emergence of 
resistant bacterial strains, especially in ICUs, where the repercussions are severe. Therefore 
individual factors of the patient’s health status and resistance patterns in ICUs should decide 
whether the benefit for the patient outweighs the risk of potentiating resistance. 
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b) Selective decontamination of the digestive tract (SDD) with additional topical 
antibiotics 
By adding mupirocin to the classic topical SDD regimen of tobramycin, polymyxin E and 
amphotericin B, Nardi et al. showed a significant decrease of pneumonia rates.250 Their aim was 
to increase the effect of SDD due to the high rates of MRSA (60%) in Italian ICUs. Two other 
studies did find an alternative SDD regimen to be superior over the conventional one. 
Since resistance patterns of bacterial strains differ from country to country, adding new 
substances to the traditional components might be a way to improve the effect of SDD, but the 
efficacy and safety has to be evaluated in detail for each of the new approaches. 
c) Interventions to reduce the bacterial reflux load 
Various interventions to decrease VAP rates by reducing the bacterial reflux load have been 
studied and were included in our analysis. 
Among these, the type of stress ulcer prophylaxis is a central issue that has been evaluated by 
several reviews and meta-analyses with somewhat discordant results and recommendations for 
implementation.3, 67, 72-74, 92, 331, 340, 348-350 
According to our data, sucralfate significantly decreased VAP-rates compared to H2-antagonists. 
Results just failed to reach significance when sucralfate was compared with H2-antagonists 
combined with antacids (p=0.05) and when compared with antacids alone (p=0.06), but a trend 
in the effectiveness can be assumed. Mortality rates were not influenced by the type of stress 
ulcer prophylaxis used. 
The most adduced reason for concerns with preferring sucralfate over H2-antagonists or antacids 
is the possible risk of a higher incidence of bleeding in patients treated with sucralfate. Of the 
trials included in our analysis, Cook et al. reported a significantly higher incidence of bleeding in 
the patient group receiving sucralfate compared to those receiving H2-antagonists.71 Since this 
large trial provides about half of the patient population in this comparator group, a higher 
incidence of bleeding has to be taken into account when clinicians decide to administer 
sucralfate for stress ulcer prophylaxis for prevention of VAP. Nevertheless, it has to be 
emphasized that none of the other trials reported an increase of bleeding in patients treated with 
sucralfate. 
Of the other attempts to reduce the bacterial burden of the stomach only the performance of early 
gastrostomy in patients requiring enteral feeding in a study of Kostadima et al. showed 
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significant results in reducing VAP rates.198 There was no significant effect on mortality, and so 
far, none of the current guidelines have evaluated early gastrostomy as a prevention strategy. 
When interpreting these results, the small sample size of only 41 patients has to be taken into 
account. Furthermore, gastrostomy as an invasive method is neither easy nor cheap to implement 
on a broad ICU population. Therefore, more data and an evaluation of risks and benefits is 
needed before it can be considered as a preventative strategy for VAP. 
The application of enteral naloxone in patients under opioid analgesia in a trial of Meissner et al. 
just failed to reach statistical significance with p=0.05 and the confidence interval extending to 
1.01.237 Naloxone has been shown to increase gastric emptying, and given enterally it has a local 
but a limited systemic opioid-antagonistic effect due to a high hepatic first-pass metabolism.115, 
243
 Meissner et al. showed that with enteral naloxone the suppressive effects of opioids on GI 
motility could be antagonized successfully and that the gastric tube reflux and pneumonia rates 
were significantly reduced. 
So far, this is the only RCT of naloxone administered for antagonism of opioid effects in the GI 
tract and it has not been mentioned by any of the guidelines thus far. The mechanism of action of 
naloxone and its possible value for the prevention of VAP in patients under opioid analgesia 
sound very promising and more data of large RCTs would be helpful to evaluate its effects more 
reliably. 
With the enteral administration of metoclopramide, Yavagal et al. hypothesized reduced 
pneumonia rates due to the antagonistic effect it has on dopaminergic D2 receptors of the upper 
GI tract.142, 381 Even though by this interaction the pressure of the esophageal sphincter and 
gastric contractility is increased and therefore the gastroesophageal reflux supposedly declines, 
the authors could not demonstrate an effect neither on VAP rates in the subgroup included in our 
analysis, nor on pneumonia rates in a more general ICU population. Metoclopramide was 
mentioned, but not recommended by one guideline only.67 
Of the other interventions intented to reduce the bacterial reflux load, none showed significant 
results in the reduction of VAP or mortality rates. 
Intermittent as opposed to continuous enteral feeding, with the aim to decrease the gastric pH by 
not feeding the patient continuously, had no effect on the patient’s pneumonia or mortality rates. 
Even though we did identify new evidence224, 332, these results are in accordance with two of the 
guidelines evaluating intermittent feeding, giving no recommendation for its usage.67, 331 
In regard to small intestinal versus gastric feeding and the acidification of enteral feeds there was 
no evidence for a treatment effect, although there was a trend in the results towards a reduction 
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of pneumonia rates. There was no recommendation for both of these strategies by two of the 
VAP prevention guidelines.67, 331 Further research with sufficiently powered RCTs revealing a 
possible positive effect are needed. 
Overall, the reduction of the bacterial reflux load with interventions that lower the gastric pH 
levels proved to be clinically relevant, and seem to be an essential part in the prevention of VAP. 
Nevertheless, not all interventions studied showed a significant treatment effect, partly due to a 
lack of appropriately powered RCTs. 
d) H2-antagonist vs. antacid 
So far, a superiority of H2-anatagonists over antacids regarding the prevention of VAP has not 
been proven, and no recommendation for the use of one of the two agents has been made by the 
current VAP prevention guidelines. 
Comparing the antacid pirenzepine with the H2-antagonist ranitidine, Tryba et al. could not prove 
a significant difference in the treatment effects of these agents, although there was a trend 
towards a better outcome with pirenzepine (p=0.06).347 In another trial, Thomason et al. did not 
find a difference in the pneumonia rates of patients receiving antacids or ranitidine.337 This study 
does not appear in the analysis of this comparator group for methodological reasons. Being a 
study with three intervention groups, it was already considered in the comparator group 
sucralfate vs. antacids and patients would have been included twice in the analysis. 
Neither antacids nor H2-antagonists were superior with regard of the prevention of VAP.  
e) Enriched enteral nutrition 
Although some of the studies administering enriched enteral nutrition had significant effects of 
both, de- and increased, VAP rates, the overall effect of our analysis was not significant. Due to 
the variable feeding formulas of the four trials summarized in this group the results need to be 
interpreted with caution.  
Our results are in accordance with an earlier meta-analysis of immunonutrition of Heyland et al., 
who did not find a difference in infection and mortality rates in patients receiving enriched 
enteral nutrition.154 Nevertheless, another meta-analysis of immunonutrition in critically ill 
patients, published by Montejo et al. reported a significantly lower rate of nosocomial 
pneumonia, taking eleven studies into account.245 Discrepancies to our results can be explained 
by the different patient population, since patients in this meta-analysis did not have to be 
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mechanically ventilated, whereas our inclusion criteria were restricted to RCTs evaluating the 
outcome VAP. 
Of the VAP prevention guidelines only Collard et al. made a statement regarding glutamine 
nutritional support, giving no recommendation for its administration.67 
At this point there is not enough data, or data of too discrepant feeding formulas, to discard an 
effect of enriched enteral nutrition on VAP rates. If the beneficial effects of immunonutrition on 
various infectious outcomes in a population of critically ill patients reported by Montejo et al. 
can also be reached in the subgroup of mechanically ventilated patients, needs to be proven by 
sufficiently powered RCTs. 
f) Early enteral nutrition 
Our results of early enteral nutrition are difficult to interpret due to the diverging methods of 
implementation between the two trials. While Kompan et al.193 compare early enteral feeding at 
admission to feeding after 24 hours, Ibrahim et al.163 compare full caloric goals at day one or day 
five after admission. While in the study of Kompan et al. pneumonia rates were statistically 
significantly decreased, the opposite was the case in the study of Ibrahim et al. 
A beneficial effect of enteral feeding regarding infectious complications, especially compared 
with parenteral nutrition can not be discarded, and could be the reason for the result of Kompan 
et al.246, 272 Nevertheless, bacterial overgrowth and gastroesophageal reflux due to enteral 
nutrition should be taken into account, and could explain the outcome of Ibrahim et al. Of the 
guidelines only the European expert group makes early enteral nutrition a subject of discussion 
emphasizing the controversity in the possible benefits but also disadvantages.340 Whether early 
or late enteral nutrition plays a role in preventing VAP remains unclear and if the diverging 
results are due to the different feeding protocols needs to be investigated in future trials. 
g) Enteral vs. parenteral feeding 
Kudsk et al. showed a significant reduction of VAP rates and ventilator days in patients receiving 
enteral nutrition support as opposed to those with total parenteral feeding.201 This is in 
accordance with a recently published guideline of nutrition support in mechanically ventilated 
critically ill patients by Heyland et al., that emphasized the superiority of enteral vs. parenteral 
feeding regarding infectious complications by their strong recommendation.152 In an earlier 
meta-analysis, Moore et al. showed a reduction of septic complications in high risk surgical 
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patients fed enterally.246 Of the VAP prevention guidelines only the American Thoracic Society 
addresses this issue, recommending enteral feeding over parenteral.3 
Due to our inclusion criteria of at least 90% of MV some of the studies included by Heyland et 
al., which were clearly below this margin, were not included in our analysis. Still it is reasonable 
to assume, that a certain regimen that brings a benefit to critically ill patients in general is also of 
advantage for ventilated patients. Only the fact that enteral feeding can produce bacterial 
overgrowth in the stomach, especially when the bowel is malfunctioning and not processing the 
food, could lead to the assumption that there could be an adverse effect on VAP, which might 
therefore be more frequent in these patients. On the other hand, the protective features of enteral 
feeding like improved wound healing, decreased catabolic response to injury, GI functioning, 
and improvement of clinical outcomes, as reported by Heyland et al. , seem to outweigh the risks 
of enteral feeding.148 
Even though the statistically significant result of enteral versus parenteral feeding is supported 
by only one study, taking additional evidence of the literature into account, it is fair to assume a 
clinically relevant effect of enteral over parenteral feeding. 
4.4. Positioning 
a) Rotational therapy 
Rotational therapy is one of various positioning strategies that are implemented in the care of 
ICU patients in order to improve oxygenation and prevent the development of VAP. 
Overall, results for rotational bed therapy and the reduction of VAP rates were statistically 
significant (p<0.01), with both of the subgroups, kinetic therapy (automated turning of the 
patient in his bed of at least 40 degrees to each side), and continuous lateral rotation therapy 
(CLRT, automated turning of the patient in his bed of up to 40 degrees to each side), being 
significant. There was no clinically relevant difference in mortality rates or the length of MV and 
ICU stay between treatment and control groups however. 
Three recently published meta-analysis evaluating rotational therapy techniques reported 
comparable results, even though these were papers of a broader patient population, not solely on 
mechanically ventilated patients.70, 85, 130 
Despite this, the CDC provides no recommendations for rotational therapy as a preventive 
strategy in their guidelines for the prevention of health-care associated pneumonia.331 One reason 
for this discrepancy might be that the CDC has also considered trials of a more general ICU 
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population, not only mechanically ventilated patients, e.g. a trial of liver transplant patients. It is 
possible, that mechanically ventilated patients might specifically benefit from rotational therapy. 
Furthermore, the CDC did not consider all of the studies included in this systematic review; in 
addition no overall estimates were calculated in their recommendations. 
Other guidelines claim that clinicians should keep their implementation in mind. Again, some of 
these guidelines did not include the latest publications which are included in this meta-analysis, 
or considered interventions that failed to demonstrate efficacy according to our analysis.67, 92, 248 
In a recently published national survey of positioning therapy in German ICUs, Bein et al. 
reported that approximately 30% of ICUs in Germany frequently implement either CLRT or 
kinetic therapy.21 High costs for special beds and patient intolerance are the most frequent 
reasons why kinetic therapy is not utilized. 
Study quality of some of the included trials was not always optimal, nevertheless rotational 
therapy seems to be an effective method for the prevention of VAP. However, the high costs will 
probably always limit its usage on a broad ICU patient population. 
b) Prone vs. supine positioning 
RCTs considering prone positioning as a preventive strategy for VAP have been published only 
recently. They have shown that oxygenation can be improved by prone positioning, but 
complications like pressure sores, tube obstruction and selective extubation have also been 
reported.48, 125, 136, 205, 271, 287, 371 Two of the current VAP prevention guidelines and one recently 
published meta-analysis on prone positioning have evaluated prone positioning as a preventive 
strategy for VAP5, 12, 92, 248, 338, without recommending its usage for VAP prevention apart from 
one of the meta-analysis329 that included two trials not meeting our inclusion criteria. Results of 
our analysis are statistically not significant, although with p=0.13 and p=0.09 for pneumonia and 
mortality rates, respectively, one can note a trend towards a treatment effect. Prone sessions 
differed slightly between groups, which might have introduced bias to the interpretation of the 
results. In contrast to the recently published meta-analyses, we distracted the number of patients 
with pneumonia at study entry for data analysis of the trial of Voggenreiter et al.370 
Clinicians in Germany seem to consider prone positioning as advantageous, since according to 
the survey of Bein et al. mentioned above, prone positioning is preferred over rotational therapy 
of 39% of German ICUs.21 
A benefit regarding VAP could not be confirmed by our analysis, although we do not discard its 
beneficial effect in lung oxygenation, which might be proven by future studies. 
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c) Semirecumbent vs. supine positioning 
Semirecumbent positioning is widely accepted in ICUs and has been recommended as a 
preventive strategy for nosocomial pneumonia in all of the recently published guidelines. 3, 67, 92, 
248, 331, 340
 These recommendations are mainly based on the results of Drakulowic et al. and two 
other studies, published by Orozco-Levi et al. and Torres et al., revealing that in the 
semirecumbent position the reflux of radioactively labelled gastric contents into the airways was 
significantly lower than in the supine position.94, 262, 343 The trial of Draculovic had no intention-
to-treat analysis and excluded patients not maintained at 45° for more than 45 minutes. 
In 2006 Nieuwenhoven et al. demonstrated in an intention-to-treat analysis that the targeted 45° 
could not be reached, measuring backrest elevation with a computer-based pendulum system.364 
The mean head-of-bed elevation achieved in their study was about 30°, and compared to their 
ICU standard of 10° head of bed elevation, the reduction of VAP rates was not significant. 
The third study of our analysis of Keeley et al. which compares 45° to 25° head-of-bed elevation, 
statistically significant results in this small study of thirty patients were not achieved.172 
In a second analysis we integrated a study of Girou et al. who combined semirecumbency of 30° 
with subglottic secretion drainage.129 Since subglottic secretion drainage has been proven to be 
highly significant in reducing pneumonia rates, we would have expected an overinterpretation of 
the treatment effect of semirecumbent positioning by integrating the results of this trial. But 
considering the results were negative, we assumed the influence on the outcome by subglottic 
secretion drainage was minimal in this case, and added this trial to the analysis of this group. 
Results of our analysis did not reach statistical significance, not for pneumonia or mortality rates. 
Still, the effect on pneumonia just failed to reach statistical significance in both of the analyses 
(p=0.06, p=0.07). Due to the heterogeneity in the angles applied in the treatment and control 
groups, we applied the random effects model for analysis; however the test for heterogeneity was 
not significant. 
Draculovic and Keeley were the only authors who claimed to have reached the 45° degrees of 
head-of-bed elevation, with a significant reduction of VAP rates in the Draculovic-study, and a 
possible trend in the reduction of pneumonia rates in the study of Keeley et al. Nevertheless, 
Nieuwenhoven et al. have demonstrated in a high quality trial that it is unclear that 45° head–of-
bed elevation in ICUs can be achieved, even when it is specifically attempted for the concerns of 
a study. Reasons might have been health-care worker related or due to patient discomfort. The 
achieved 30° of backrest elevation compared to 10° did not lead to a statistically significant 
reduction of VAP rates. How Draculovic and Keeley reached a head of bed elevation of 45° 
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while other authors failed to do so is an interesting discrepancy. Nieuwenhoven et al. argue that 
elevating the patient head of bed too much, microleakage around the tracheal tube cuff enhanced 
by gravity could actually provoke nosocomial pneumonia. Also, according to the authors, 
changing the patient’s position for medical or nursing care could facilitate microleakage. 
Furthermore, they state that it might be more reasonable to compare 45° to an elevation of 10°, 
and not 0° as it was done by Drakulovic, Torres and Orozco-Levi, because a position of 0° does 
not resemble real life conditions, especially if patients are fed enterally. 
There is evidence suggesting that backrest elevation of 45° significantly reduces VAP rates. 
Nevertheless, we have to question the relevance of this preventive strategy in reality, since the 
targeted 45° are hardly achieved. Also, whether or not microleakage is enhanced by backrest 
elevation due to gravity, needs to be investigated further. 
4.5. ET Tubes 
a) Subglottic secretion drainage 
Our anaylsis showed a highly significant reduction of VAP rates in patients undergoing drainage 
of subglottic secretions through a lumen above the tube cuff (p<0.01), while there was no 
evidence for a reduction of mortality rates. No serious adverse events were reported. These 
findings are in accordance with previous results and recommendations of meta-analyses and 
guidelines, with the difference that we were able to identify new evidence underlining the 
effectiveness of this strategy. 3, 90, 92, 248, 331 Controversies regarding subglottic suctioning reported 
by the guideline of the European expert group, which is the least recent of the guidelines, should 
be clarified by the new evidence published after the communication of these guidelines.340 
In contrast to the other studies, Lorente et al. utilized newly developed tubes with a polyurethane 
cuff.218 Polyurethane used in tube cuffs promises an important reduction of microleakage, 
although RCTs comparing conventional material with polyurethane are still pending. Therefore, 
the authors partly explain their positive results with this new cuff material.  
Trial quality was good in most cases, although allocation concealment was unclear in six of the 
seven trials. Also, in the two Chinese studies the suctioning intervals were unclear.36, 212  
The study of Mahul et al. was conducted in a two by two factorial design, and was the only study 
in our analysis where patients were included twice, in the stress ulcer prophylaxis group and the 
subglottic suctioning group.227 Since the authors have proven the absence of interaction between 
the two factors, the chance of having introduced bias to our results by doing so can be discarded. 
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The reported additional costs of about 25% for the special tubes needed for subglottic secretion 
drainage should be taken into account with regard to the positive treatment effect of this 
strategy.227 
Overall, subglottic secretion drainage has proven to be an essential strategy for the prevention of 
VAP, even though mortality rates could not be positively influenced. 
b) Silver-coated tube 
VAP rates could be significantly reduced with a newly designed silver-coated tube without 
provoking adverse events associated with this device. Rello et al. did not reach a significant 
reduction of pneumonia rates in a trial of 155 patients, but did show a reduction of the bacterial 
burden of the airways.284 Kollef et al. conducted a multicenter trial with 54 participating centers 
including 1509 patients and demonstrated a significant reduction of VAP rates. The authors 
found the effect of the silver coated tube to be greatest within the first ten days of intubation. The 
antimicrobial effect of silver and the reduction of biofilm formation and bacterial adhesion on 
catheters has been described in the literature,10, 28, 122 however the current guidelines have not 
addressed this issue so far. 
Overall, there seems to be sufficient evidence to consider silver coated tubes efficient and safe 
devices for VAP prevention. 
c) Automated control of endotracheal tube cuff pressure 
Valencia et al., who recently developed a device for pressure control, hypothesized a reduction in 
leakage and subsequent pneumonia rates if cuff pressures are constantly maintained at 
20mmHg.109, 357 Although the device functions reliably, there was no significant effect on VAP 
rates by automated control of the tube cuff pressure. Whether or not the little power was the 
reason for the nonsigificant effect is difficult to tell at this point. Also, no statement can be made 
for other devices used for tube cuff pressure control, since this was a study of a device developed 
by the authors previously. Whether or not an automated control of the tube cuff pressure has an 
impact on VAP rates has not been evaluated by the guidelines so far. 
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4.6. Non-classifyable preventive strategies 
a) Aerosolized antibiotics 
Our results showed a significant reduction of pneumonia rates by application of aerosolized 
antibiotics, with no effect on mortality rates. 
One aspect should be considered when these results are interpreted, though. The study of Li et al. 
and Greenfield et al. were not blinded or placebo-controlled.134, 209 Neither blinding nor placebo-
control were inclusion criteria for our meta-analysis, because for some of the preventive 
strategies for VAP they are not reasonably practicable. This is not true for the application of 
aerosolized antibiotics, though, which could have been easily implemented in the study protocols 
of these trials. 
The latest published guideline on VAP prevention by Muscedere et al. includes aerosolized 
antibiotics in their considerations, giving no recommendation for its implementation as a 
preventive strategy.248 
Since a probable facilitation of resistance always has to be taken into account when 
administering antibiotics prophylactically and there are some methodological limitations to the 
studies of this analysis, the application of aerosolized antibiotics should be considered as a 
preventive strategy for VAP with caution. 
b) IV antibiotics 
In patients receiving systemic antibiotic prophylaxis, VAP rates were significantly reduced while 
mortality rates were unchanged. This was mainly due to the results of Sirvent et al. who showed 
a 50% reduction of pneumonia rates by administering a twofold dose of cefuroxime at intubation 
and twelve hours later.315 The reason for a significant increase in the duration of MV is unclear to 
us at this point and should not be overinterpreted without further investigation given the small 
sample size. 
So far, the administration of systemic antibiotics for prevention of VAP has not been 
recommended for general use by nearly all of the current guidelines.3, 92, 248, 331, 340 As mentioned 
above, administering antibiotics prophylactically, given the fear of creating resistance is 
reasonable, and it is up to the clinician to evaluate the pros and cons for their patient. 
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c) Pharyngeal vs. tracheal decontamination 
In the study of Martinez-Pellus et al. there was no evidence demonstrating that pharyngeal 
decontamination was superior to tracheal in reducing VAP rates, which is an issue that has not 
been addressed by the guidelines thus far.236 Compared with a historical control group, which 
was not included in our analysis due to lack of randomization, pneumonia rates were 
significantly reduced by either one of the decontamination strategies. This is in accordance with 
the significant effect of other decontamination strategies outlined above, whereas, given the 
available data, tracheal decontamination does not seem to be superior to pharyngeal 
decontamination.  
d) Systemic search for maxillary sinusitis 
Even though not confirmed by our analysis (we used the chi-square test) Holzapfel et al. were 
able to demonstrate a significant reduction of VAP rates by systematically searching for 
maxillary sinusitis via CT scan.157 In addition, the authors were able to demonstrate a reduction 
in mortality but have cautiously recommended that such results need to be repeated.  However, 
since this intervention explicitly aims at patients intubated by the nasotracheal route, it is unclear 
whether orally intubated patients would benefit from systematically conducted CT scans to 
detect sinusitis. This may be one of the reasons why only two of the current guidelines include 
systemic search for maxillary sinusitis but don’t recommend its implementation.92, 248 
e) Chest physiotherapy 
In a small study, Ntoumenopoulos et al. showed a significant reduction of pneumonia rates by 
chest physiotherapy, consisting of gravity-assisted drainage, chest wall vibrations and airway 
suctioning twice daily.258 According to these results chest physiotherapy seems to be an 
appropriate method to assist in the clearance of the lungs from secretions which are impaired by 
the endotracheal tube and MV. Nevertheless, some aspects of the physiotherapy treatment require 
a cautious interpretation of these results. 
First, airway suctioning as a determined part of the physiotherapy protocol alone might have 
contributed to the positive outcome. The nursing staff also implemented airway suctioning in the 
control group, but only if considered necessary. In another study by the same author, which is 
discussed below, postural drainage and manual lung hyperinflation did not have significant 
treatment effects on VAP rates.257 In that study, airway suctioning was part of the standard 
nursing care and applied to both patient groups in the same manner. 
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Second, the randomization according to the date of admission and the small patient population 
could have limited the validity of these results. Dodek et al. were the only that integrated chest 
physiotherapy into their guidelines without recommending its usage.92 In the updated version of 
this guideline, this prevention strategy remains unmentioned.248 
More data with a sufficiently powered randomised controlled trial is needed to evealute the effect 
of this physiotherapy protocol. 
f) Manual lung hyperinflation and postural drainage 
As mentioned above, Ntoumeopoulos et al. did not show a reduction of pneumonia rates with a 
physiotherapy protocol, implementing manual lung hyperinflation and postural drainage.257 The 
effects of manual lung hyperinflation, as there is re-expansion of the atelectatic lungs, 
improvement of the lung compliance and oxygenation as well as sputum clearance have been 
reported in the literature.155, 221, 268, 293, 314 Nevertheless, the applied pressure of 40mmHg in this 
trial could also have damaged the lung tissue and therefore a treatment effect could have been 
concealed. None of the current guidelines have approached this prevention strategy so far. 
Whether a treatment effect on VAP was not proven due to the little power of this study or due to 
a lack of effect or even adverse effect of the intervention, needs to be examined in a large 
randomized controlled trial. 
g) Granulocyte colony-stimulating factor 
The effect of a granulocyte colony-stimulating factor is supposed to help the body in critically ill 
patients to fight pathogens and infections by promoting the differentiation and proliferation of 
neutrophil precursor cells, prolonging the survival of neutrophils and acting as a chemotactic 
trigger for granulocytes and TNF-alpha suppression.20, 131, 320, 374 
In a level II trial implementing two different doses of the granulocyte colony-stimulating factor 
filgrastim, Heard et al. could not show a significant treatment effect regarding VAP rates and of 
the current guidelines only the CDC refers to granulocyte colony-stimulating factors as a 
preventive strategy but gives no recommendation for its usage.143, 331 The authors argue that this 
could be due to the late onset of filgrastim or due to the small sample size of this study. They 
also state that it might be due to the fact that filgrastim enhances lung tissue damage and 
potential for ARDS due to the neutrophilia it provokes and the neutrophil products that are 
dispensed during migration to the lungs. These hypotheses should be explored by further 
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investigations, therefore at this stage the role of granulocyte-stimulating factors as a preventive 
strategy for VAP remains unclear. 
h) Decontamination of the subglottic area 
Pneumatikos et al. conducted a study of an antibiotic decontamination regimen of polymyxin E, 
tobramycin and amphotericin B. This was continuously administered to the subglottic area and 
suctioned at least once hourly through a dorsal lumen of the ET- tube.273 They added the 
antibiotic regimen used for SDD, to the prevention strategy of subglottic secretion drainage. The 
reduction of VAP rates was highly significant (p=0.03), but there was no influence on mortality 
rates. Tracheal colonization and the length of stay were significantly lower in the treatment 
group. 
The small sample size and some methodologic features, like the nondescribed randomization 
technique and the little concretized diagnosis of pneumonia, limit the quality of this trial. 
Nevertheless, the antibiotic decontamination of a crucial area for the development of VAP, the 
subglottic area above the tube cuff, combined with subglottic secretion drainage may add up the 
effects of two preventive techniques that have already proven to be significant on their own. As 
with the SDD regimen, resistance has to be taken into account, even though the area the 
antibiotics are applied to is small. So far, the guidelines have not mentioned decontamination of 
the subglottic area as a preventive strategy, and more data should be gathered to strengthen the 
evidence available at this point. 
i) Early PEEP 
In the study by Pepe et al. pneumonia rates could not be reduced by applying an early PEEP of 
8cmH2O for 72 hours in addition to intermittent positive pressure ventilation.269 The same is true 
for the main outcome, ARDS, and mortality rates. In a recently published trial by Manzano et 
al.231, applying PEEP of 5-8cmH2O to nonhypoxemic patients could significantly reduce VAP 
rates, and the overall outcome of our analysis for the reduction of VAP rates of early PEEP was 
statistically significant. A protective effect of PEEP regarding lung edema and ventilator-induced 
lung injury has been described in the literature97, 358, but so far, it has not been discussed by the 
current guidelines. 
Manzano et al. emphasize that their positive results are only applicable to nonhypoxemic patients 
and therefore the application of PEEP can not be recommended for general use as a prevention 
strategy. Nevertheless a positive treatment effect was evident from this trial and further 
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investigation should strengthen this evidence and could clarify whether the application of early 
PEEP is protective for a general ICU population. 
j) Antioxidant therapy 
In severly ill patients, oxidative stress is high and the possibility to support antioxidant 
biochemical pathways by supplementation of trace elements and vitamins, has been widely 
described in the literature.23, 267, 275, 282, 375 In a recently published meta-analysis of Heyland et al., 
a possible survival benefit for ICU patients treated with antioxidant therapy containing selenium 
was described, whereas this preventive strategy remains unmentioned by the guidelines.153 
Two studies met our inclusion criteria and significantly reduced VAP rates in a population of 
burn and trauma patients, applying two different regimens of a parenteral antioxidant therapy.  
Berger et al. applied a regimen containing zinc, selenium and copper through a central line 
catheter during eight, fourteen or twenty-one days, in severly burned patients.24 
The regimen applied to trauma patients by Porter et al. for seven days, consisted of N-
acetylcysteine, selenium and vitamins C and E.274 
The small patient populations of the studies could limit the validity of these results. Furthermore, 
the publication of Berger et al. aggregates data of two conducted randomized controlled trials. 
Even though they were of almost identical design, there might be methodological limitations. 
The first study was published in detail in 1998.25 The second study was published as a poster but 
did not give detailed information on the clinical outcomes we were interested in, and we could 
not include it in our analysis.26 Since the study protocols were almost identical, apart from the 
slightly different time interval of study drug administration (eight vs. fourteen and twenty-one 
days), we considered the risk of introducing bias by integrating the aggregated data as being 
small. 
Antioxidant therapy appears to be effective in reducing VAP rates in trauma and burn patients. 
Whether this is true for a general and larger ICU population needs to be demonstrated with more 
RCTs of this prevention strategy. 
k) Endonasal mupirocin 
In a study aimed at reducing MRSA pneumonia by applying nasal mupirocin versus placebo 
three times a day for three days, Di Filippo et al. could not show a significant effect of this 
prevention method.91 However, colonization rates of the nares with MRSA in the treatment 
group, was significantly lower. Only one of the VAP guidelines mentions mupirocin 
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decontamination, without giving a recommendation concearning its usage.248 A larger, 
sufficiently powered RCT would be needed to detect a significant treatment effect. 
4.7. Limitations 
Even though our inclusion criteria were strict, some limitations of this meta-analysis have to be 
mentioned. 
First, the quality of some of the trials included in our analysis was not always optimal, and the 
trial quality was given no weight in our statistical calculations by the program we used (RevMan 
4.2). 
Also, since we wanted our results to be valid for a broad ICU population, we did not 
differenciate between the subgroups of patients with different underlying conditions, e.g. burn 
patients, trauma patients, medical patients, etc. We can not rule out that this was a source of bias 
for our results. 
Furthermore, even though our search strategy was profound, there might be evidence that was 
not captured by our search strategy, even though the chance for this is negligible. 
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5. Conclusion 
From the results of this meta-analysis, various methods and techniques for the prevention of VAP 
were demonstrated as being effective and clinically relevant and allow for conclusions regarding 
the pathogenesis of VAP. 
The endotracheal tube itself, impairs natural defenses and allows micro-leakage of contaminated 
secretions, and seems to be the most important factor in the development of VAP; therefore, this 
type of pneumonia could even be regarded as intubation-associated rather than ventilator-
associated. Non-invasive, as opposed to invasive MV (OR=0.14, 0.07-0.25), subglottic secretion 
drainage (OR=0.34, 0.24-0.49) and the usage of a silver-coated tube (OR=0.62, 0.44-0.89) 
appears to significantly reduce VAP rates. 
Another decisive factor in the prevention of VAP seems to be the reduction of the bacterial load, 
and various strategies with statisctically significant results aimed at different origins and sites of 
potential contamination. Oral decontamination with antiseptics (OR=0.60, 0.45-0.82) and 
subglottic decontamination (OR=0.17, 0.05-0.56) target the buccal cavity. Selective 
decontamination of the digestive tract (OR=0.32, 0.24-0.43), sucralfate versus H2-antagonists 
(OR=0.77, 0.64-0.93) early gastrostomy (OR=0.18, 0.03-0.99) and enteral versus parenteral 
nutrition (OR=0.30, 0.10-0.85) appeal to the digestive tract. The lung itself is the target of the 
application of aerosolized antibiotics (OR=0.55, 0.34-0.87). Systemic approaches for the 
reduction of infectious complications include administration of systemic antibiotics (OR=0.56, 
0.32-0.99) and antioxidant therapy (OR=0.12, 0.03-0.42). 
Preventative strategies aimed at better ventilation of all lung areas and clearance of secretions, 
which proved to be statistically significant, are rotational therapy (OR=0.34, 0.23-0.52) and chest 
physiotherapy (OR=0.14, 0.03-0.70). 
An intervention which proved to be statistically significant but was restricted to nonhypoxemic 
patients was the application of early PEEP (OR=0.41, 0.18-0.91). 
Why other interventions, which are believed to be effective or have been described as effective 
in the literature, did not reach statistical significance in this meta-analysis, was either due to new 
evidence or insufficient power due to small sample sizes and should be subject to further 
research. In particular, the effects of semirecumbent positioning and early tracheostomy should 
be reconsidered. 
When implementing a prevention strategy, various factors determine whether it is feasible and 
safe, and this dictates its usage. With the pharmacologic strategies, resistance rates can be 
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facilitated, and even though various decontamination regimen proved to be highly significant, it 
is up to the treating physician to decide whether a potential benefit for the patient regarding VAP 
rates outweighs the risk of introducing resistance. This is especially true for antibiotic 
decontamination regimens, unlike decontamination with antiseptics which has a lower risk for 
resistance. 
Costs are another key factor determining whether a strategy is implemented in ICUs, and if it 
should be taken into account when future research is done. Even though there are strategies like 
rotational therapy that have shown to be clinically effective, they can be very unpopular among 
physicians due to the high costs, and might not be within the budget of ICUs. 
On the other hand, promising new developments in tube devices, like new polyurethane cuffs or 
silver coating of the inner surface of the tubes, seem to be effective and affordable and continues 
to be advanced by the industry and researchers. 
Even though a strategy proved to be statistically significant in reducing VAP rates, in most cases 
the secondary outcomes including mortality, the duration of mechanical ventilation and the 
length of ICU stay, remained unchanged. In part, this might be due to the fact that there was not 
enough power to demonstrate a treatment effect, especially regarding mortality rates. 
Nevertheless, an effect of VAP on mortality has not been clearly proven so far. 
Future research should focus on prevention strategies that are feasible and safe to implement and 
that are in accordance with the available budget and human recources in ICUs. To reduce 
microleakage of contaminated secretions of the tube cuff is the crucial factor for reducing VAP 
rates. 
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6. Summary 
In this quantitative systematic review, we summarized and compared the efficacy of all 
interventions that have been studied for the prevention of VAP and compared them to current 
recommendations and guidelines. By applying a consistent statistical method for analysis to all 
prevention strategies, results are comparable between one another. This gives clinicians an 
overview of all the available evidence and its effectiveness. 
We searched Pubmed, Embase, the Cochrane-library, Scientific Indexing and clinicaltrials.gov 
for relevant randomised controlled trials and complemented it with a hand search of the 
reference lists of relevant articles. 
A total of 1948 citations were screened of which 169 met our pre-defined inclusion criteria. The 
overall results, including odds ratios (OR), confidence intervals (CI), numbers of studies and 
patients are displayed in a forest plot in Figure 35.  
The following interventions, ordered according to their effect sizes, were statistically significant 
and were represented by more than one study: non-invasive as opposed to invasive MV 
(OR=0.14, 0.07-0.25), selective decontamination of the digestive tract (OR=0.32, 0.24-0.43), 
subglottic secretion drainage (OR=0.34, 0.24-0.49), rotational therapy (OR=0.34, 0.23-0.52), 
aerosolized antibiotics (OR=0.55, 0.34-0.87), systemic antibiotics (OR=0.56, 0.32-0.99), oral 
decontamination with antiseptics (OR=0.60, 0.45-0.82), silver coated tubes (OR=0.62, 0.44-
0.89) and sucralfate versus H2-antagonists (OR=0.77, 0.64-0.93). Antioxidant therapy with trace 
elements was statistically significant and studied by more than one trial, but in a small number of 
patients only (OR=0.12, 0.03-0.42). 
In addition, the following interventions were statistically significant, but were represented by 
only one study: chest physiotherapy (OR=0.14, 0.03-0.70), subglottic decontamination 
(OR=0.17, 0.05-0.56), early gastrostomy (OR=0.18, 0.03-0.99) and enteral vs. parenteral 
nutrition (OR=0.30, 0.10-0.85). 
Statistically significant, but applicable only to a subgroup of nonhypoxemic patients, was the 
early application of PEEP (OR=0.41, 0.18-0.91). 
All other interventions, e.g. the type of humidifier or filter, suction technique or changes of 
breathing circuits failed to reach statistical significance. This was also true for semirecumbent 
positioning (OR=0.40, 0.15-1.04), early tracheostomy (OR=0.66, 0.31-1.38) and prone 
positioning (OR=0.79, 0.59-1.07). 
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The incidence of VAP can be reduced by a number of mechanical, chemical and antibiotic 
interventions, all of which most likely work through a reduction of the microaspiration-related 
bacterial load of the lower airways. Current reviews or guidelines are not always supported by 
the current available evidence. To understand the reasons why interventions with limited efficacy 
get implemented into clinical practice while other well documented and with superior efficacy do 
not, could be invaluable for health care policy initiatives. 
Figure 35: Forest plot of overall results 
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10. Appendix 
10.1. Deutsche Zusammenfassung 
In diesem quantitativen systematischen Review haben wir die Effektivität aller Interventionen 
zusammengefasst und verglichen, die als Strategien zur Prävention von beatmungsassoziierter 
Pneumonie (ventilator-associated pneumonia, VAP) in Studien untersucht wurden, und sie 
außerdem mit den aktuellen Empfehlungen und Leitlinien verglichen. Indem wir zur Analyse der 
Präventionsstrategien eine einheitliche statistische Methode angewandt haben, sind die 
Ergebnisse miteinander vergleichbar. Dies gibt Klinikern einen Überblick über die gesamte 
vorhandene Evidenz und ihre Wirksamkeit. 
Wir durchsuchten Pubmed, Embase, die Cochrane-library, Scientific Indexing und 
clinicaltrials.gov nach relevanten randomisierten kontrollierten Studien und vervollständigten die 
Suche mit einer Durchsicht der Referenzlisten relevanter Artikel. 
Insgesamt wurden 1948 Zitate überprüft, von denen 169 unseren vordefinierten 
Einschlusskriterien entsprachen. Die Ergebnisse sind in ihrer Gesamtheit als „Forest Plot“, 
inklusive der Odds Ratios (OR), Konfidenzintervalle (CI) und der Anzahl der Studien und 
Patienten in der unten stehenden Abbildung dargestellt. 
Die folgenden Interventionen, angeordnet entsprechend ihrer Effektgröße, waren statistisch 
signifikant und wurden von mehr als einer Studie untersucht: nicht-invasive im Gegensatz zu 
invasiver mechanischer Beatmung (OR=0.14, 0.07-0.25), selektive Darmdekontamination 
(OR=0.32, 0.24-0.43), subglottische Absaugung (OR=0.34, 0.24-0.49), Rotationsbetten 
(OR=0.34, 0.23-0.52), als Aerosol verabreichte Antibiotika (OR=0.55, 0.34-0.87), systemisch 
verabreichte Antibiotika (OR=0.56, 0.32-0.99), orale Dekontamination mit Antiseptika 
(OR=0.60, 0.45-0.82), mit Silber beschichtete Endotrachealtuben (OR=0.62, 0.44-0.89) und 
Sukralfat versus H2-Antagonisten (OR=0.77, 0.64-0.93). Antioxidative Therapie durch Zufuhr 
von Spurenelementen wurde zwar von mehreren Studien, jedoch in nur kleinen Patientengruppen 
untersucht (OR=0.12, 0.03-0.42). 
Außerdem waren die folgenden Interventionen statistisch signifikant, wurden jedoch nur von 
einer Studie untersucht: Physiotherapie des Thorax (OR=0.14, 0.03-0.70), subglottische 
Dekontamination (OR=0.17, 0.05-0.56), frühzeitige Gastrostomie (OR=0.18, 0.03-0.99) und 
enterale versus parenterale Ernährung (OR=0.30, 0.10-0.85). 
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Statistisch signifikant war außerdem die frühzeitige Anwendung von PEEP (OR=0.41, 0.18-
0.91), jedoch nur in einer Untergruppe von nicht hypoxämischen Patienten. 
Alle anderen Interventionen, beispielsweise die Art der Atemwegsbefeuchter oder –filter, 
Absaugetechniken und –vorrichtungen und Wechseln der Beatmungsschläuche waren statistisch 
nicht signifikant. Dies galt auch für die Oberkörperhochlagerung (OR=0.40, 0.15-1.04), 
frühzeitige Tracheostomie (OR=0.66, 0.31-1.38) und Bauchlagerung (OR=0.79, 0.59-1.07). 
Die Inzidenz von VAP kann durch eine Anzahl an mechanischen, chemischen und antibiotischen 
Interventionen, die wahrscheinlich über eine Reduktion der durch Mikroaspiration bedingten 
Keimbelastung wirken, gesenkt werden. Diese Daten bestätigen jedoch nicht immer 
Schlussfolgerungen von Reviews oder Leitlinien. Die Hintergründe zu verstehen, warum 
Interventionen mit begrenzter Effektivität im klinischen Alltag eingesetzt werden andere mit gut 
dokumentierter und besserer Wirksamkeit nicht, könnte für gesundheitspolitische Initiativen von 
unschätzbarem Wert sein. 
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10.3. Tables 
a) Study characteristics of included trials 
Table 27: Study characetristics Oral Care 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Bopp 200644 RCT 5 pts., mixed Suctioning toothbrush using 0.12% 
chlorhexidine solution (cheeks, teeth, ET-
tube) twice daily vs. standard oral care 
P, M, (MV), (LOS) A Unclear Unclear  - Various intents to contact 
authors regarding pneumonia 
definition were unsuccessful 
Fourrier 2000118 RCT, single-blind 60 pts., medico-
surgical 
0.2% chlorhexidine gel (oral cavity) thrice 
daily vs. standard oral care (bicarbonate 
serum + aspiration) 
P, M, MV, LOS  B a) fever or hypothermia 
b) CXR 
c) leukocytosis or leucopenia 
d) pos. tracheal aspirate or BAL culture  
Unclear  
Fourrier 2005119 RCT, double-blind, 
placebo-controlled, 
multicenter 
228 pts., mixed 0.2% chlorhexidine gel (gingival and 
dental plaque) thrice daily vs. placebo gel  
P, M, MV, LOS A a) fever or hypothermia 
b) CXR 
c) leukocytosis or leucopenia 
d) pos.  tracheal aspirate or BAL culture  
Unclear  
Koeman 2006179 RCT, double-blind, 
placebo-controlled, 
multicenter 
157 pts,  mixed, 
surgical 
2 % chlorhexidine gel (buccal cavity) four 
times daily vs. placebo gel 
P, M, MV, LOS B CXR plus at least three of the following: 
a) fever or hypothermia 
b) leukocytosis and/or left shift or 
leucopenia 
c) purulent tracheal aspirate 
d) pos. culture from tracheal aspirates 
(>48h of MV) 
48 h - Chlorhexidine/ colistin 
decontamination group 
excluded 
Tantipong 
2008333 
RCT 110 pts., mixed 2% chlorhexidine rinse (toothbrushing and 
mucosa of oral cavitiy) four times daily vs. 
saline rinse 
P, (MV) D CXR plus at least three of the following: 
a) fever or hypothermia 
b) leukocytosis or leukopenia 
c) purulent tracheal aspirate 
d) pos. tracheal culture 
48 h - Subgroup data of pts. 
mechanically ventilated for 
more than 48 h abstracted 
Kollef 2006.192 RCT, double-blind, 
placebo controlled 
709 pts., mixed Isaganan oral rinse (9mg) six times daily 
vs. placebo rinse 
P, M A CXR, pos. BAL culture plus at least two of 
the following: 
a) fever or hypothermia 
b) leukocytosis or leucopenia 
c) purulent sputum or tracheal secretions 
48 h 
 
 
Seguin 2006306 RCT 67 pts., surgical 
with severe head 
trauma 
10 % povidone-iodine rinse (oro- and 
nasopharynx) vs. saline rinse 
P, M, MV, LOS A CXR plus two of the following  
a) fever or hypothermia 
b) purulent endotracheal 
aspirate 
c) leukocytosis or leucopenia 
(all symptoms for >48 h) 
48 h - Standard care group (no 
instillation but aspiration of 
secretions) excluded 
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Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 28 Study characteristics Airway Management: Tracheostomy 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Blot 200734 RCT, multicenter 123 pts., medical, 
surgical 
Early (<4d) tracheostomy vs. prolonged 
endotracheal intubation 
P, M, (MV), (LOS) A a) CXR 
b) fever 
c) leukocytosis 
d) purulent tracheal secretions or gas 
exchange alterations 
e) pos. pos. BAL, PSB, catheter or tracheal 
aspirate cultures 
7 d - Unpublished data 
- Author contacted for 
methodological details 
Bouderka 
200445 
RCT 63 pts, head trauma Early (<5d) tracheostomy vs. prolonged 
endotracheal intubation  
P, M, MV B CDC-criteria123 5 d  
Sugerman 
1997330 
RCT 112 pts., trauma, 
non-trauma 
Early (3-5d)  tracheostomy vs. prolonged 
endotracheal intubation until day 14 
P, M, LOS A a) leukocytosis or left shift 
b) fever 
c) CXR 
d) pos. sputum culture 
3 d - Only early randomization 
group included 
Saffle 2002302 RCT 44 pts., burn center Early (3-4d)  vs. late (14d) tracheostomy P, M, MV, LOS A CDC-criteria123 48 h  
Barquist 
200619 
RCT 60 pts., trauma Early (<8d) vs. late (>28d) tracheostomy  P, M, (MV), (LOS) A CDC-criteria123 3 d  
Rodriguez 
1990291 
RCT 106 pts., surgical Early (<8d) vs. late (>8d) tracheostomy  P, M, MV, LOS D a) fever 
b) leukocytosis 
c) pos. Gram stain 
d) pos. sputum culture 
e) CXR 
24 h  
Rumbak 
2004298 
RCT 120 pts., medical Early (<2d) vs. late (14-16d) tracheostomy P, M, MV, LOS A a) clinical criteria 
b) pos. PSB or BAL culture 
14 d  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 29: Study characteristics Airway Management: Weaning 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Marelich 
2000232 
RCT 335 pts., medical, 
trauma 
Weaning protocol vs. physician-directed 
weaning  
P, M, (MV) A  Clinical suspition of pneumonia plus two 
of the following: 
a) pos. endotracheal aspirate or 
bronchoscopy cultures 
b) fever or leukocytosis 
c) CXR  
48 h  
Antonelli 
199813 
RCT 64 pts., mixed Noninvasive vs. invasive MV P, M, MV, LOS B  a) CXR 
b) fever or hypothermia 
c) purulent tracheobronchial 
secretions 
d) leukocytosis 
e) worsening of gas exchange 
f) pos. BAL culture 
Unclear  
Chen 200157 RCT 24 pts., respiratory 
(COPD) 
Noninvasive vs. invasive MV after 3d of 
invasive MV 
P, M, MV B  CXR plus at least 2 of the following: 
a) fever 
b) leukocytosis 
c) purulent tracheal secretions 
3 d - Article translated from 
Chinese 
Conti 200269 RCT 49 pts., respiratory 
(COPD) 
Noninvasive vs. invasive MV P, M, MV, LOS A  CXR plus at least two of the following: 
a) leucocytosis 
b) fever 
c) purulent aspirations 
d) pos. BAL culture 
Unclear - Author provided 
pneumonia definition 
- Patients with persistent 
weaning failure 
Ferrer 2003110 RCT  43 pts., mixed Noninvasive vs. invasive MV after 3d of 
weaning failure from invasive MV with T-
piece 
P, M, MV, LOS B  CXR plus at least two of the following: 
a) fever or hypothermia  
b) leukopenia or leukocytosis 
c) purulent tracheal secretions 
Unclear  
Girault 1999128 RCT 33 pts., medical Noninvasive vs. invasive MV after 2h of 
weaning failure from invasive MV with T-
piece 
P, M, MV, LOS B  CXR plus at least two of the following: 
a) fever 
b) leukocytosis 
c) pos. endotracheal secretion cultures 
48 h - Author provided 
pneumonia definition 
Nava 1998253 RCT 50 pts., respiratory 
(COPD) 
Noninvasive vs. invasive MV after weaning 
failure from invasive MV with T-piece 
P, M, MV, LOS A  CXR plus at least two of the following: 
a) fever 
b) leukocytosis 
c) pos. Gram stain of suctioning material 
from the lower respiratory tract 
36 h  
Trevisan 
2008345 
RCT 65 pts., mixed Noninvasive vs. invasive MV after weaning 
failure from invasive MV after 30 min 
P, M, MV, LOS A CPIS ≥7278 or: 
Clinical findings or pos. CXR plus at least 
one of the following: 
a) purulent tracheal secretions 
b) fever 
48 h  
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c) leukocytosis 
Wang 2005373 RCT, multicenter 90 pts., respiratory, 
medical (COPD) 
Noninvasive vs. invasive MV after invasive 
MV 
P, M, MV, LOS B a) >48h of MV 
b) CXR 
c) physical examination 
d) plus at least one of the following: 
- leukocytosis or leucopenia ± left shift 
- fever 
- purulent airway secretion 
- pos. culture of bronchial secretions 
Unclear 
 
 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 30: Study characteristics Airway Management: Closed vs. open endotracheal suctioning 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Combes 
200068 
RCT 104 pts., 
neurosurgical 
Closed vs. open endotracheal suctioning P, M, MV, LOS B  a) CXR 
b) purulent secretions with a positive 
sputum culture 
c) leukocytosis or leukopenia 
d) fever 
(>48h of MV) 
48 h  
Deppe 199088 RCT 84 pts., surgical Closed vs. open endotracheal suctioning P, M B  a) purulent sputum (Gram stain) and 
sputum culture 
b) fever or hypothermia 
c) CXR 
d) leukocytosis or leucopenia 
e) in hospital ≥48h 
48 h  
Johnson 
1994165 
RCT 35 pts., surgical, 
trauma 
Closed vs. open endotracheal suctioning P D CXR plus two the following: 
a) purulent sputum (Gram stain) 
b) fever  
c) leukocytosis  
Unclear - Patients ≥ 17 years 
Lee 2004207 RCT 70 pts., mixed Closed vs. open endotracheal suctioning P, (MV), LOS D CDC-criteria123 Unclear - Article translated from 
Korean 
Lorente 
2005220 
RCT 308 pts., medical-
surgical 
Closed vs. open endotracheal suctioning P, (M), (MV) B  a) purulent sputum 
b) fever or hypothermia 
c) leukocytosis or leukopenia 
d) CXR 
e) pos. culture of respir. secretions or blood  
48 h - Patients with MV <48h 
excluded from analysis 
Lorente 2006 
I216 
RCT 213 pts., medical-
surgical 
Closed vs. open endotracheal suctioning P, (M), (MV) B  a) purulent sputum 
b) fever or hypothermia 
Unclear - Patients with MV <48h 
excluded from analysis  
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c) leukocytosis or leukopenia 
d) CXR 
e) pos. culture of respir. secretions or blood  
Rabitsch 
2004280 
RCT 24 pts., medical Closed vs. open endotracheal suctioning P A  American College of Chest Physicians: 
CXR plus one of the following: 
a) radiographic evidence of cavitation 
b) histological evidence  
c) positive blood culture  
d) purulent tracheal aspirate 
e) pos. pleural fluid culture with two of the 
following: 
- fever 
- leukopenia or leukocytosis 
72 h  
Topeli 2004339 RCT 78 pts., medical Closed vs. open endotracheal suctioning P, M, MV, LOS B CXR plus two of the following: 
a) fever or hypothermia 
c) leukocytosis or leukopenia 
d) purulent tracheobronchial secretions or 
pos. Gram stain 
48 h  
Zeitoun 
2003384 
RCT 47 pts., medical-
surgical 
Closed vs. open endotracheal suctioning P B  a) fever  
b) CXR 
c) leukocytosis  
d) purulent tracheobronchial secretions  
48 h - Patients ≥ 13 years 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 31: Study characteristics Airway Management: Daily vs. no daily changes of in-line suction catheters 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Kollef 1997187 RCT 521 pts., mixed Daily vs. no routine changes of in-line 
suction catheters 
P, M, MV, LOS A CXR (>48h of MV) plus one of the 
following: 
a) radiographic evidence of pulmonary 
abscess formation 
b) histologic evidence c) pos. blood or 
pleural fluid culture 
d) two of the following: 
- fever 
- leukocytosis 
- purulent tracheal aspirate 
12 h   
Darvas 200378 RCT 101 pts., medical-
surgical 
Daily vs. 48 hr-change of closed suctioning 
catheter 
P, M, MV, LOS A CXR plus one of the following: 
a) pos. pleural fluid or blood cultures for 
48 h - Patients >16 years 
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same organism as in tracheal aspirate 
b) radiographic cavitation 
c) histopathologic evidence 
d) two of the following: 
- fever 
- leukocytosis 
- purulent tracheal aspirate 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 32: Study characteristics Airway Management: Heat and moisture exchanger (HME) vs. heated humidifier (HH) 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Martin 1990233 RCT 73 pts., mixed Hydrophobic HME vs. HH P, M, MV B  a) purulent sputum 
b) pos. respiratory cultures 
c) CXR  
24 h  
Roustan 
1992295 
RCT 116 pts., mixed Hydrophobic HME vs. HH P, M, MV, LOS B a) CXR 
b) fever 
c) leukocytosis 
d) purulent tracheobronchial secretions 
Unclear  
Boots 1997 
A43 
RCT 62 pts., general Hygroscopic HME vs. HH P, M, (MV) B a) CXR 
b) fever or hypothermia 
c) leukocytosis or leucopenia 
d) pos. culture of tracheal aspirate 
e) purulent sputum 
f) ↓PaO2/FiO2 
48 h - HME group with 2-day 
changes divided and 
integrated in both 
comparisons  
Dreyfuss 
199595 
RCT 164 pts., mixed Hygroscopic HME vs. HH P, M, MV B  a) CXR 
b) purulent tracheal aspirates 
c) pos. PSB or catheter culture or pos. 
blood culture with same organism isolated 
from blood and sputum specimens 
d) 48h of MV 
48 h  
Memish 
2001238 
RCT 243 pts., medical-
surgical 
Hygroscopic HME vs. HH P, M, MV D  CDC-criteria123 plus at least one of the 
following: 
a) purulent sputum 
b) pos. blood culture 
c) pos. transtracheal aspirate culture 
d) virus or viral antigen in respiratory 
secretions 
e) antibody titer 
f) histopathologic evidence 
48 h  
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Lorente 2006 
II217 
RCT 104 pts., medical-
surgical 
HME vs. HH with double-heated wire 
circuits 
P, MV B a) purulent sputum 
b) fever or hypothermia 
c) leukocytosis or leukopenia 
d) CXR 
e) pos. culture of respir. Secretions 
f) >48h of MV 
5 d  
Boots 2006 
A42 
RCT 189 pts., general HME vs. HH with single-heated wire 
circuits 
P, M, (MV), (LOS) B Onset of a new clinical syndrome (>48h of 
MV) consistent with pneumonia as 
determined by the treating consultant and 
on the basis of a CPIS ≥6278 
48 h - HME group divided and 
integrated in both 
comparisons 
Boots 2006 
B42 
RCT 192 pts., general HME vs. HH with double-heated wire 
circuits 
P, M, (MV), (LOS) B Onset of a new clinical syndrome (>48h of 
MV) consistent with pneumonia as 
determined by the treating consultant and 
on the basis of a CPIS ≥6278 
48 h - HME group divided and 
integrated in both 
comparisons 
Kirton 1997176 RCT 280 pts., trauma HME vs. HH with heated wire circuits P B CDC criteria123 3 d - Patients ≥ 15 years 
Lacherade 
2005202 
RCT, multicenter 369 pts., surgical-
medical  
Hygroscopic HME vs. HH with heated 
wire circuits 
P, M, MV, LOS A CXR, ˃48h of MV, pos. culture of 
protected telescoping catheter or BAL plus 
two of the following: 
a) fever or hypothermia 
b) leukocytosis or leukopenia  
c) purulent tracheal secretions 
48 h  
Branson 1996 
A47 
RCT 103 pts., medical-
surgical 
Hygroscopic condenser humidifier vs. HH 
with heated wire cicuits 
P, MV D a) purulent sputum 
b) pos. respiratory cultures 
c) fever  
d) CXR 
24 h - Study divided for 2 
comparisons 
Kollef 1998188 RCT 310 pts., medical-
surgical 
Hygroscopic condenser humidifier vs. HH 
with heated wire circuits 
P, M, MV, LOS A American College of Chest Physicians: 
CXR (>48h of MV) plus one of the 
following: 
a) radiographic evidence of pulmonary 
abscess 
b) histologic evidence  
c) pos. blood or pleural fluid culture 
d) two of the following:  
- fever 
- leukocytosis 
- purulent tracheal aspirate 
Unclear  
Abbreviations: RCT: randomized controlled trial; pts: patients; HH: heated humidifier; HME: heat and moisture exchanger; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush, CPIS: Clinical 
Pulmonary Infection Score; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
Appendix 
114 
 
Table 33: Study characteristics Airway management: Extended use of heat and moisture exchanger 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Davis 200081 RCT 160 pts., surgical 24-hr vs. 120-hr. change of a hygroscopic 
HME 
P, MV B  CDC-criteria123 48 h - Hydrophobic HME group 
(120-hr change) excluded 
since no control group 
Thomachot 
2002334 
RCT 155 pts., trauma, 
medical, 
postoperative 
1- vs. 7-day change of a hydrophobic HME P, M, MV, LOS B a) purulent tracheal aspirates 
b) deterioration of arterial PaO2  
 c) CXR 
d) pos. PSB or BAL culture 
48 h  
Abbreviations: RCT: randomized controlled trial; pts: patients; HME: heat and moisture exchanger; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 34: Study characteristics Airway Management: Components of heat and moisture exchanger 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Boyer 200346 RCT 43 pts., medical 2 models of hygroscopic HME (Hygrolife 
and EdithFlex) 
P, MV B  a) CXR 
b) purulent tracheal aspirate 
c) pos. PSB or BAL culture 
48 h  
Thomachot 
1998336 
RCT 136 pts., head 
trauma, medical, 
postoperative 
Hygroscopic vs. hydrophobic HMEF P, M, MV B a) purulent tracheal aspirates 
b) deterioration of arterial PaO2 
c) CXR 
d) pos. PSB or BAL culture  
24 h  
Thomachot 
1999335 
RCT 140 pts., head 
trauma, medical, 
postoperative 
2 different hygroscopic HMEF (CaCl2 vs. 
AlCl2 impregnated) 
P, M, MV B a) purulent tracheal aspirates 
b) deterioration of arterial PaO2 
c) CXR 
d) pos. PSB or BAL culture 
24 h  
Abbreviations: RCT: randomized controlled trial; pts: patients; HME: heat and moisture exchanger; HMEF: heat and moisture exchange filter; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 35: Study characteristics Airway Management: Change of ventilator circuits 
Study ID Methods Participants Interventions Outcomes AC Definition for Pneumonia Min. 
duration 
of MV 
Notes 
Craven 198675 RCT 233 pts., medical, 
surgical, cardiac 
24hr- vs. 48hr-change of ventilator circuits P, (M), (MV) D a) purulent sputum 
b) pos. sputum culture 
c) leukocytosis 
d) fever 
e) CXR 
48 h  
Dreyfuss 
199196 
RCT 73 pts., mixed 48hr- vs. no change of ventilator circuits P, M, MV D  a) CXR 
b) purulent tracheal aspirates 
a) pos. PSB culture 
48 h  
Lorente 
2004215 
RCT 304 pts., medical-
surgical 
48hr- vs. no change of ventilator circuits  P, M, MV B  a) purulent sputum 
b) fever or hypothermia 
c) leukocytosis or leukopenia 
d) CXR 
e) pos. culture of respir. secretions or blood 
72 h  
Boots 1997 
B43  
RCT 54 pts., general HME with 2-day vs. 4-day circuit change  P, M, (MV) B a) CXR 
b) fever or hypothermia 
c) leukocytosis or leucopenia 
d) pos. culture of tracheal aspirate 
e) purulent sputum 
f) ↓PaO2/FiO2 
48 h - HME group with 2-day 
changes divided and 
integrated in both 
comparisons 
Long 1996214 RCT 447 pts., medical, 
neurosciences 
Change of ventilator circuits once vs. 
thrice weekly 
P D  CXR, consolidation, cavitation, or pleural 
effusion plus one of the following: 
a) purulent sputum  
b) pos. blood culture 
c) pos. culture of bronchial washing, 
brushing, or biopsy 
d) isolation of virus or detection of viral 
antigen  
e) diagnostic antibody titer 
f) histopathologic evidence 
Unclear  
Kollef 1995189  RCT 300 pts., mixed 7-day vs. no routine change of ventilator 
circuits 
P, M, MV A CXR plus one of the following: 
a) pos. pleural or blood cultures 
b) roentgenographic cavitation 
c) histopathologic evidence 
d) two of the following: 
- fever 
- leukocytosis 
- purulent tracheal aspirate 
5 d  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 36: Study characteristics Airway Management: Heated vs. non-heated wire circuits 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Branson 1996 
B47  
RCT 97 pts., medical-
surgical 
HH with heated- vs. non-heated wire 
circuits 
P, MV D  a) purulent sputum 
b) pos. respiratory cultures 
c) fever  
d) CXR 
24 h - Study divided for 2 
comparisons 
Abbreviations: RCT: randomized controlled trial; pts: patients; HH: heated humidifier; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 37: Study characteristics Airway Management: Oro- vs. nasotracheal intubation 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Holzapfel 
1993158  
RCT 300 pts., general Oro- vs. nasotracheal intubtion P, M, (MV), LOS B  a) CXR 
b) fever or hypothermia 
c) leukocytosis or leukopenia and/or 
purulent tracheobronchial secretions 
d) pos. PSB culture 
7 d - Patients >15 years 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 38: Study characteristics Airway Management: Bacterial filter 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Lorente 
2003219  
RCT 171 pts., medical-
surgical 
Bacterial filter P, M, MV, LOS B a) purulent sputum 
b) fever or hypothermia 
24 h - Subgroup of patients with 
MV >48 h evaluated 
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c) leukocytosis or leucopenia 
d) CXR 
e) pos. culture of respiratory secretions or 
blood  
 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 39: Study characteristics Gastrointestinal Interventions: Selective decontamination of the digestive tract (SDD) 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duratio
n of MV 
Notes 
Bergmans 
200127 
RCT, placebo-
controlled, double-
blind 
226 pts, medical, 
surgical, trauma, 
neurologic 
SDD: 
topical (oral only) 
P, M, (MV), (LOS) A a) CXR 
b) at least three of the following: 
- fever or hypothermia 
- leukocytosis ± left shift or leucopenia 
- pos. Gram stain 
- pos. tracheal aspirate culture 
c) pos. BAL, PSB, blood or pleural fluid 
culture 
48 h - Two control groups 
combined (treatment and 
control patients in same 
ICU or separarted). 
- Patients ≥ 16 years. 
Pugin 1991277 RCT, double-blind, 
placebo-controlled 
52 pts., surgical SDD: 
topical (oral only) 
P, M, MV, LOS 
 
A CPIS ≥7during the course of intubation that 
remained elevated (≥7) for ≥3 d276 
48 h   
Rios 2005288 RCT, double-blind, 
placebo-controlled 
96 pts., surgical, 
medical, trauma 
SDD: 
topical (oral only) 
P, M, MV, LOS A a) CXR 
b) pos. tracheal aspirate or blood culture 
b) two of the following 
- fever or hypothermia 
- leukocytosis or leucopenia 
- purulent tracheal aspirate 
96 h - Patients ≥16 years 
Rodriguez-
Roldan 1990290 
RCT, double-blind, 
placebo-controlled 
28 pts., mixed SDD: 
topical (oral only)  
P, M, (MV) B At least one of each of the following 
criteria: 
a) clinical criteria: fever, purulent 
bronchorrhea, leukocytosis, ↓PaO2/FiO2 
b) radiologic criteria 
c) bacteriologic criteria: pos. culture of 
tracheal aspirate  
Unclear  
Camus 2005 
A50 
RCT, placebo-
controlled, 
multicenter 
256 pts., mixed SDD: 
topical (oral+GI) 
(control group: no regimen) 
P, M, (MV), (LOS) B CDC-criteria123 48 h - Study group received 
polymyxin plus 
tobramycin; control group 
received no regimen 
Camus 2005 
B50 
RCT, placebo-
controlled, 
multicenter 
259 pts., mixed SDD:  
topical (oral+GI) 
(control group: mupirocin/chlorhexidine) 
P, M, (MV), (LOS) B CDC-criteria123 48 h - Study group received 
polymyxin, tobramycin, 
nasal mupirocin and 
chlorhexidine wash; 
control group received 
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nasal mupirocin and 
chlorhexidine wash only. 
Ferrer 1994111 RCT, placebo-
controlled, double-
blind 
80 pts., respiratory SDD: 
topical (oral +GI) 
P, M, MV, LOS B a) CXR  
b) purulent tracheal secretions 
c) fever 
d) leukocytosis or leukopenia 
72 h - All patients received iv-
prophylaxis, 
- Data and definition of 
clinically suspected 
pneumonia abstracted 
Gastinne 
1992124 
RCT, placebo-
controlled, double-
blind, multicenter 
445 pts., medical, 
trauma, 
postoperative 
SDD: 
topical (oral + GI) 
P, M, (MV), LOS B a) CXR  
b) purulent tracheal aspirate 
c) fever  
d) leukocytosis 
e) >48h after admission  
24 h - Patients > 15 years 
Hammond 
1992140 
RCT, double-blind, 
placebo-controlled 
239 pts., medical, 
surgical and trauma 
SDD: 
topical (oral +GI) 
P, M, LOS B a) CXR (>48 h after admission) 
b) purulent bronchial secretions  
c) fever 
d) leukocytosis or left shift 
e) pos. Gram stain 
f) pos. tracheal aspirate culture 
g) ↓PaO2/FiO2 
48 h - All patients received IV-
prophylaxis 
Korinek 
1993196 
RCT, placebo-
controlled, double-
blind 
123 pts., 
neurosurgical 
SDD: 
topical (oral+GI) 
P, M, MV, LOS A a) fever  
b) leukocytosis  
c) purulent sputum 
d) CXR 
e) pos. PSB or plugged telescoping catheter 
culture  
5 d  
Langlois-
Karaga 1995206 
RCT, double-blind, 
placebo-controlled 
97 pts., multiple-
trauma 
SDD: 
topical (oral+GI) 
P, (MV) A a) purulent bronchial secretions 
b) fever  
c) leukocytosis 
d) CXR 
e) ↓PaO2/FiO2 
48 h - Patients ≥ 15 years 
Lingnau 
1997211  
RCT, double-blind, 
placebo-controlled 
310 pts., trauma SDD: 
topical (oral+GI) 
P, M, MV, LOS A a) purulent sputum  
b) pos. culture of bronchial secretions  
c) deterioration of lung function 
48 h - All patients received iv-
prophylaxis 
- PTA group (polymyxin E, 
tobramycin, amphotericin 
B) and PCA group 
(polymyxin E, 
ciprofloxacin, 
amphotericin B) combined  
Quinio 1996279 RCT, double-blind, 
placebo-controlled 
148 pts., multiple 
trauma 
SDD: 
topical (oral+GI) 
P, M, MV, LOS A a) purulent tracheal aspirate 
b) fever  
c) leukocytosis  
d) CXR  
Unclear - Patients ≥16 years 
Sanchez Garcia 
1998 A304 
RCT, placebo-
controlled, double-
blind 
197 pts., medical, 
surgical 
SDD: 
topical (oral+GI) 
P, M, (MV), (LOS) A CXR plus at least three of the following: 
a) fever  
b) leukocytosis or leukopenia  
c) purulent tracheal aspirate 
d) pos. culture of lower airway secretions 
48 h - Patients ≥ 16 years 
- Sucralfate vs. antacids as 
possible confounding 
factor 
Unertl 1986356 RCT 39 pts., SDD: P, M, (LOS) A a) CXR 6 d  
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anesthesiologic, 
neurological, 
neurosurgical 
topical (oral+GI) b) purulent tracheobronchial secretions 
c) at least two of the following: 
- fever 
- leukocytosis or leukopenia 
- ↓PaO2/FiO2 
Verwaest 1997 
A367 
RCT, placebo-
controlled 
286 pts., mixed SDD: 
topical (oral+GI) (ofloxacin-amphotericin 
B) 
P, M, (LOS) A a) purulent tracheal aspirate (Gram stain) 
b) pos. tracheal aspirate culture 
c) fever  
d) leukocytosis  
e) CXR 
48 h - All patients received 
systemic iv ofloxacin 
prophylaxis 
Verwaest 1997 
B367 
RCT, placebo-
controlled 
292 pts., mixed SDD: 
topical (oral+GI) (polymyxin E-tobramycin-
amphotericin B) 
P, M, (LOS) A a) purulent tracheal aspirate (Gram stain) 
b) pos. culture from tracheal aspirate 
c) fever  
d) leukocytosis  
e) CXR 
48 h - All patients received 
systemic iv cefotaxime 
prophylaxis 
Wiener 1995377 RCT, placebo-
controlled, double-
blind 
61 pts., medical, 
surgical 
SDD: 
topical (oral+GI) 
P, M, (MV), (LOS) B a) CXR 
b) fever and/or leukocytosis  
c) pos. culture of lower respiratory tract 
secretions 
48 h  
Abele-Horn 
19974 
RCT 88 pts., mixed SDD: 
topical (oral only) + systemic 
P, M, MV, LOS D CPIS >7 for ≥3d278 4 d  
Aerdts 19908  RCT 56 pts., mixed SDD: 
topical (oral + GI) + systemic 
P, M, (MV), (LOS) D Pos. culture and Gram stain of tracheal 
aspirate, plus at least two of the following: 
a) purulent tracheal aspirate 
b) leukocytosis 
c) fever 
5 d - Two control groups, 
receiving antibiotics 
effecting the colonizing 
resistance or not in case of 
infection, were grouped. 
- Patients ≥ 16 years; 
- Outcome: ‘lower 
respiratory tract infection’, 
not explicitly pneumonia 
Blair 199131  RCT 256 pts., mixed SDD: 
topical (oral+GI) + systemic 
P, M, (LOS) B a) fever 
b) leukocytosis or leucopenia 
c) CXR 
d) purulent sputum  
Unclear - 93% of patients intubated 
- Data of secondary 
infection (>48h in ICU) 
abstracted 
- Outcome ‘respiratory 
infection’, not explicitly 
pneumonia 
Finch 1991113  RCT 44 pts., mixed SDD: 
topical (oral + GI) + systemic 
P, M A a) CXR 
b) systemic signs of sepsis 
c) evaluation of sputum obtained by tracheal 
aspiration or bronchoscopy  
Unclear - Unpublished data 
- Author contacted for 
methodological details, 
results extracted from 
review of D’amico et al. 77  
Hammond 
1995139  
RCT, placebo-
controlled, double-
blind 
135 pts., mixed SDD: 
topical (oral + GI) + systemic 
P, M, LOS B a) CXR (>48 h after admission) 
b) purulent bronchial secretions  
c) fever 
d) leukocytosis or left shift 
e) pos. Gram stain 
f) pos. tracheal aspirate culture 
48 h - Patients with primary or 
secondary infection at 
study entry 
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g) ↓PaO2/FiO2 
Kerver 1988173  RCT 96 pts., surgical SDD: 
topical (oral +GI) + systemic 
P, M, (LOS) B CXR plus at least three of the following: 
a) fever 
b) leukocytosis or leukopenia 
c) left shift 
d) decrease in platelet count 
Unclear - All patients also received 
chlorhexidine rinse 
- Outcome ‘lower 
respiratory tract infection’, 
not explicitly pneumonia 
Krueger 
2002200  
RCT, double-blind, 
placebo-controlled, 
multicenter 
546 pts., surgical, 
trauma 
SDD:  
topical (oral+GI) + systemic 
P, M, (MV), (LOS) A a) CXR or ↓PaO2/FiO2 
b) purulent tracheobronchial secretions 
(Gram stain) 
c) at least one of the following: 
- fever  
- leukocytosis  
- leukopenia  
- left shift 
Unclear - Intubation rate: 93% 
(treatment group) vs. 92% 
(control group) 
Palomar 
1997264  
RCT, multicenter 129 pts., medical, 
surgical 
SDD: 
topical (oral+GI) + systemic 
P, M B CDC-criteria123 4 d - Third study group 
(sucralfate + iv–
antibiotics) excluded 
Rocha 1992289  RCT, placebo-
controlled, double-
blind 
101 pts., mixed SDD: 
topical (oral+GI) + systemic 
P, M, MV, LOS A a) purulent pulmonary secretions 
b) CXR 
c) one of the following: 
- fever or hypothermia 
- leukocytosis or leukopenia 
- physical examination 
- ↓PaO2/FiO2 
3 d - Outcome ‘lower 
respiratory tract infection’, 
not pneumonia 
Sanchez Garcia 
1998 B304  
RCT, placebo-
controlled, double-
blind 
74 pts., medical, 
surgical 
SDD: 
topical (oral+GI), systemic 
P, M, (MV), (LOS) A CXR plus at least three of the following: 
a) fever  
b) leukocytosis or leukopenia  
c) purulent tracheal aspirate 
d) pos. culture of lower airway secretions 
48 h - Patients ≥ 16 years 
- Sucralfate vs. antacids as 
possible confounding 
factor 
Stoutenbeek 
2007325  
RCT, multicenter 401 pts., trauma SDD: 
topical (oral+GI) + systemic 
P, M, (MV), (LOS) A a) CXR (>48 h) 
b) purulent tracheal aspirate 
c) fever  
d) leukocytosis or leukopenia  
Unclear  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 40: Study characteristics Gastrointestinal Interventions: SDD with additional topical agents 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duratio
n of MV 
Notes 
Konrad 1991194  RCT 40 pts., surgical SDD: 
nasal gentamicin in addition to SDD: 
topical (oral+GI) + systemic  
P, M B a) CXR 
b) purulent tracheal secretions with pos. 
Gram stain 
c) pos. bacterial culture 
d) one of the following: 
- fever 
- leukocytosis 
- pos. auscultation  
4 d  
Laggner 
1994204  
RCT, double-blind, 
placebo-controlled 
67 pts., mixed SDD: 
orally administered gentamicin  
in addition to standardized amphotericin B 
P, M, MV, LOS A  a) CXR 
b) tracheal colonization 
c) fever  
d) leukocytosis or leukopenia 
5 d - All patients received 
sucralfate, amphotericin B 
and oral disinfectants  
Nardi 2001250  RCT, double-blind 223 pts., mixed Nasal mupirocin decontamination in 
addition to SDD: topical (oral+GI) 
P, M, MV, LOS A a) CXR 
b) purulent tracheal secretions 
c) fever 
d) leukocytosis or leukopenia 
e) hypoxemia 
48 h  - Data and definition of 
clinically suspected 
pneumonia abstracted 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 41: Study characteristics Gastrointestinal Interventions: Interventions to reduce the bacterial reflux load 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duration of 
MV 
Notes 
Colardyn 
199066  
RCT 113 pts., medical Sucralfate vs. H2-antagonists  (cimetidine) P, M B  Clinical and radiological criteria Unclear - Abstract 
Cook 199871  RCT, double-blind, 
placebo-controlled 
1200 pts., mixed Sucralfate vs. H2-antagonists (ranitidine) P, M, (LOS) A  CDC-criteria123 48 h - Data of CDC definition of 
pneumonia abstracted 
Driks 1987 B99  RCT 38 pts., surgical, 
medical, coronary 
Sucralfate vs. H2-antagonists (cimetidine or 
ranitidine) 
P, (M), (MV) B CXR plus at least three of the following: 
a) purulent sputum (Gram stain) 
b) pos. tracheal aspirate culture 
c) leukocytosis  
d) fever 
24 h - Control group divided 
through numbers of 
comparisons (three) 
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Eddleston 
1991101  
RCT 60 pts., mixed Sucralfate vs. H2-antagonists (ranitidine) P, M, MV, LOS B  a) CXR 
b) ↓PaO2/FiO2 
c) pos. culture from tracheal aspirate 
d) fever or leukocytosis 
e) organism colonized in ascending order 
the stomach, oropharynx and trachea 
4 d - Patients ≥ 15 years 
Fabian 1993106 RCT 278 pts., trauma Sucralfate vs. H2-antagonists (bolus or 
continuous cimetidine) 
P, M, (LOS) B  a) CXR 
b) purulent tracheal aspirate 
c) pos. culture 
d) fever 
e) leukocytosis  
Unclear - Cimetidine groups 
(bolus+continuous) 
combined 
Kantorova 
2004169  
RCT, placebo-
controlled 
140 pts., trauma Sucralfate vs. H2-antagonists (famotidine)   P, M, MV, LOS A  CXR plus at least 3 of the following: 
a) purulent tracheal aspirate  
b) leukocytosis or left shift 
c) fever 
d) pos. BAL, PSB or tracheal aspirate 
culture 
e) pos. blood or pleural fluid culture 
48 h - Placebo and proton pump 
inhibitor group excluded 
Kappstein 
1991170  
RCT 104 pts., 
anesthesiologic 
Sucralfate vs. H2-antagonists (cimetidine) P, M, (MV) D  CXR plus at least three of the following: 
a) purulent tracheal secretions 
b) pos. culture of tracheal secretions 
c) leukocytosis 
d) fever  
24 h  
Laggner 
1989203  
RCT 32 pts., mixed Sucralfate vs. H2-antagonists (ranitidine) P, M, MV B  a) CXR 
b) bronchial colonization 
c) leukocytosis  
d) fever 
48 h  
Pickworth 
1993270  
RCT 92 pts., trauma Sucralfate vs. H2- antagonists (ranitidine) P, M, (MV), (LOS) B  CXR plus three of the following: 
a) fever 
b) leukocytosis 
c) pos. sputum culture 
d) pos. Gram stain 
Unclear - Patients ≥15 years 
Prod’hom 
1994 A276  
RCT 122 pts., medical, 
surgical 
Sucralfate vs. H2- antagonists (ranitidine) P, M A  CXR plus at least one of the following: 
a) one of the following: 
-pos. pleural fluid or blood culture with 
same pathogen as isolated in tracheal 
aspirate  
- radiographic cavitation 
- histopathologic evidence 
b) At least two of the following: 
- pos. Gram stain 
- leukocytosis  
- fever  
24 h - Sucralfate group divided 
for comparison with the 
antacid and ranitidine group 
Ryan 1993299  RCT 114 pts., medical, 
surgical 
Sucralfate vs. H2-antagonists (cimetidine) P, M, (MV) B CDC-criteria123 48 h - Patients >16 years 
Stoehr 1998 
A323  
RCT 50 pts., surgical Sucralfate vs. H2-antaginists (ranitidine)  P, M B  Unclear (conference report) 3 d - All patients received 
subglottic lavage and 
suctioning 
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- Various attempts to contact 
authors regarding pneumonia 
definition failed 
Thomason 
1996 A337  
RCT 120 pts., trauma, 
surgical, 
neurosurgical 
Sucralfate vs. H2-antagonists (ranitidine)  P, M, (MV) B  CXR plus three of the following: 
a) leukocytosis  
b) pos. tracheal or blood culture 
c) pos. Gram stain 
d) fever 
24 h  
Tsiotras 
1993352  
RCT 100 pts., head 
trauma 
Sucralfate vs. H2-antagonists (ranitidine) P, M, MV B a) CXR 
b) fever 
c) leukocytosis 
d) purulent tracheal secretions 
48 h  
Bonten 199540  RCT, double-blind 141 pts., mixed  Sucralfate vs. antacids P, M, LOS A  CXR, pos. BAL, PSB, blood or pleural 
fluid culture plus at least one of the 
following: 
a) fever or hypothermia 
b) leukocytosis and/or left shift or 
leucopenia 
c) pos. Gram stain 
3 d - Patients ≥ 15 years 
Driks 1987 A99  RCT 59 pts., surgical, 
medical, coronary 
Sucralfate vs. antacids P, (M), (MV) B  CXR plus at least three of the following: 
a) purulent sputum (Gram stain) 
b) pos. tracheal aspirate culture 
c) leukocytosis  
d) fever  
24 h - Control group divided 
through numbers of 
comparisons (three) 
Mahul 1992 
A227  
RCT 145 pts., medical, 
surgical 
Sucralfate vs. antacids P, (M), (LOS) B  a) CXR (after 48h of intubation) 
b) pos. BAL culture 
3d - No interactions between 
SDD and subglottic 
suctioning proven by 
statistical testing 
Prod’hom 
1994 B276  
RCT 122 pts., medical, 
surgical 
Sucralfate vs. antacids P, M A   CXR plus at least one of the following: 
a) one of the following: 
-pos. pleural fluid or blood culture with 
same pathogen as isolated in tracheal 
aspirate  
- radiographic cavitation 
- histopathologic evidence 
b) At least two of the following: 
- pos. Gram stain 
- leukocytosis 
- fever 
24 h - Sucralfate group divided 
for comparison with the 
antacid and ranitidine group 
Thomason 
1996 B337  
RCT 122 pts., trauma, 
surgical, 
neurosurgical 
Sucralfate vs. antacids P, M, (MV) B  CXR plus three of the following: 
a) leukocytosis  
b) pos. tracheal or blood culture 
c) pos. Gram stain 
d) fever 
24 h  
Tryba 1987346  RCT 100 pts., surgical Sucralfate vs. antacids P, M, (MV) B  CXR plus three of the following: 
a) fever 
b) leukocytosis 
c) bacteria in the tracheal smear 
24 h  
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d) suggestive changes in the arterial blood 
gases 
Eddleston 
1994100  
RCT, placebo-
controlled 
26 pts., mixed Sucralfate vs. placebo P, M B a) CXR 
b) ↓PaO2/FiO2 
c) pos. culture from tracheal aspirate 
d) fever or leukocytosis 
e) organism colonized in ascending order 
the stomach, oropharynx and trachea 
Unclear - Data of ‘retrograde 
pneumonia’ (see pneumonia 
definition (e ) 
Driks 1987 C99  RCT 33 pts., surgical, 
medical, coronary 
Sucralfate vs. antacids + H2-antagonists 
(cimetidine or ranitidine) 
P, (M), (MV) B CXR plus at least three of the following: 
a) purulent sputum (Gram stain) 
b) pos. tracheal aspirate culture 
c) leukocytosis  
d) fever 
24 h - Control group divided 
through numbers of 
comparisons (three) 
Maier 1994228  RCT 98 pts., trauma Sucralfate vs. H2-antagonists (ranitidine) + 
antacids 
P, M, MV, LOS B  CDC-criteria123 72 h  
Sirvent 1994316  RCT 51 pts., mixed Sucralfate vs. H2-antagonists (ranitidine) + 
antacids 
P B  a) fever  
b) leukocytosis  
c) purulent sputum 
d) CXR 
e) pos. bronchial brushing culture 
5 d - Article translated from 
Spanish. 
Holzapfel 
1990159  
RCT 128 pts., mixed H2-antagonists (cimetidine) + antacids vs. 
no treatment 
P B  a) classical criteria 
b) pos. PSB culture 
Unclear - Abstract 
Hanisch 1998 
A141  
RCT, placebo-
controlled 
72 pts., surgical Pirenzepine vs. placebo P, M, (MV), (LOS) A  a) CXR 
b) purulent tracheal secretions or pos. 
tracheal aspirate culture 
c) fever 
d) leukocytosis 
48 h - Placebo group divided for 
comparison with ranitidine 
and pirenzepine 
- Comparison ranitidine vs. 
pirenzepine excluded 
Hanisch 1998 
B141  
RCT, placebo-
controlled 
86 pts., surgical H2-antagonists (ranitidine) vs. placebo P, M, (MV), (LOS) A a) CXR 
b) purulent tracheal secretion or pos. 
tracheal aspirate culture 
c) fever 
d) leukocytosis 
48 h - Placebo group divided for 
comparison with ranitidine 
and pirenzepine 
- Comparison ranitidine vs. 
pirenzepine excluded 
Heyland 
1999151  
RCT, double-blind, 
placebo controlled 
95 pts., mixed Acidified enteral feeds vs. control feeds P, M, (MV), (LOS) A  Clinical evaluation plus at least one of the 
following: 
a) pos. pleural fluid culture 
b) rapid cavitation of lung infiltrate (CT) 
c) histopathologic evidence  
48h - Authors describe different 
pneumonia definitions and 
corresponding data 
Tulaimat 
2005353  
RCT, double-blind, 
placebo-controlled 
29 pts., respiratory Acidified feeds (potassium sorbate) vs. 
standard feeding formula 
P, M A CXR plus at least two of the following: 
a) fever or hypothermia 
c) leukocytosis  or leukopenia 
d) purulent sputum 
e) pos. blood or pleural fluid culture for the 
same organism isolated from sputum or 
BAL fluid 
f) radiographic cavitation 
Unclear - Patients ≥16 years 
Kostadima 
2005198  
RCT 41 pts., stroke or 
head injury 
Early gastrostomy (within 24h of 
intubation) vs. nasogastric tube feeding 
frequency of VAP, 
length of ICU stay, 
duration of MV, 
B  American Thoracic Society: 
CXR plus at least two of the following: 
a) fever 
Unclear  
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ICU mortality, 
mortality 
attributed to VAP 
b) leukocytosis or leukopenia 
c) purulent tracheal aspirates 
Kearns 2000171  RCT 44 pts., medical Small intestinal vs. gastric feeding P, M, MV, LOS A  CXR plus two of the following: 
a) leukocytosis 
b) fever 
c) pos. glucose test or blue discoloration in 
the endotracheal secretions  
24 h  
Kortbeek 
1999197  
RCT 80 pts., trauma Small intestinal (duodenum) vs. gastric 
feeding 
P, M, (MV), (LOS) A  CDC-criteria123 48 h  
Montecalvo 
1992244  
RCT 38 pts., medical and 
surgical 
Small intestinal (jejunal) vs. gastric tube 
feeding 
P, M, MV, LOS B CXR (>5 d) plus three of the following: 
a) purulent sputum (pos. Gram stain) 
b) pos sputum culture 
c) fever 
d) leukocytosis 
Unclear - Author confirmed MV rate 
of 100% 
Bonten 199641 RCT 60 pts., mixed, 
cardiosurgical 
Intermittent enteral feeding (20 h 
continuous with a 4 h fast) 
P, M A  CXR, pos. BAL, blood or pleural fluid 
culture plus at least three of the following: 
a) fever or hypothermia 
b) leukocytosis and/or left shift or 
leukopenia  
c) pos. Gram stain 
d) pos. tracheal aspirate culture  
3 d - Patients ≥ 15 years 
MacLeod 
2007224  
RCT 164 pts., trauma Intermittent (every 4 h) vs. continuous 
enteral feeding  
P, M, LOS A  CDC-criteria123 48 h  
Skiest 1996317  RCT 16 pts., medical, 
surgical 
Intermittent (16 h continuous with a 8 h 
fast) vs. continuous enteral feeding 
P B  a) CXR 
b) purulent tracheal secretions 
c) pos. tracheal secretion, pleural fluid or 
bronchoscopy culture 
d) leukocytosis or fever 
4 d  
Tamowicz 
2007332  
RCT 40 pts., mixed Intermittent (18h continuous with a 6h fast) 
vs. continuous enteral feeding 
P B a) >48h of MV 
b) fever 
c) leukocytosis or leukopenia 
d) CXR 
e) physical examination 
f) ↓PaO2/FiO2 
g) pos. PSB, endotracheal aspirate and 
blood culture  
6 d  
Meisner 
2003237  
RCT, double-blind, 
placebo-controlled 
84 pts., mixed Enteral naloxone P, M, (MV), (LOS) A  CXR plus at least one of the following: 
a) leukocytosis or leukopenia 
b) fever or hypothermia 
7 d  
Yavagal 
2000381 
RCT, double-blind, 
placebo-controlled 
136 pts., mixed Enteral metoclopramide (10mg every 8h) P, (M) B a) CXR 
b) pos. tracheal or sputum culture 
c) fever 
d) leukocytosis or leukopenia 
Unclear - Subgroup data of 
mechanically ventilated 
patients abstracted 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 42: Study characteristics Gastrointestinal Interventions: H2-antagonist vs. antacid 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Tryba 1988347 RCT 61 pts., surgical, 
anesthesiological 
H2-antagonist vs. antacid P B  a) CXR 
b) fever 
c) leukocytosis 
d) bacteria in tracheal swab 
e) major alterations in blood gases 
unclear - Subgroup of patients 
receiving MV 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 43: Study characteristics Gastrointestinal Interventions: Enriched enteral nutrition 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Caparros 
200151 
RCT, single-blind, 
multicenter 
220 pts., medical, 
surgical , trauma 
High-protein diet enriched with arginine, 
fiber, and antioxidants 
P, M, (MV), (LOS) A  CXR, plus at least two of the following: 
a) fever or hypothermia 
b) leukocytosis or leukopenia 
c) pos. sputum, bronchial aspirates or 
bronchial brushing culture 
d) pos. blood culture 
e) antibody titer 
5d - MV rate: 96,7% (study group) 
vs. 98% (control group) 
Houdijk 
1998160  
RCT 72 pts., multiple-
trauma 
Glutamine-enriched enteral nutrition P, (MV) A  CXR plus one of the following: 
a) leukocytosis 
b) fever 
c) pos. Gram stain 
d) pos. sputum culture  
Unclear 
 
 
Mendez 
1997239  
RCT, placebo-
controlled, double-
blind 
43 pts., trauma Immune-enhancing diet (supplemental 
arginine, trace elements, increased omega-
3 acids) 
P, M, (MV), (LOS) A a) CXR 
b) fever 
c) leukocytosis 
d) pos. Gram stain and sputum culture 
Unclear - Author confirmed MV rate of 
100% 
Spindler-Vesel 
2007321  
RCT, double-blind, 
placebo controlled 
113 pts., surgical Enriched enteral nutrition (glutamine, 
fiber, peptide) vs. standard feeding 
P, (MV), (LOS) A  CDC-criteria and consensus conferences 
on VAP123, 286 
Unclear - Treatment groups A-C 
combined for comparison with 
control group D 
- Author confirmed MV rate of 
100% 
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Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 44: Study characteristics Gastrointestinal Interventions: Early enteral nutrition 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Ibrahim 
2002163  
RCT 150 pts., medical High- vs. low-caloric early enteral feeding  P, M, (MV), LOS B  American College of Chest Physicians: 
CXR: 
a) plus one of the following: 
- pos. pleural/blood cultures for the same 
organism cultured from tracheal aspirate or 
sputum 
- radiographic cavitation 
- histopathologic evidence  
b) or plus two of the following: 
- fever 
- leukocytosis 
- purulent tracheal aspirate 
24 h  
Kompan 
2004193  
RCT 52 pts., trauma Early enteral feeding (0 vs. 24h after 
admission)  
P, M, MV, LOS A  CXR plus at least two of the following: 
a) purulent tracheal aspirate  
b) fever 
c) leukocytosis  
Unclear  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 45: Study characteristics Gastrointestinal Interventions: Enteral vs. parenteral feeding 
Study ID Methods Participants, ICU 
type 
Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Kudsk 1992201  RCT 98 pts., trauma Enteral vs. parenteral feeding P, MV B  a) fever 
b) leukocytosis 
c) pos. sputum/ BAL culture or purulent 
sputum 
d) CXR  
Unclear - Author confirmed MV rate 
of 100% 
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Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 46: Study characteristics Positioning: Rotational Therapy 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Ahrens 200411  RCT, multicenter 234 pts., medical, 
surgical, trauma 
Kinetic therapy (arc of ≥80˚ for ≥18h per 
day) vs. manual turning every 2h 
P, M, MV, LOS D American College of Chest Physicians: 
CXR (>48h of MV) plus one of the 
following: 
a) radiographic evidence of pulmonary 
abscess formation 
b) histologic evidence 
c) pos. blood or pleural fluid culture  
d) two of the following: 
- fever  
- leukocytosis 
- purulent tracheal aspirate 
Unclear  
Demarest 
198986  
RCT 30 pts., trauma Kinetic therapy (arc of ≤120˚, 
continuously) vs. manual turning every 2h 
P, M A  a) purulent sputum 
b) CXR 
c) fever 
Unclear  
Fink 1990114  RCT 99 pts., trauma Kinetic therapy (arc of 80˚ for 10-16h per 
day) vs. manual turning every 2h 
P, M, (MV), (LOS) A  a) fever  
b) purulent sputum (Gram stain) 
c) pos. sputum culture  
d) CXR  
Unclear - MV-rate: 100% (control 
group) vs. 92.2%  (treatment 
group) 
Gentilello 
1988126  
RCT 65 pts., surgical Kinetic therapy (arc of 124˚, continuously) 
vs. manual turning every 2h 
P, M, MV, LOS B a) purulent tracheal aspirate and pos. Gram 
stain 
b) pos. bacterial cultures 
c) CXR 
d) leukocytosis or leukopenia or left shift 
e) fever 
Unclear - MV-rate of 100% 
confirmed by author 
Kirschenbaum 
2002175  
RCT 37 pts., chronic 
ventilator unit 
Continuous Lateral Rotation Therapy 
(CLRT) (arc of 60˚, 18h per day, plus 
percussion every 2h) vs. manual turning 
every 2 h 
P, M, MV D a) fever 
b) CXR 
c) pos. BAL or deep tracheal aspirate 
culture 
Unclear - Only tracheostomized 
patients 
MacIntyre 
1999223  
RCT, multicenter 104 pts., mixed Continuous Lateral Rotation Therapy 
(CLRT) (arc of 60˚, continuously) vs. 
manual turning according to ICU standard 
P, M B  CXR (>24h after initiation of therapy) or 
pos. PSB culture plus at least two of the 
following: 
a) fever 
b) leukocytosis 
c) purulent sputum 
24 h - Outcome: ‘lower 
respiratory tract infection’, 
not explicitly pneumonia 
Appendix 
129 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 47: Study characteristics Positioning: Prone vs. supine positioning 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Beuret 200229  RCT 51 pts., comatose Prone (4h per day) vs. supine positioning  P, M, MV, LOS B  a) CXR 
b) purulent tracheal secretions 
c) pos. PSB culture  
Unclear  
Guerin 2004136  RCT 781 pts., mixed Prone (8h per day) vs. supine positioning  P, M, MV A  CXR (>48h of MV), pos. BAL or 
Wimberley brush culture, plus at least one 
of the following: 
a) fever or hypothermia 
b) purulent tracheal aspirates  
c) leukocytosis or leukopenia 
48 h  
Mancebo 
2006229  
RCT, multicenter 136 pts., mixed 
(with severe 
ARDS) 
Prone vs. supine positioning (targeted daily 
20-h prone sessions) 
P, M, LOS A  No standardized criteria. Every center 
applied own criteria 
Unclear - Author contacted for 
pneumonia criteria 
Voggenreiter 
2005370  
RCT 40 pts., trauma Prone vs. supine positiong (daily  8- to 23-
h prone sessions) 
P, M, MV A a) fever 
b) CXR 
c) pos. BAL culture 
Unclear - MV-rate of 100% 
confirmed by author 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 48: Study characteristics Positioning: Semirecumbent vs. supine positioning 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Keeley 2007172  RCT 30 pts., mixed Semirecumbent positioning vs. 25° head of 
bed elevation 
P  A CXR plus at least two of the following: 
a) fever 
b) leucopenia or leukocytosis 
c) purulent tracheal secretions 
24 h - Data of clinically 
suspected pneumina 
abstracted 
Drakulovic 
199994  
RCT 86 pts., respiratory, 
medical 
Semirecumbent vs. supine positioning  P, M, MV, LOS A  CXR plus at least two of the following: 
a) fever  
Unclear - Data of clinically 
suspected pneumonia 
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b) leucopenia or leukocytosis  
c) purulent tracheal secretions 
abstracted 
Nieuwenhoven 
2006364  
RCT, multicenter 221 pts., mixed Semirecumbent vs. supine positioning P, M, (MV), (LOS) A  CDC-criteria123 48 h - Data of clinically 
suspected pneumonia 
abstracted 
Girou 2004129 RCT 18 pts., medical Semirecumbent positioning (30°) and 
continuous subglottic secretion drainage vs. 
supine positioning 
P, (MV) B  a) fever  
b) leukocytosis  
c) purulent tracheal secretions 
d) CXR 
e) pos. PSB culture and/or pos. direct 
examination of BAL fluid 
5d  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 49: Study characteristics ET tubes: Subglottic secretion drainage 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Bo 2000 36  RCT 68 pts., surgical Subglottic secretion drainage P, M B Modified CPIS >6278 72 h - Article translated from 
Chinese 
- Suctioning intervals unclear 
Liu 2006 212  RCT 108 pts., 
respiratory 
Subglottic secretion drainage P, M, MV B CXR plus at least two of the following: 
a) fever 
b) leukocytosis or leukopenia 
c) purulent secretions 
d) pos. sputum culture 
48 h - Article translated from 
Chinese 
- Suctioning intervals unclear 
Mahul 1992 B 
227
  
RCT 145 pts., medical, 
surgical 
Subglottic secretion drainage (1h intervals)  P, M B a) CXR (>48h of intubation) 
b) pos. BAL culture 
3 d - Stress ulcer prophylaxis 
and subglottic suctioning 
were tested for interaction 
Metz 1998 241  RCT 24 pts., trauma, 
surgical 
Subglottic lavage and secretion drainage 
(3h intervals) 
P B a) fever 
b) leucocytosis or leucopenia 
c) CXR 
d) purulent tracheal secretions 
e) pos. BAL or tracheal secretions culture 
3 d We dropped the pharyngeal 
lavage group 
Smulders 
2002319  
RCT 150 pts., general Subglottic secretion drainage (20sec 
intervals) vs. standard endotracheal tube 
P, M, MV, LOS A American College of Chest Physicians: 
CXR infiltrate plus: 
a) radiographic evidence for cavitation or 
histologic evidence or pos. blood culture  
b) pos. pleural fluid culture 
c) two of the following: 
- fever 
72 h  
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- leukocytosis or leukopenia, 
- purulent tracheal aspirate 
Stohr 1998 B 
323
  
RCT 50 pts., surgical Subglottic lavage and secretion drainage (4 
h intervals) vs. standard endotracheal tube 
P, M B Unclear (conference report) Unclear -Various attempts to contact 
authors regarding pneumonia 
definition failed 
Valles 1995 359  RCT 152 pts., medical, 
surgical 
Subglottic secretion drainage (continuous) 
vs. no drainage 
P, M, (MV), (LOS) B a) fever 
b) leukocytosis or leucopenia 
c) purulent secretions 
d) CXR 
e) pos. PSB or BAL culture 
72 h  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; CPIS: Clinical Pulmonary Infection Score; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 50: Study characteristics ET Tubes: Silver coated endotracheal tube 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Rello 2006 284  RCT, single-blind, 
multicenter 
121 pts., mixed Silver coated tube vs. standard 
endotracheal tube 
P, M, MV B Modified CPIS >6278 24 h - CPIS˃6 score was infection 
threshold, not explicitly 
‘pneumonia threshold’ 
Kollef 2008186 RCT, single-blind, 
multicenter 
1509 pts., mixed Silver coated tube vs. standard 
endotracheal tube 
P, (M), (MV), 
(LOS) 
A Quantitative BAL fluid cultures obtained at 
suspicion of VAP or positive CXR plus 2 
clinical signs (fever/hypothermia, 
leukocytosis/leukopenia, purulent tracheal 
aspirate) 
24.h  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; CPIS: Clinical Pulmonary Infection Score; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
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Table 51: Study characteristics ET Tubes: Automated control of endotracheal tube cuff pressure 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumonia Min. 
duration 
of MV 
Notes 
Valencia 2007 
357
  
RCT 142 pts., 
respiratory, general 
Automated control of endotracheal tube 
cuff pressure vs. conventional management 
of the tube cuff pressure 
P, M, LOS A CXR plus at least two of the following:  
a) fever or hypothermia  
b) leukocytosis or leucopenia 
c) purulent respiratory secretions.  
48 h  
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used; 
 
Table 52: Study characteristics Non-calssifyable Interventions 
Study ID Methods Participants Interventions Outcomes AC Definition of pneumoniaeumonia Min. 
duration 
of MV 
Notes 
Claridge 2007 
62
  
RCT, double-
blind, placebo-
controlled 
105 pts., trauma Aerosolized ceftazidime P, M, (MV), (LOS) A  Pos. quantitative BAL cultures plus at least 
three of the following: 
a) leukocytosis or leukopenia 
b) fever or hypothermia 
c) CXR 
d) purulent secretions 
Unclear  
Greenfield 
1973 134  
RCT 58 pts., respiratory-
surgical 
Aerosolized polymyxin P, M, (MV), (LOS) B a) CXR 
b) pos. Gram stain of sputum  
c) pos. sputum culture 
d) evaluation of temp. course and white 
blood cell count 
24 h  
Li 2002 209  RCT 114 pts., mixed Aerosolized gentamicin P B  At least two of the following for >48h: 
a) fever or increase of at least 1˚C/day 
b) leukocytosis or leukopenia 
c) purulent sputum and pos. sputum culture 
d) CXR 
4 d - Article translated from 
Chinese 
Wood 2002 379  RCT, placebo-
controlled, 
double-blind 
40 pts., trauma Aerosolized ceftazidime P, M, MV, LOS A  Pos. BAL culture plus American College of 
Chest Physicians criteria for the systemic 
inflammatory response syndrome 
7 d - Patients ≥ 16 years 
Acquarolo 
2005 6  
RCT 38 pts., general-
neurological (brain 
injury) 
Intravenous ampicillin-sulbactam (3-day 
regimen) 
P, M, MV, LOS A a) CXR,  
b) pos. BAL or mini-BAL culture 
c) one of the following: 
48 h - Data of late-onset 
pneumonia abstracted 
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- fever or hypothermia 
-  leukocytosis or leucopenia 
Martinez-
Pellus 1994 235  
RCT 113 pts., trauma Intravenous cefotaxime (4-day regimen) 
in addition to pharyngeal 
decontamination  
P, M, MV, LOS B  CDC-criteria:123 72 h - Article translated from 
Spanish 
Sirvent 1997315  RCT 100 pts., head injury 
or stroke 
Intravenous cefuroxime (twofold high 
dose at intubation) 
P, M, LOS B  CXR, pos. BAL culture plus two of the 
following: 
a) fever  
b) leukocytosis  
c) purulent tracheal secretions 
d) ↓PaO2/FiO2 
e) CPIS >6278 
72 h  
Martinez-
Pellus 1996 236  
RCT 59 pts., trauma Topical pharyngeal decontamination vs. 
topical tracheal decontamination 
P, M, MV, LOS B  CXR (>48h in ICU) plus at least one of the 
following 
a) fever  
b) leukocytosis 
c) ↓PaO2/FiO2 
72 h - Historical control group 
excluded 
- Article translated from 
Spanish 
Holzapfel 1999 
157
  
RCT 399 pts., mixed Systemic search for maxillary sinusitis P, M, MV, LOS A  a) CXR 
b) fever or hypothermia 
c) leukocytosis or leucopenia and /or 
purulent tracheobronchial secretions 
d) pos. PSB culture  
7 d - Patients > 15 years 
Ntoumenopoul
os 2002 258  
RCT, partly 
blinded  
60 pts., medical, 
surgical, trauma 
Chest physiotherapy twice daily P, M, (MV), (LOS) D  Clinical diagnosis and CPIS278 of same 
calendar day 
48 h - ICU staff excluding 
physiotherapists were 
blinded to physiotherapy, 
physiotherapists were 
blinded to diagnosis of 
VAP 
Ntoumenopoul
os 1998 257  
RCT 46 pts., trauma Manual lung hyperinflation and postural 
drainage twice daily 
P, M, MV, LOS A  CXR plus at least three of the following: 
a) fever 
b) leukocytosis 
c) purulent sputum with bacteria on Gram 
stain 
d) pos. culture 
24 h - Data of confirmed 
pneumonia abstracted, 
since criteria for clinically 
suspected pneumonia 
insufficient 
Heard 1998 A 
143
 
RCT, placebo-
controlled, 
double-blind, 
multicenter 
21 pts., traumatic 
head injury or 
intracerebral 
hemorrhage 
Daily subcutaneous injection of 
recombinant human granulocyte colony-
stimulating factor (filgrastim, 75µg) 
P, (MV), (LOS) B  a) CXR 
b) pos. quantitative culture of secretions 
from the lower respiratory tract 
 
If no bronchoscopy possible a) plus clinical 
criteria 
72 h - Control group divided for 
both comparisons 
Heard 1998 B 
143
  
RCT, placebo-
controlled, 
double-blind, 
multicenter 
23 pts., traumatic 
head injury or 
intracerebral 
hemorrhage 
Daily subcutaneous injection of 
recombinant human granulocyte colony-
stimulating factor (filgrastim, 300µg) 
P, (MV), (LOS) B  a) CXR 
b) pos. quantitative culture of secretions 
from the lower respiratory tract 
 
If no bronchoscopy possible a) plus clinical 
criteria 
72 h - Control group divided for 
both comparisons 
Pneumatikos 
2002 273  
RCT 79 pts., trauma Selective decontamination of the 
subglottic area vs. placebo followed by 
P, M, MV, LOS B Clinical and laboratory data plus pos. PSB 
culture 
5 d  
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subglottic secretion drainage 
Manzano 
2008231 
RCT 127 pts., general, 
trauma 
Early application of PEEP in 
nonhypoxemic pts. 
P, M, (MV), (LOS) A CDC-criteria123 48 h  
Pepe 1984 269  RCT 92 pts., mixed Early vs. late application of PEEP P, M B a) pos. culture from endotracheal aspirate 
b) fever 
c) leukocytosis 
d) CHR, congestive heart failure or 
extensive atelectasis 
Unclear  
Porter 1999 274  RCT 18 pts., trauma Antioxidant therapy (selenium, vitamin 
E, vitamin C, N-acetycysteine) vs. no 
treatment 
P, LOS A a) fever 
b) leukocytosis 
c) CXR 
d) change in sputum quality or quantity 
e) pos. sputum Gram stain 
f) pos. PSB or BAL culture 
unclear - Patients ≥15 years 
- Author confirmed MV-
rate of 100% 
Berger 2006 24  RCT, placebo-
controlled, 
double-blind 
35 pts., burn center Antioxidant therapy (selenium, copper 
and zinc) vs. placebo 
P, (M), (MV), (LOS) B  a) SIRS (fever, tachycardia, leukocytosis)  
b) CXR 
c) hypoxemia 
d) purulent sputum or tracheal secretion 
e) pos. BAL or mini-BAL culture 
f) >48h of MV 
24h - Two trials combined 
- Only patients with MV 
>24h included 
Di Filippo 
1999 91  
RCT, double-
blind 
48 pts., mixed Endonasal mupirocin (3× for 3d) vs. 
placebo 
P B a) at least one of classic sepsis criteria 
(tachycardia, hypocapnia or 
hyperventilation, fever or leukocytosis) 
b) purulent sputum ± CXR 
c) pos. PSB culture 
48h - Article translated from 
Italian 
- Outcome: MRSA 
pneumonia 
Abbreviations: RCT: randomized controlled trial; pts: patients; CXR: chest X-ray; BAL: bronchoalveolar lavage; PSB: protected specimen brush; CPIS: Clinical Pulmonary Infection Score; 
Outcomes: P: pneumonia, M: mortality, MV: duration of mechanical ventilation, LOS: length of stay, Outcome in brackets: data reported but not abstractable; 
AC: allcocation concealment: A=adequate, B=unclear, C=inadequate, D=not used 
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b) Study characteristics of excluded trials 
Table 53: Excluded trials with reason for exclusion 
Study ID Reason for exclusion Intervention Group 
Adams 1997 7  Liver transplant patients AM 
Aerdts 1991 9  Double publication (see Aerdts 1990, J Antimicrob Chemother) GI 
Apte 1992 14  31% (study group) vs. 22% (control group) mechanically ventilated GI 
Armstrong 1992 15  No pneumonia data, no % of MV GI 
Badger 1991 17  Liver transplant patients GI 
Barker 2002 18  No pneumonia/VAP as an outcome NC 
Ben-Menachem 1994 22  65% (control), 72% (sucralfate) and 76% (cimetidine) mechanically 
ventilated 
GI 
Beuret 2002 29  Double-publication (see Beuret 2002, Intensive Care Med)  P 
Blot 2003 33  Study protocol, no trial AM 
Blunt 2001 35  No pneumonia as an outcome ET 
Boldt 1999 38  No RCT, no VAP NC 
Brook 1999 49  No pneumonia as an outcome NC 
Cerra 1992 53  Pneumonia data not abstractable since not number of patients but number of 
episodes reported 
GI 
Chastre 2005 55  Abstract of Kollef 2006 OC 
Chen 2006 58  No abstractable pneumonia data GI 
Choi 2005 60  No RCT AM 
Cioffi 1994 61  60% (antacids+cimetidine-group) vs. 58% (sucralfate-group) of patients 
intubated 
GI 
Clini 2006 63  Patients not MV NC 
Cockerill 1992 65  89% vs.80% intubated GI 
Croton 1981 76  No ICU patients, postop. patients NC 
Daschner 1988 79  Randomization? No response from author AM 
Davis 2000 80  Abstract of Davis 2000 Crit Care Med AM 
De Jonge 2003 82  No outcome VAP or Pneumonia 
treatment group: 83.7% intubated 
control group: 86.9% intubated 
GI 
De La Cal 2005 83  74% (treatment group) vs. 80% (control group) intubated GI 
deBoisblanc 1993 84  86% (study group) vs. 84% (control group) mechanically ventilated P 
Demetriou 1993 87  No RCT, comment on original publication (Montecalvo 1992) GI 
DeRiso 1996 89  Heart surgery patients OC 
Douzinas 2006 93  Patients all already had VAP; gastro-esophageal reflux, not VAP is outcome 
of this trial 
GI 
Dries 2004 98  Retrospective study, no RCT AM 
Ephgrave 1998 105  No report on % of ventilated patients, author contacted: most patients were 
intubated over night, but only 25-35% for >48h  
GI 
Fagon 2000 108  No preventive strategy AM 
Ferrer 2006 112  Control group not MV AM 
Flaherty 1990 116  Open heart surgery patients, mean duration of mech. vent. 1.8 days GI 
Freytag 2003 120  No pneumonia/VAP as outcome AM 
Geroulanos 1986 127  Cardiac surgery patients NC 
Gosney 2006 132  None of the patients required mech. vent. GI 
Grap 2004 133  No incidence of VAP reported. Author contacted but no response. OC 
Hammarqvist 1999 137  Double-publication: same contents as original Houdijk-publication (Lancet 
1998) 
GI 
Hammond 1993 138  Subgroup analysis of patients included in study published by Hammond in 
the Lancet 1992 
GI 
Heslet 2002 145  No RCT  
Hoffer 1999 156  No VAP as outcome, no % of mechanically ventilated patients, not the 
intervention and study population we are looking at 
GI 
Houston 2002 161  Cardiovascular patients OC 
Kindgen Milles 2002 174  Excluded patients requiring mech. vent. for >48h AM 
Kirton 1997 177  Patients included in Kirton 1997 in Chest AM 
Klastersky 1974 178  25.5% (study group) vs. 21.4% (control group) MV NC 
Kollef 1999 191  Cardiac Surgery Patients ET 
Konrad 1995 195  No pneumonia/VAP as an outcome NC 
Leur 2003361 Pneumonia episodes, not cases reported; no preventive strategy for VAP AM 
Levy 1997 208  72% (ranitidine group) vs. 50% (omeprazole group) mechanically ventilated GI 
Lode 1992 213  No RCT NC 
Mandelli 1989 230  48.1% (cefoxitin group) vs. 44.9% (penicillin group) vs. 47.7% (control 
group) intubated at admission 
GI 
Martin 1993234 Not clear how many % of  patients intubated; attempt to contact author 
considering the definitions for study entry it is unlikely 
GI 
Metz 1993240 93% (study group) vs. 80% (placebo group) mechanically ventilated GI 
Mustafa 1995249 Letter, no RCT GI 
Nathens 2002252 Only about 80% MV (author contacted) NC 
Nelson 1992254 No abstractable pneumonia/VAP data, only “pulmonary process 
complications” 
P 
Normand 2005256 No pneumonia/VAP as outcome OC 
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Ogata 2004259 No pneumonia/VAP as outcome OC 
Okuda 2003260 No pneumonia/VAP as an outcome, not our study population OC 
Ong 2004261 No abstractable pneumonia data NC 
Ortiz 1998263 No VAP/pneumonia as outcome GI 
Palomar 1992265 Double publication; patients included in publication of Palomar 1997 GI 
Rathgeber 1993281 Children included NC 
Rossi 2004292 No ICU or critically ill patients NC 
Ruiz 1998296 No preventive strategy, diagnostic strategy NC 
Ruiz 1998297 No preventive strategy, diagnostic strategy NC 
Sacks 2003300 No RCT NC 
Segers 2006305 Cardiac surgery patients OC 
Siempos 2007309 No RCT OC 
Silvestri 2007312 No RCT GI 
Simms 1991313 No report on % of intubated patients at admission;  
at diagnosis of pneumonia 78% intubated 
GI 
Stoller 2003324 Not randomized, no RCT AM 
Strong 1992327 Not our study population, "malnoutrished, hospitalized patients"; 
unclear, how many % of patients intubated 
GI 
Traver 1995344 89.8% vs. 88.7% mechanically ventilated P 
Tryba 1988351 Double publication (J Clin Anesth 1988) GI 
Tulli 1986354 Post-op patients, not our study population GI 
Ulrich 1989355 77% (treatment group) vs. 83% (control group) mechanically ventilated GI 
Valles 1991360 Preliminary data of Valles 1995, Ann Int Med ET 
Van Enckevort 2001362 Liver transplant patients; 
no VAP as outcome  
GI 
Van Nieuwenhoven 2004363 No RCT, no VAP/pneumonia as outcome GI 
Van Saene 2006365 No RCT GI 
Vogel 1981369 No RCT NC 
Whiteman 1995376 Liver transplant patients P 
Winter 1992378 Control group partly retrospectively studied, 85% mechanically ventilated 
(author contacted) 
GI 
Wood 2007380 No RCT, review NC 
Young 1999382 No pneumonia/VAP as an outcome ET 
Young 2006383 No pneumonia/VAP as an outcome ET 
Zeitoun 2001385 Abstract of Zeitoun 2003-J Clin Nurs AM 
Zhang 2004386 No VAP as outcome  P 
Zwaveling 2002387 Liver transplant patients GI 
Abbreviations: AM: Airway Management, ET: Endotracheal Tube, GI: Gastrointestinal Inetrventions, NC: Not Classifyable, OC: Oral Care, P: 
Positioning, 
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c) Table of guideline recommendations 
Table 54: Table of guideline recommendations 
 Torres 2001340 Collard 200367 
Tablan 2004 
(CDC-
guideline)331 Dodek 200492 
Am. Thor. Soc. 
Guidelines 20053 
Muscedere 
2008248 
Metaanayltic results 
and 
recommendations 
Oral Care        
Antiseptic Decontamination        
Chlorhexidine   
no recommendation for 
routine use  
no recommendation for 
routine use should be considered ++ 
Povidone-Iodine      should be considered ++ 
Iseganan      not recommended +/- 
        
Airway Management        
Tracheostomy    no recommendation  no recommendation +/- 
Weaning        
Weaning protocol     recommended  (+) 
Non-invasive MV 
probably beneficial but 
should be investigated  recommended  recommended  ++ 
Closed vs. open endotr. suct. still controversial  no recommendation 
closed suctioning 
system recommended 
 
closed suctioning 
system recommended +/- 
Daily vs. no daily change of in-line 
suction catheters still controversial  no recommendation   
change for every new 
patient recommended +/- 
Heat and moisture exchanger vs. 
heated humidifier still controversial no recommendation no recommendation 
heat and moisture 
exchangers 
recommended no recommendation no recommendation +/- 
Extended use of heat and moisture 
exchanger 
 
less changes 
recommended 
not routine change more 
frequently than every 48 
h weekly changes  
extended use of 5-7 
days (+) 
Components os heat and moisture 
exchanger       +/- 
Change of ventilator circuits (less 
frequent) weekly changes 
less changes 
recommended no routine changes no routine changes  no scheduled changes (+) 
Heated vs. non-heated wire circuits       +/- 
Oro- vs. nasotracheal intubation 
orotracheal intubation 
recommended 
 
orotracheal intubation 
recommended 
orotracheal intubation 
recommended 
orotracheal intubation 
recommended 
orotracheal intubation 
recommended (+) 
Bacterial filter   no recommendation   not recommended +/- 
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 Torres 2001340 Collard 200367 
Tablan 2004 
(CDC-
guideline)331 Dodek 200492 
Am. Thor. Soc. 
Guidelines 20053 
Muscedere 
2008248 
Metaanayltic results 
and 
recommendations 
Gastrointestinal Interventions        
Selective Decontamination of the 
digestive tract (SDD) 
recommendation for 
subgroups of patients no recommendation 
no recommendation for 
routine use no recommendation 
no recommendation for 
routine use no recommendation ++ 
SDD with additional topical 
antibiotics 
      +/- 
Interventions to reduce the bacterial 
reflux load        
Sucralfate vs. H2-antagonists still controversial 
recommendation for 
sucralfate no recommendation  
recommendation for 
sucralfate and H2-
antagonists  ++ 
Sucralfate vs. Antacids still controversial 
recommendation for 
sucralfate no recommendation    (+) 
Sucralfate vs. Placebo still controversial  no recommendation no recommendation   +/- 
Sucralfate vs. H2-antagonists + 
antacids still controversial  no recommendation    (+) 
No treatment vs. H2-antagonists 
+antacids still controversial 
recommendation for 
sucralfate no recommendation    +/- 
Placebo vs. Pirenzepine       +/- 
Placebo vs- H2-antagonist       +/- 
Acidified enteral feeds  no recommendation no recommendation    +/- 
Early gastrostomy       (+) 
Small intestinal vs. Gastric 
feeding  no recommendation no recommendation    +/- 
Intermittent enteral feeding  no recommendation no recommendation    +/- 
Enteral naloxone       (+) 
Enteral metoclopramide  not recommended     +/- 
H2-antagonist vs. Antacid       +/- 
Enriched enteral nutrition  
no recommendation 
(glutamine)     +/- 
Early enteral nutrition still controversial      +/- 
Enteral vs. Parenteral feeding     
enteral feeding 
recommended 
 ++ 
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 Torres 2001340 Collard 200367 
Tablan 2004 
(CDC-
guideline)331 Dodek 200492 
Am. Thor. Soc. 
Guidelines 20053 
Muscedere 
2008248 
Metaanayltic results 
and 
recommendations 
Positioning        
Rotational therapy  
consideration in select 
patient populations 
(surgical, neurological) no recommendation should be considered  should be considered ++ 
Prone vs. Supine positioning    no recommendation  no recommendation (+) 
Semirecumbent vs. Supine 
positioning recommended recommended recommended recommended recommended recommende (+) 
 
       
Endotracheal tubes        
Subglottic secretion drainage still controversial 
no recommendation for 
general use Recommended Recommended Recommended 
recomended in pts. 
ventilated 72h ++ 
Silver coated tube       ++ 
Automated cuff presure control       +/- 
        
Non-classifyable preventive 
strategies        
Aerosolized antibiotics      no recommendation ++ 
Intravenous antibiotics still controversial  no recommendation no recommendation 
no recommendation for 
routine use no recommendation ++ 
Pharyngeal vs. tracheal 
decontamination       +/- 
Systemic search for maxillary 
sinusitis 
   no recommendation  no recommendation (-) 
Chest physiotherapy    no recommendation   ++ 
Manual lung hyperinflation       +/- 
Granulocyte colony-stimulating 
factor 
  no recommendation    +/- 
Decontamination of the subglottic 
area       ++ 
Early PEEP       +/- 
Antioxidant therapy       ++ 
Endonasal mupirocin      no recommendation +/- 
Abbreviations: ++ recommended or statistically significant, (+) probably beneficial but non-significant, +/- equivocal or no recommendation, (-) possibly harmful and therefore not recommended, --  should be avoided because 
harmful 
 
